Views from a vaccine manufacturer: Q&A – Abdul Muktadir, Incepta Pharmaceuticals 01/04/2021 Priti Patnaik The debate around technology transfer is proving to be critical in addressing shortages in the production of vaccines. We wanted to know from developing country manufacturers on the challenges they face in making vaccines for COVID-19. Geneva Health Files brings you an interview with Abdul Muktadir, Chairman and Managing Director of the Dhaka-based company Incepta Pharmaceuticals Limited. Established in 1999, Incepta specialises in biosimilars and vaccines, employing nearly 10,000 people and producing about 1000 different medicines and vaccines – including oral cholera vaccines, vaccines for influenza, measles, rubella, and Hepatitis B. Incepta exports to 67 countries across the world, has 3 manufacturing sites, and 17 factories and research facilities. Geneva Health Files (GHF): What, according to you, are the real impediments for technology transfer in the process of production of vaccines in the developing world? Abdul Muktadir (AM): The innovator companies are preoccupied with the supply commitments to the governments from which they have taken advance payment. They have successfully transferred the technology to all the Contract Research Organizations (CROs) so the technical difficulties that are often referred to may not be a big impediment. The innovator companies are at ease working within their comfort zone and do not want to deal with unknown companies. This is the real barrier that the innovator companies do not feel comfortable working with many companies from the developing world. Abdul Muktadir, an industrial pharmacist by training, who is Chairman & Managing Director for Incepta Pharmaceuticals Limited GHF: In policy debates in Geneva, developed countries argue that intellectual property has not been a barrier for the production of vaccines. What are your thoughts on this? AM: In the current context, the IP right is not the impediment as the companies from the developing world would act either as a CRO or as a license holder. The innovator companies should utilize as many manufacturing bases as possible and then increase their production. In this case there is no issue of IP violation. GHF: It has also been argued that developing country manufacturers may not have the skills and equipment to engage in technology transfer. What are your views on the expertise and manufacturing capacities in the developing world? AM: There are several technological platforms for production of currently approved COVID-19 vaccines, and for each platform there are differences in upstream and downstream processes. The vaccine manufacturing is not very widely distributed but the companies that manufacture vaccines – they understand the process fairly well. So, the capacity and expertise are available with the manufacturers of the developing world – otherwise Serum Institute and other Indian manufacturers would have faced difficulties. The equipment might require some re-tooling to accommodate the new process but certainly it is possible. GHF: As a developing country manufacturer, what in your view is a preferred way for technology transfer: non-exclusive licensing or bilateral arrangements? And why? AM: Here, the primary objective is to increase the volume of production. My argument is: if a company can deliver 1 billion doses a year then we should try to increase that capacity to 4 billion using the same principle. No company was prepared to deliver 1 billion doses a year, but the companies are doing this now. The task of manufacturing should be distributed based on the capability of each manufacturing partner. The best way should be to mass manufacture antigen [vaccine active ingredient] bulk in a few places and then the antigen could be distributed for fill/finish wherever the capacity is available. We are referring to any licensed Covid-19 vaccine such as Moderna, Pfizer, Astrazeneca, Johnson & Johnson. If we receive the active bulk ingredient, we have the capacity to fill and finish. This way we can involve many companies in many different countries. This would also eliminate impediments on cross border transportation. We observe now that most of the manufacturing countries are putting barriers in previously agreed supply commitments. The above process would involve both non-exclusive licensing and bi-lateral arrangements. We can avoid non-exclusive licencing if the innovator company can make the agreements through multi-party contract manufacturing. In such a case the technology transfer requirement would be as per the requirement of each task. If the bulk antigen can be produced in a few places then the requirement of tech transfer would be very minimal, and the innovator company’s technology can remain very well guarded. The current technology of manufacturing the COVID-19 vaccine is probably known to many vaccine companies, including companies from the developing world like ours. The biggest challenge in introducing a new vaccine is to successfully conduct an efficacious clinical trial and this remains the main barrier for a new vaccine. So, our best option would be to manufacture the already-approved vaccines on a massive scale and provide them fair reward for their innovation. GHF: Can you share specific details on your operations in Bangladesh in terms of capacity for technology transfer? What would be the easiest vaccines to produce and what are the potential areas for improvements in your manufacturing plants? Incepta Pharmaceuticals has full-scale vaccine manufacturing facilities – including antigen production lines, bioreactors, and fill-and-finish capacity. AM: We have full-scale vaccine and biosimilar manufacturing facilities. We can manufacture bulk antigen using almost all technology platforms. We have the bulk antigen production facilities which could be utilized to adapt almost all technology platforms (e.g. mRNA, DNA, adenoviral & insect/baculoviral etc ) available for COVID-19 vaccine. For example, we have developed a meningococcal polysaccharide subunit vaccine (ACYW135), hepatitis B sub-unit vaccine (VLP based), and whole cell oral cholera vaccine from our own bulk, and obtained licensure for these vaccines in Bangladesh. Moreover, a cell culture-derived rabies vaccine that we developed is in a clinical trial now. A pre-clinical study for typhoid conjugate vaccine is on-going. In addition, we have more vaccines in the pipelines. Depending on a particular process we have to re-tool the facility to accommodate the manufacturing of a new vaccine. Once we have a process in hand, then we would know the extent of re-tooling requirements. Once the facility is ready then we have to optimize the manufacturing process and it requires some time. For us the easiest COVID vaccine technologies would be the protein subunit vaccines [such as the one produced by Novavax] and mRNA vaccines [such as those produced by Pfizer/BioNTech and Moderna]. We would also be able to manufacture adenovirus vaccines. We have the bulk antigen production facilities which could be used to adapt technology related to mRNA vaccines and protein subunit vaccines for COVID-19. We have a 500L bioreactor which could be used to produce insect cells/baculovirus based protein sub-unit vaccines like the one from Novavax. At the moment, we have a licensed protein sub-unit vaccine for hepatitis B which we developed using the yeast technology platform. If we have access to mRNA technology, we believe we can easily adapt this technology. We have all the reactors and purification tools required for mRNA vaccine production. If we get the antigen then the production can start immediately, as we have two and a half production lines sitting idle. In one line we can handle multiple dose vials, and with 20 doses a vial, we can deliver about 500 million doses a year. If we re-tool the other two lines for larger, multiple vial capability then we would be able to deliver another 600 million doses. But this would require a lead time for the supply of tools from machine manufacturers, and this may require a lead time of 6-8 months. But we now have one line fully ready to deliver about 500 million doses a year in multiple dose vials (the lines we have are suitable to fill any type of vaccine). At the moment we don’t have any deals with any innovators. Priti Patnaik is the founding editor of Geneva Health Files – a reporting initiative that tracks power and politics in global health. This interview is a part of a series under a collaboration arrangement between Geneva Health Files and Health Policy Watch. Image Credits: Incepta. The Clock Is Ticking For Vaccine Equity, But WHO Remains Hopeful 01/04/2021 Svĕt Lustig Vijay Dr. Tedros Adhanom Ghebreyesus, WHO Director General, at the press briefing on Thursday. The World Health Organization (WHO) is hopeful that all healthcare workers can be vaccinated by mid-April, but the clock is ticking away, leaving rich countries only nine days to donate surplus COVID-19 vaccines to the global COVAX facility – which has run out of doses at a crucial time. So far, the WHO has not received any donations since it called on countries last week to donate surplus doses they have accumulated, said Dr. Tedros Adhanom Ghebreyesus at a press conference on Thursday. “Last week, I made an urgent request to countries with surplus vaccines that have WHO emergency use listings to share 10 million doses with COVAX,” said Dr. Tedros. “This challenge has been heard, but we’re yet to receive commitments for those. I’m still hopeful that some forward looking and enlightened leaders will step up.” COVAX Facing “Serious Challenges” Although the global COVAX facility has already delivered 35 million doses to more than 78 countries across the globe, it is facing “serious” shortfalls in doses – mainly because of India’s recent move to halt vaccine exports to the rest of the world as it attempts to fend off an outbreak that has grown to some 70,000 cases a day from only 15,000 since early March – an increase in cases by a factor of four in just a month. Despite the WHO’s call on rich countries and vaccine manufacturers to donate surplus vaccine doses last week, a whopping 100 countries still lack adequate access to vaccines, said Turkey’s Health Minister Fahrettin Koca, who also spoke at the press conference. Of those, two dozen countries that have signed up to the WHO co-sponsored COVAX initiative are ready to begin vaccinating healthcare workers – but they lack the supplies to begin before the 100th day of 2021 – the target date WHO had said for vaccine campaigns to start everywhere in the world. These include Cameroon, Haiti, Congo, Burkina Faso, Niger, Vanuatu, Papua New Guinea, Kyrgyzstan, the Dominican Republic and Mauritania, among others. “I know this is a challenging time for many countries as cases and hospitalization are spiking, but conversely, it’s when cases are spiking that it’s the most important time to share vaccines equitably and protect our workers, and at-risk communities,” Dr Tedros said. Going forward, the concerning gaps in equity “could be addressed” by increasing local and regional vaccine production capacity and by moving forward on the intellectual property waiver spearheaded by South Africa and India, said the WHO Director General. “I think we should be able to produce vaccines everywhere, all over the world without intellectual property rights being a problem,” added Koca. “So that’s why I think we need to be taking concrete steps about this issue.” Turkish Health Minister Fahrettin Koca at the press briefing on Thursday. Turkey Announces Digital Platform To Commemorate Healthcare Workers Meanwhile, in celebration of the International Year of Health and Care Workers, Koca announced the creation of a digital platform to tell the stories of the heroic and essential work carried out by healthcare workers since the pandemic began. The platform will be run in collaboration with WHO. “The whole of humanity is grateful to you right now,” said Koka. “[Your] stories need to be told in the common language of humanity. For this purpose, as a first step, we are working on creating a digital platform with WHO, to serve as a memorial dedicated to health and care workers.” Since the start of the pandemic, millions of healthcare workers have been infected with the coronavirus and thousands have died. Those that have survived are struggling with a range of mental health issues, including heightened stress, anxiety, depression, insomnia, and exhaustion. That toll, said Dr Tedros, has been far too great – but it can be reversed by strengthening the capacity of the healthcare workforce, improving salaries, and ensuring healthcare workers are equipped with adequate personal protective equipment so they can do their job safely and effectively. “Far too many health and care workers have died in the pandemic,” he said. “As we work to end the pandemic and recover together….We must ensure that they are trained, protected, and supported to do their job safely and effectively.” Image Credits: Our World In Data, WHO. DNDi Strategy For The Decade: Delivering And Developing Treatments For Neglected Tropical Diseases 01/04/2021 Raisa Santos A man with symptoms of the deadly NTD African trypanosomiasis (sleeping sickness), is examined by Dr Victor Kande in the Democratic Republic of Congo (DRC). Kande was principle investigator for clinical trials of fexinidazole, the first oral sleeping sickness treatment approved by the European Medicines Agency (EMA) in 2018. Developed by DNDi, it is being rolled out in DRC. Global health experts expressed their frustration with the lack of research and attention towards neglected tropical diseases (NTDs) and vulnerable populations, calling for health systems to address NTDs in a more sustainable and holistic way. Speaking at the launch of a new strategic plan for the Geneva-based Drugs for Neglected Diseases initiative (DNDi) on Tuesday, DNDi Executive Director Bernard Pécoul said greater emphasis should be placed on expanding access and developing treatments for patients in low- and middle-income countries (LMICs) affected by neglected tropical diseases (NTDs), as well as neglected viral diseases like HIV/AIDS, and also pandemic-prone and climate-sensitive diseases. “Treatments were abandoned for years or decades because they fell outside commercial markets,” said Pécoul, at the launch of the plan that charters an eight-year journey to 2028, aiming to deliver 15 – 18 additional treatments, in addition to eight already developed, for a total of 25 new or improved, and highly effective, NTD treatments. “The frustration is where the idea was born – from the experience of humanitarian doctors, frustrated, while treating patients with vaccines that were ineffective, unsafe, or unaffordable, or never developed at all because the research and development was abandoned,” Pecoul added, speaking of his own experience in the past working with Medecins Sans Frontieres (MSF). DNDi, a WHO-supported organization of private and public sector actors, has committed to five strategic imperatives for the next eight-years: to deliver new treatments and expand access for neglected patients of NTDs and related viral diseases; join with public health leaders and Research and Development (R&D) stakeholders in low- and middle-income countries to advance sustainable health systems; contribute to building a proactive agenda for maternal, child health, and gender-responsive R&D; champion open science and transparency; and leverage new technologies to accelerate R&D. “It is our hope that we will identify safe, effective, and affordable medicines to help countries fight the health and social burden put on them by COVID-19. While all global attention is focused on development and purchase of COVID-19 vaccines, we should not forget about treatment and diagnostics,” said Marie-Paule Kieny, Director of Research, INSERM and DNDi Board Chair, at the Tuesday DNDi launch. Challenging The Status Quo DNDi’s Strategic Plan launch event panel: clockwise: Patricia Amira, moderator; Dr Somya Swaminathan; Dr Marie-Paule Kieny; Dr Jeremy Farrar; Dr Bernard Pecoul; Dr Berhards Ogutu Also appearing at the event, Jeremy Farrar, director of the Wellcome Trust. also expressed frustration with the ‘status quo’ that has defined R&D for global health, and called for more attention to be brought to three areas that would ‘define the 21st century’ – neglected and infectious disease, climate change, and mental health. “These three things are going to define our time – which have a focus on youth, and which have an inequitable impact on societies around the world. [DNDi is committed to] not just doing the science, but making sure that science is shared equally with everybody in the world,” he said. Over the next decade, DNDi will work to accelerate sustainable disease elimination in diseases with existing treatments, such as sleeping sickness and Chagas disease, and increase access to lifesaving and safer treatments for HIV and leishmaniasis. DNDi – founded in 2003 to discover, develop, and deliver safe, effective, and affordable treatments for neglected and marginalized patients – will also work with leaders and institutions in LMICs to bolster research capacity and generate more sustainable production and supply of NTD treatments. The initiative has grown into a network of over 200 partner institutions, and has so far delivered eight new treatments for people with sleeping sickness, visceral leishmaniasis, Chagas disease, HIV, and malaria. Clinical Trials for Mild COVID Cases Launching in 13 African Countries Africa launches largest COVID clinical trial COVID-19 has highlighted the need to prioritize and finance research in LMICs, as well as government preparedness to ensure both transparency and equitable access. In addition to working on NTDs and viral illnesses, DNDi will also address unmet medical needs, utilizing its ‘dynamic portfolio’ approach to explore new interventions in diseases with clear R&D gaps, including snakebite, dengue fever, schistosomiasis, and pandemic-prone diseases. At the start of the strategic planning period, DNDi also is coordinating ANTICOV – the largest African-led clinical trial testing for mild-to-moderate COVID-19. The ANTICOV platform deals with the outpatient population, which is the majority of people with COVID, and is trying to answer the question of how to treat people to prevent them from getting ill and needing hospitalization, said Dr Soumya Swaminathan, WHO Chief Scientist. Carried out by a group of 26 prominent African and global R&D organizations in 13 countries, ANTICOV will simultaneously test and adjust treatments for COVID-19, and identify new treatments, fast-tracking research for patients and health systems in resource-limited settings. Swaminathan said that the high costs of the COVID-19 pandemic should not come at the expense of cutting or reducing budgets for NTDs, saying that the ‘collaborative science’ seen over the past year as proof that knowledge could be shared openly and freely. “Because of this vision, and the collective mission to solve the problem of COVID and develop new tools, it is possible to [share knowledge more widely].” Though DNDi is primarily focused on R&D, the organization will also identify gaps in access to care, and build the partnerships needed to overcome them, laying the groundwork for more affordable care. Said Swaminathan: “When there’s a new technology, which can make a big impact, especially when it’s related to health and disease, it should be considered a global public good, and be made available to people who need it, regardless of their ability to pay.” Image Credits: DNDi, DNDi, ClimateWed/Twitter. France Enters Third Lockdown, While Europe’s Vaccine Rollout Is Critiqued As “Unacceptably Slow” 01/04/2021 Madeleine Hoecklin A patient getting tested for COVID-19 at the Paris Charles de Gaulle Airport in January 2021. French President Emmanuel Macron imposed strict lockdown measures amid of surge of new coronavirus cases. France is going into its third national lockdown since the start of the COVID-19 pandemic, after a deadly third wave hit Europe, causing soaring infection and death rates. With an average of more than 37,000 daily new cases over the past week, tougher restrictions have become inevitable. French President Emmanuel Macron announced the new restrictions in a televised address on Wednesday, saying that the government had waited “until the last moment” to impose the latest lockdown. The daily death toll reached 355 on Wednesday and health authorities recorded 569 new intensive care patients in 24 hours on Tuesday, the highest since April 2020. Over 5,000 COVID-19 patients are currently in intensive care units. Infections have doubled since February, likely due to the spread of the more transmissible B.1.1.7 SARS-CoV2 variant, first detected in the United Kingdom. France “risks losing control” without strict measures, said Macron. France is approaching the grim milestone of 100,000 total COVID deaths, with 95,798 deaths recorded as of Wednesday. Lockdown Measures Put in Place Lockdown restrictions include classes being taught remotely for the next three weeks, non-essential businesses will be closed, and travel within the country will be banned for a month after the Easter weekend (2-4 April). Residents will be limited to a 10 kilometer radius from their homes and will be subject to a curfew between 7pm and 6am. “We must limit all contact as much as we can, including family gatherings. We know now: these are where the virus spreads,” said Macron. Some 3,000 additional intensive care beds will be added to hospitals in the hardest-hit regions in an attempt to prevent health systems from becoming overwhelmed. The national lockdown will begin on Saturday and will last four weeks. Emmanuel Macron, the French President, in a televised address on Wednesday announcing the country’s third COVID-19 lockdown. Over a dozen regions were put under partial lockdown in early March with night-time curfews. The regional restrictions avoided closing schools or stores in an effort to keep the economy open. The existing restrictions at the regional level, which were implemented in early March in an attempt to avoid stricter measures, were unable to curb the spread of the virus. Macron was hesitant to impose nationwide restrictions, resisting calls from experts for tougher measures since January. “The outlook is worse than frightening. We’re already at the level of the second wave, and we’re quickly getting close to the threshold of the first wave,” said Jean-Michel Constantin, head of the intensive care unit at the Pitié-Salpêtrière hospital in Paris, in an interview on RMC radio on Monday. According to the French Health Minister, Olivier Veran, France could reach the peak of the epidemic in seven to 10 days, “then we need two extra weeks to reach a peak in intensive care units (ICUs) that could occur at the end of April,” he told Inter radio on Thursday. “We have endured a year of suffering and sacrifice, but if we stay united and organized, we will reach the end of the tunnel,” said Macron. “April will be a critical month.” France’s vaccination campaign is seen as the path out of the pandemic and will be accelerated in the coming weeks, according to Macron. France, along with the rest of the European Union, was plagued by a slow rollout of vaccines due both to shortages as well as a lack of a well-coordinated health sector response in many countries, with systems that are either highly fragmented or else too centralized to permit for smooth and efficient rollouts at the local level. WHO Calls Europe’s Vaccination Program “Unacceptably Slow” Amidst rising infection and death rates in the WHO European region, which encompasses 53 countries, the region’s vaccine “rollout is unacceptably slow,” said Hans Kluge, the WHO Regional Director for Europe, in a statement released on Wednesday. Europe has recorded 1.6 million new cases and close to 24,000 deaths in the last week, quickly nearing one million total deaths. It is the second most affected region by SARS-CoV2 in the world. The B.1.1.7 variant has a greater public health impact and requires numerous measures in place to control it, said the statement. Currently, 27 countries in Europe are under partial or nationwide lockdown and 23 have tightened restrictions over the past two weeks. However, some 13 countries have ease measures and nine plan to follow suit. “My message to governments in the region is…that now is not the time to relax measures. We can’t afford not to heed the danger,” said Kluge. “We must keep reining in the virus.” Hans Kluge, WHO Regional Director for Europe. “Vaccines present our best way out of this pandemic,” Kluge said. However, “as long as coverage remains low, we need to apply the same public health and social measures as we have in the past to compensate for delayed schedules.” In addition to implementing public health measures to limit transmission, efforts must be made to scale up vaccine production and administer as many jabs as possible, as quickly as possible. “We must speed up the process by ramping up manufacturing, reducing barriers to administering vaccines, and using every single vial we have in stock, now,” said Kluge. Only 10% of the region’s population have received one dose of a COVID-19 vaccine. While there has been a shortage of vaccines, countries must avoid vaccine nationalism and hoarding supplies, the statement said. Once a nation’s healthcare workers and vulnerable individuals have been vaccinated, Kluge urged governments to “share excess doses of WHO-approved vaccines with COVAX or with countries in need” in order to ensure that healthcare workers and older individuals in every country are inoculated. This message was echoed by Dr Tedros Adhanom Ghebreyesus, WHO Director-General, at a press conference on Thursday, who made an “urgent request to countries with surplus vaccines that have WHO emergency use listings to share 10 million doses with COVAX.” In order to reach the goal of vaccinating all healthcare workers in the first 100 days of 2021, rich countries have nine days remaining to to donate excess doses to the COVAX facility, which has run out of doses at a critical time. WTO Head Says Pharma Companies Should Either Scale Up Manufacturing Or Share Know-How with LMICs Meanwhile, the new Director-General of the World Trade Organization (WTO), Ngozi Okonjo-Iweala, called it “unacceptable” that low- and middle-income countries (LMICs) were being left at the “end of the queue” for COVID-19 vaccines. “The kind of inequities we see in vaccine access are really not acceptable, you can’t have a situation in which…10 countries have administered 70% of vaccine doses in the world, and there are countries that don’t have one single dose,” said Okonjo-Iweala at a WTO trade forecast press conference on Thursday. Ngozi Okonjo-Iweala, Director-General of the WTO, at a press conference on Thursday. She urged pharma companies to follow AstraZeneca’s lead in making deals with production facilities in LMICs to expand the manufacturing capacity for their vaccines. “Let’s have the same kind of arrangement that AstraZeneca has with the Serum Institute of India,” the world’s largest vaccine manufacturer and the main source of COVID-19 vaccines for LMICs, Okonjo-Iweala said. Voluntary licensing of technology could begin to address the inequity in access to vaccines, she said. While an intellectual property waiver for certain COVID-19 tools and technology – designed to allow more drug manufacturers to make the vaccines and improve access – is under consideration by WTO member states, Okonjo-Iweala said this was an issue for the next pandemic. Instead of pursuing the WTO TRIPS waiver, the focus now to meet the threat from COVID should be put on enlarging manufacturing capacity, she said. Image Credits: France24, Flickr – International Monetary Fund, BBC. A Good Place To Start To Beat The COVID Obesity Pandemic – Warning Labels on Unhealthy Foods 01/04/2021 Svĕt Lustig Vijay The obesity pandemic is in “the same room” as the COVID pandemic in terms of its threats to health – putting people at greater risk of premature death from multiple causes, including SARS-CoV-2, the virus that leads to COVID-19. And ever since stay-at-home measures became routine, people have gained even more weight – up to 1.5 pounds a month according to one recent US study. Yet countries have the tools to address obesity, note Trish Cotter and Dr. Nandita Murukutla at Vital Strategies, a global public health NGO. We spoke to Ms. Cotter and Dr. Murukutla to find out more: Health Policy Watch (HPW): A third of the global population now suffers from overweight, and rates of obesity are growing across the world, including in poor countries. How can we explain these trends? Vital Strategies (VS): Over the last 40 years, obesity rates around the world have ballooned. High-income countries, like the United States, were the first to experience substantial weight gains of their populations, but the 21st century has seen that phenomenon spread to all parts of the globe. Now, the average adult is three times as likely to be overweight as the average adult in the 1970s. There are a number of reasons for this alarming trend, which began well before COVID-19, starting with the environments in which people live, as well as poverty, discrimination, increasing availability of unhealthy foods in schools, dwindling levels of physical activity, and a lack of knowledge of unhealthy diets and products. However, the fundamental reason is the rapid change in our diets and the broader food environment. Ultra-processed products or “junk food”, such as soft drinks, ice creams, or prepared frozen dishes, are one of the key drivers of growing obesity worldwide. They are high in sugar, salt and fat and, unfortunately, widespread in most societies. Yet their harmful effects are poorly understood. One in three people worldwide are overweight HPW: Why are ultra-processed foods so ubiquitous? VS: They are cheap, easily available, and because of additives and preservatives, they have a long shelf-life. They’re made to feel and look attractive, and they’re made to taste good. Importantly, they’re also hyper-marketed by the food industry. Advertising campaigns are very good at making unhealthy products seem part of the fabric of society: unhealthy foods are made to seem crucial to family gatherings and entertainment, so they become part of the social norm that normalizes unhealthy foods. And much of the advertising around unhealthy foods is so enticing that it gets children hooked at a young age. In what ways is advertising of ultra-processed products misleading? Unhealthy products are often marketed cleverly as convenient substitutes for healthy, minimally processed options that include whole grains, fruits and vegetables. They are marketed as convenient breakfast foods, snacks, juices, and sometimes they are also marketed as being more sanitary than fresh fruits and vegetables. But that’s misleading, because current evidence demonstrates that ultra-processed products result in worse diets and ultimately overweight and obesity, which exacerbates the risk of contracting a range of chronic diseases as well as suffering poorer outcomes from infectious diseases like COVID-19. Claims that ultra-processed products are healthy alternatives are untrue. Can you give a concrete example of a strategy that misleads customers into thinking they’re buying healthy products? Labels on the front and back of food packages are often really hard to accurately decode. And many of these labels use clever algorithms to hide unhealthy levels of sugar, salt, and saturated fat. Customers may not always realize that the product they are buying is unhealthy. Late last year, you co-authored a guide to help policymakers introduce clear, yet highly effective warning labels on foods and beverages to nudge customers away from unhealthy foods. How do these warning labels work? Front-of-Package (FOP) nutrient labels, sometimes called warning labels, tell consumers immediately, on the front of products, and simply when a product contains high levels of unhealthy nutrients. That means customers don’t need to spend several minutes trying to work out whether each product is healthy or not. This system is simple, visual, and easy to understand. And it is effective, as seen from studies across the world, in triggering immediate behavior change. The front-of-package labels serve as behavioral nudges, protecting people from making unintended unhealthy purchases. In other words, the warning labels work by reminding consumers that the products they are purchasing are unhealthy, thus nudging them to make healthier choices. But they also have important knock-on effects: they help change social norms around unhealthy eating. Example of warning labels on food products in Chile to nudge customers away from unhealthy foods. Translation from top-left to bottom-right: high in calories; high in sugars; high in sodium; high in saturated fats. Source: Ministry of Health of Chile. You mentioned that warning labels can help change social norms that promote the consumption of unhealthy foods. Can you unpack that? One study found that children pestered their parents to buy healthier products that did not have warning labels, partially because teachers at school would not accept unhealthy snacks. In some cases, teachers would even confiscate unhealthy snacks brought by children. This suggests that something as simple as a warning label can challenge the idea that ultra-processed products are desirable, and start to change the social norm. It’s also important to reiterate that warning labels are a highly cost-efficient approach because you’re able to target consumers rapidly, constantly, and at the point of decision making to make a purchase or not, with little to no cost to the government. And the costs of not addressing obesity during the pandemic could amount to $US 7 trillion by 2025, according to the latest review by the World Obesity Federation. Furthermore, out of a total of 2.5 million deaths from COVID reported as of February, 2021, 2.2 million were in countries where over half of the population is overweight. Countries with high proportions of overweight people had coronavirus death toll that were ten times higher than those with low proportions of overwheight people So far, six countries including Chile have legally mandated warning labels, although many have put in place “voluntary” systems. How well do the voluntary systems work ? The voluntary systems, which do not legally mandate warning labels on every single food product, are not effective. As warning labels may reduce sales of unhealthy foods, the food industry is unlikely to take them up. That’s why mandatory regulations on warning labels are crucial if we want to make a real dent into obesity and overweight. We’ve seen these warning labels work very well in Chile where they contributed to a decrease in the consumption of sugar-sweetened beverages by almost 25%. This was achieved through a comprehensive approach to addressing obesity, which also included: restrictions on child-directed marketing of unhealthy foods and beverages on the radio, television, cinema, and internet; a ban of unhealthy foods and beverages in schools and daycare; and a tax on sugary drinks. What kinds of labels work best? There are two broad categories of labels. The first category, the so-called “reductive” labels, outline how much of each nutrient is contained in foods, but they don’t help the consumer decide whether the product is healthy or not. These labels are less effective. The second category of labels, the so-called “interpretive” labels, are much more effective. They draw attention to the nutrients of concern or summarize the overall healthfulness of the product. Thus, they can help consumers distinguish between healthy and unhealthy products immediately through clear visual cues. The so-called “interpretive” labels can help consumers quickly identify nutrients of concern in food products to make healthier decisions What are the challenges to getting countries to act? Although a number of high-level commitments have been made to fight obesity, including the inclusion of a target in the SDGs , The UN High-Level Meetings on NCDs as well as the UN Decade of Action on Nutrition, a lot more can and needs to be done. But that said, there is very strong industry pushback, and that’s also not surprising. We have seen decades of this with regard to other issues like tobacco control. Industry pressure cannot be underestimated and industry interference is often what holds governments back. However, governments should not feel powerless to take on food policy. The tools are out there to help them do this effectively and cheaply. Are there any other policies that can be used alongside mandatory warning labels to cut obesity and overweight? Sugary drinks taxes are among the most effective and cost-efficient ways to reduce access to unhealthy foods. Marketing restrictions and the removal of misleading advertising, especially in schools and environments in which children reside, is crucial. Bans on unhealthy products in schools can also help. We also need to ensure that healthy food becomes the default option by making sure that it’s easily available and cheap enough to buy – and at the same time ensure that unhealthy foods like ultra-processed foods are less available. And as mentioned earlier, it’s important to change those social norms around unhealthy foods so that they’re not associated with what marketers want you to associate them with – families, warmth, love, sports – and all of the things that bring people together. Where do we go from here? And let’s be honest that food labels are not a panacea – what about access to healthier diets generally, which are often more expensive than unhealthy diets. And what about environments where people can be physically active? With more than one-third of the world’s population overweight or obese, and the COVID-19 pandemic revealing deep structural inequities in food environments, the push to combat obesity has become more urgent than ever. Many individuals are powerless in the face of food shortages and the over-availability of cheap ultra-processed foods. The onus is on governments to act, and to act now. There were a number of factors, from environmental, structural to social, that brought us where we are today, and we will likewise need a concerted and cohesive set of actions to reverse these trends. FoP warning labels are a strong place to start. Read more here on Vital Strategies’ new guide to help policymakers design and implement warning labels on foods and beverages. Trish Cotter, MPH, Global Lead, Food Policy Program and Senior Advisor, Vital Strategies Dr. Nandita Murukutla, Vice President for Global Policy and Research, Vital Strategies Image Credits: University of Michigan, World Obesity Federation, Vital Strategies, Food Standard Agency, Vital Strateggies, Vital Strategies. Nigeria Pivots From AstraZeneca To Johnson & Johnson COVID-19 Vaccine 31/03/2021 Paul Adepoju The Nigerian government has ditched the AstraZeneca COVID-19 vaccine and will soon shift to the Johnson & Johnson’s one-shot vaccine. EXCLUSIVE – IBADAN – The Nigerian government has quietly ditched the AstraZeneca COVID-19 vaccine meant to vaccinate tens of millions of citizens, and will gradually shift to the Johnson & Johnson’s one-shot vaccine, saying it is easier to administer. Documents from the Nigerian Primary Healthcare Development Agency (NPHCDA) obtained by Health Policy Watch show that the agency intends to begin rolling out the J&J vaccine to almost 30 million people as soon as it can obtain the vaccine supplies. While denying that safety concerns are an issue, the Nigerian government’s move also comes amidst growing global concerns about AstraZeneca’s efficacy against the SARS-CoV2 virus variant first identified in South Africa, as well as safety concerns that have led to the suspension of AstraZeneca vaccines for people under the age of 60 in Germany, and elsewhere (see related story). Nigeria had already commenced the rollout of the AstraZeneca vaccine, with vaccines supplied by the WHO co-sponsored COVAX initiative. The country was meant to get more AstraZeneca supplies though the African Medical Supplies Platform (AMSP) – having already placed the largest order on the continent through the AMSP, as previously confirmed by the Africa Centres for Disease Control (CDC). However, according to the documents, the AstraZeneca vaccine doses reserved through the AMSP will be replaced with Johnson & Johnson vaccines. “Based on this, Nigeria’s total allocation is now 29,850,000 of Johnson & Johnson (Janssen) COVID-19 vaccine which is one dose shot to cover 29,850,000 eligible Nigerians as originally planned,” the agency stated. That would be enough to cover about 15% of Nigeria’s population of 200 million people. Government Says J&J ‘One Jab’ Vaccine, not Safety Worries, Are Behind Shift Government officials in Nigeria attributed the shift to J&J’s to the vaccine’s single jab technology – which will make it much easier to administer as compared to AstraZeneca’s two-dose shot – as well as ensuring the vaccine coverage stretches even further. They denied that it was linked to issues of safety and efficacy. However, behind the scenes, another factor is the J&J vaccine’s documented efficacy against the B.1351 virus variant identified in South Africa – and now spread to some 16 other countries on the continent, including nearby Ghana. South Africa on Monday announced that it has secured 30 million J&J vaccines after a small clinical trial and genomic surveillance showed the AstraZeneca vaccine was not strongly effective against that variant. In an earlier advisory, the Africa CDC stated that African countries where the B.1351 variant is the predominant SARS-CoV-2 strain should consider swapping the AstraZeneca vaccine for others that have shown more efficacy. Neither the AMSP or the Africa CDC could confirm when the J&J doses will become available. A recently announced J&J commitment to supply some 400 million vaccines to Africa is only scheduled to get into motion in the third quarter of 2021. Meanwhile, the continent continues to call for vaccine equality, fair distribution and local vaccine production. Nigerian Regulator’s Nod Government officials have continued to assure citizens of the safety of the vaccine despite global concerns – as it continues to roll-out the available AstraZeneca doses while it awaits the J&J vaccines. On Feb 18, just a few days after Nigeria received its first shipment of the AstraZeneca vaccine, the country’s drug regulator, the National Agency for Food and Drug Administration and Control (NAFDAC) approved the vaccine for emergency use. “The recommendation for Emergency Use Authorization was based on rigorous scientific considerations,” NAFDAC stated. Addressing a recent webinar on COVID-19 Vaccines, Dr. Faisal Shuaib, Executive Director/CEO of NPHCDA, acknowledged that the controversy around the vaccine’s safety, but urged countries in Europe and globally to continue vaccine administration as it is safe and effective. Prof Mojisola Christianah Adeyeye, NAFDAC’s Director General added that safety of the vaccine is primary to the agency and that it would be using its Med Safety App for Active Pharmacovigilance of the vaccine. Immunisation Drive Continues As at March 31, over 718,000 Nigerians had received the first doses of the available AstraZeneca vaccine supplies; coverage ranges from an over-the-top 104% target of priority patients reached in Kwara state to none at all in Kogi state – where a vaccine-hesitant government is only just now succumbing to pressure to allow citizens to receive the vaccine. But a cross section of health experts speaking at the recent Nigerian Academy of Science webinar said the bad publicity around the AstraZeneca vaccine might also have harmed vaccination in general. Recent news emanating from Europe has made the general public more suspicious of the potential lethal effects of the jabs – in addition to widespread misinformation circulating on social media. Dr Yahya Disu, Head of Risk Communication at the Nigeria Center for Disease Control (NCDC), said recent surveys show broad acceptance of vaccines among Nigerians and this is expected to ensure the country quickly achieves herd immunity – provided sufficient vaccines are made available. Disu said 86% of respondents of the surveys said they would still continue preventive measures such as wearing face masks, handwashing and social distancing even after receiving the vaccines. Pfizer Vaccine ‘Safe and Protective’ for Adolescents – Early Data Release 31/03/2021 Chandre Prince Pfizer and its German partner BioNTech say their COVID-19 vaccine is safe and protective in children as young as 12. The Pfizer-BioNTech COVID-19 vaccine is safe and protective in children as young as 12 with no serious side effects in adolescents who received the vaccination, the company said on Wednesday. Interim results of a recent clinical trial of some 2,260 adolescents ages 12-15 years old was published by the pharma company – although it has not yet undergone peer review. The adolescents who participated in the trial produced strong antibody responses and experienced no serious side effects, the company said, saying the vaccine had demonstrated “100 % efficacy”. Pfizer and its German partner BioNTech plan to ask the U.S. Food and Drug Administration and European regulators to allow emergency use of the shots among adolescents, beginning at age 12. Pfizer’s vaccine is already authorised by regulatory authorities for teens ages 16 and older.“We share th e urgency to expand the use of our vaccine,” Pfizer CEO Albert Bourla said in a statement. He expressed “the hope of starting to vaccinate this age group before the start of the next school year” in the United States. Pfizer isn’t the only company seeking to lower the age limit for its vaccine. Results also are expected soon from a U.S. study of Moderna’s vaccine in 12- to 17-year-olds. Another vaccine study of safety and efficacy in children ages 6 months to 11 years is also underway, but that has yet to yield preliminary results. See the full release here. Germany Suspends Use of AstraZeneca For Younger Population Over Reports of Rare Blood Cloth Cases 31/03/2021 Chandre Prince German Health Minister Jens Spahn and German Chancellor Angela Merkel during a joint press conference announcing the suspension of the use of the AstraZeneca COVID-19 vaccine. Germany has suspended the use of the AstraZeneca coronavirus vaccine for people under the age of 60 amidst fresh concerns of unusual blood clot cases among some people receiving the vaccine, particularly women, and leading to the deaths of nine people in all. German Chancellor Angela Merkel and Health Minister Jens Spahn made the announcement on Tuesday after the country’s Standing Committee on Vaccination (STIKO) reviewed more data on emerging cases of rare blood clots in people immunised with the vaccine, produced by the Anglo-Swedish drug maker. Germany’s medical regulator made the call after researchers at the federal government’s Paul Ehrlich Institute, said they had recorded 31 cases of rare blot clot abnormalities, among the 2.7-million Germans who have thus far received the AstraZeneca vaccine. All cases were younger than 63, and all but two were women. The cases involved cerebral venous thrombosis (CSVT), a rare clot in blood draining from the brain, but also related to abnormally low levels of platelets, which help blood clot, and bleeding near the site of vaccination. “The experts of the Paul-Ehrlich-Institut now see a striking accumulation of a special form of very rare cerebral vein thrombosis (sinus vein thrombosis) in connection with a deficiency of blood platelets (thrombocytopenia) and bleeding in temporal proximity to vaccinations with the COVID-19 vaccine AstraZeneca,” said a news release of PEI, the Federal Institute for Vaccines and Biomedicines. Several German regions — including the capital Berlin and the country’s most populous state, North Rhine-Westphalia — had already suspended use of the shots in younger people earlier on Tuesday. Merkel said that the government “cannot ignore” STIKO’s recommendation or the data about blood clots developing following shots with the vaccine. Germany Has Other Vaccine Options For Younger People Germany has suspended the use of the AstraZeneca vaccine in people under 60 years of age. “We all know that vaccination is the most important tool against the coronavirus,” said Merkel, adding there were other options for younger people. “We are not faced with the question of AstraZeneca or no vaccine,” she said. “Instead we have several vaccines at our disposal.” Spahn said the vaccine would only be administered to people aged 60 or older, unless they belong to a high-risk category for serious illness from COVID-19 and have agreed to take the vaccine despite the small risk of a serious side-effect. “In sum it’s about weighing the risk of a side effect that is statistically small, but needs to be taken seriously, and the risk of falling ill with corona,” Spahn said during a press briefing. He said the decision was taken “on the basis of currently available data on the occurrence of rare, but very serious thrombosis-related side-effects.” The commission said that it would issue guidelines on what to do for adults under 60 who had received a first AstraZeneca shot and were due another by the end of April. Suspension – A Blow To Germany’s Vaccine Roll-out The decision to suspend use of the vaccine for under-60s was “without doubt a setback” for the vaccination campaign, in which the AstraZeneca vaccine was a centrepiece, Spahn acknowledged. It comes as Germany, along with other European countries, scrambles to ramp up its vaccine programme, which lags far behind those in Britain and the United States. By Monday, some 13.2 million people in Germany, a country of some 83 million people, had received at least one dose of one of Europe’s approved vaccines, while only 4 million had received two vaccine doses. Germany is due to receive 15 million more AstraZeneca doses in the second quarter of 2021. Spahn said the new supply would be made available to people over 60 who might otherwise have had to wait longer, reducing their risk of falling seriously ill with COVID-19. Germany’s U-turn On AstraZeneca Use of the AstraZeneca vaccine was temporarily halted in Germany, as well as in several other European countries, earlier this month when concerns about occurrences of the rare blood clots first emerged. Then, just under two weeks ago, the European Medicines Agency said that the vaccine is safe and that its benefits outweigh the risks, and the vaccine rollout in Germany and elsewhere in Europe resumed. Paradoxically, earlier in the vaccine rollout, Germany had refrained from administering the AstraZeneca vaccine to people 65 and over, citing insufficient evidence of its efficacy in that age group at the time. Other Countries Restrict Use of AstraZeneca On March 29, Canada’s vaccination committee also recommended suspending the AstraZeneca jab for people under 55, citing reports coming out of Europe of blood clotting incidents. France limited its use to people older than 55. Norway, where regulators say four people died of blood clots among about 120,000 people who received the AstraZeneca jab, has also suspended the vaccine. Sweden has resumed AstraZeneca use for people older than 65. The vaccine is not yet cleared for use in the United States. An independent panel of medical experts overseeing the US trials took the unusual move last week of accusing the company of providing an “incomplete view” of efficacy data in its U.S. trials. On Monday, Canada also recommended halting the use of the jab for people under 55 “pending further analysis”. Researchers Find Association with Clots; AstraZeneca says Vaccine is “safe and effective” The suspensions also come in the wake of a March 28 pre-print report from researchers in Germany, Canada and Austria, including a scientist at the Paul-Ehrlich-Institute, which linked the vaccine to the development of a blood clotting disorder. However, some academics have said that the paper’s implication of a causal association isn’t backed up by evidence. In a statement ahead of the announcement, AstraZeneca said tens of millions of people worldwide have received its vaccines. The company said it would would analyse its own records to understand whether the rare blood clots reported occur more commonly “than would be expected naturally in a population of millions of people.” Image Credits: Clemens Bilan. SARS-CoV2 Virus Origins Report – Only Beginning Of Process Says WHO; 14 Member States Call For More Transparency 30/03/2021 Elaine Ruth Fletcher The most important takeaway about the just-released WHO report on the origins of the SARS-CoV2 virus that has infected over 100 million people to date may not be its initial findings, which need to be held under the microscope, but the fact that it has been issued at all. Speaking at a press conference on Tuesday, WHO’s Peter Ben Embarek, who coordinated the politically fraught WHO mission to Wuhan, China in January and the report produced after the visit – stressed that it was the beginning of a process – and a quest. It will take much more time for the 17 members of the international expert committee – and the world – to unravel. Glass Half Full – Half Empty WHO press briefing Tuesday with members of the international team tasked with tracing the origins of SARS-CoV2 The weaknesses of the report are already apparent, say experts, whose views were shared confidentially with Health Policy Watch. The committee’s methodology for ranking some scenarios, like transmission through food products, as very likely, while ranking others, like a laboratory biosafety incident, as “extremely unlikely” was foggy, with no real objective criteria measurement cited. The team discounted too rapidly the possibility that the virus could have emerged from a lab biosafety accident at the Wuhan Virology Institute – world-famous for its study of bat coronaviruses that are the closest known relatives of SARS-CoV2. WHO’s Peter Ben Embarek, head of the SARS CoV2 origins task team. Asked at the press briefing, how the team decided to rank the probability of the four different theories it considered, Ben Embarek said that the method was debate and discussion among the team members until they reached a consensus. And so it was also no surprise that WHO DIrector General Dr Tedros Adhanom Ghebreyesus, was already walking back on one of the report’s key conclusions. In a closed-door briefing to WHO member states, that preceded the report’s public release, the WHO Director General stated: “Although the team has concluded that a laboratory leak is the least likely hypothesis, this requires further investigation, potentially with additional missions involving specialist experts, which I am ready to deploy… I do not believe that this assessment was extensive enough. Further data and studies will be needed to reach more robust conclusions.” Significantly, Tedros himself also did not appear at the WHO media briefing – but rather let Ben Embarek, a WHO food safety expert who coordinated the mission by the international expert team to China, appear as the single WHO interlocutor on the public stage. And not long after the press conference was finished, some 14 governments led by the United States, Australia and Canada, but also including Denmark, Japan, Norway, Korea and the United Kingdom, issued a joint statement expressing, “shared concerns regarding the recent WHO-convened study in China, while at the same time reinforcing the importance of working together towards the development and use of a swift, effective, transparent, science-based, and independent process for international evaluations of such outbreaks of unknown origin in the future.” The group of 14 member states complained about the fact that the study was “significantly delayed and lacked access to complete, original data and samples”, stating that going forward, there is a need for “further studies of animals to find the means of introduction into humans. “Going forward,” the member states added,”it is critical for independent experts to have full access to all pertinent human, animal, and environmental data, research, and personnel involved in the early stages of the outbreak relevant to determining how this pandemic emerged. With all data in hand, the international community may independently assess COVID-19 origins, learn valuable lessons from this pandemic, and prevent future devastating consequences from outbreaks of disease.” Half Empty -missing and incomplete data Among the specifics being raised by experts and observers in the wake of the report’s release are the following: Weak rationale for the team’s dismissal of a coronavirus laboratory escape. As the international team members admitted themselves in the WHO press briefing, they lacked the competencies to carry out a ful-fledged laboratory investigation. The Wuhan Virology Institute staff, told the WHO team that although researchers at the institute had sequenced the genome of the RaTG13 horseshoe bat virus, which is the closest known relative to SARS CoV2, researchers did not maintain live samples of the virus on hand at the institute. that claim sounds disingenuous, because such samples were indeed collected by the institute in 2013 from a horseshoe-bat colony in Yunnan province, where a group of miners had died in 2012 from a mysterious SARS-like illness. And the institute’s research into those same coronaviruses is a matter of scientific record. In addition, the WHO team did not have access to raw data on the virology institute’s inventory samples or to data on the health status of institute employees, or serological testing, was made available to the investigators. Early spread of the coronavirus in Wuhan – the WHO-mandated team did not get full access to clinical patient data from the earliest known patients, or to the genomic sequences of the viruses with whch they were infected. Serological data available from blood banks, which could have been examined in retrospective studies similar to those carried out on Italy to identify asymptomatic virus carriers, also was not made available by the Chinese authorities. Such data would be critical to understanding where and how widely the virus was circulating prior to December 2019. Despite that, as team member Marion Kooperman’s noted at the WHO press briefing – data that the team did access suggested that as of December, there were already several coronavirus strains circulating in the city. Spread through the food cold chain – the theory touted by the Chinese government of virus spread through imported frozen food products is termed as a “possible pathway” in the report – when in fact little real evidence exists that such contamination could have triggered the Wuhan pandemic, and the conclusion that it is even “plausible” lacks analytical rigour. Evidence about spread through an intermediate wild animal host -while highly plausible as a theory, remains very incomplete, with the mapping of animal supply chains and products only at the initial stages. Half Full – Key insights gleaned Dr. Peter Daszak – President of the EcoHealth Alliance Despite the shortcomings, committee members at the briefing stressed the new evidence that they had gathered, which provides a basis to push ahead with more studies. Chief among those is a direct line of supply chain provision of wild animal products from regions such as Yunnan province, which are known to harbour bat coronaviruses similar to the SARS-CoV2 – to the Huanan Market in Wuhan – where the most intensive cluster of initial cases first appeared. Mapping of stalls in Wuhan’s Huanan market that sold farmed wildlife products from rural regions that are coronavirus hotspots. “Some of the market stalls in the (Huanan Seafood) market in Wuhan were selling [wild animal] foods foods originating from wildlife farms in known coronavirus hotspots” elsewhere in China, said Ben Embarek, citing what is perhaps one of the most important findings of the study. “From the animal side, … the events began to fit together when we looked at the molecular data the epi data and the animal data – they all seemed to fit to form a big picture story about what likely happened, and I think that’s quite exciting,” added Peter Daszak, a leading team member and president of the EcoHealth Alliance. “From the outside, it would have been incredible to have a bat with the exact same lineage of viruses, we didn’t see that yet – that will come in the future I think. “What we did see on the animal side is clear evidence… that there was a pathway to that market and animals that we know are Coronavirus carriers, from places where the nearest related viruses are. What that does is it shows you there is a pathway, that this virus could have taken to move 800-1000 miles from the rural parts of South China, Southeast Asia, into this market, that was exciting to see.” Those insights are all the more critical as the world grapples with a rapid pace of ecosystem deterioration, and more industrialized forms of animal food production, which present considerable risks of virus emergence that need to be better understood by the public at large. Dr. Marion Koopmans, Dutch virologist and epidemiologist On the patient side, despite the Chinese authorities’ fragmented provision of patient and epidemiological data, the evidence culled by the team still remains clear. Already in December 2019, there were diverse strains of the SARS-CoV2 virus already circulating in the city – suggesting that that the infection had already made its way into the city’s population some time before. Said Marion Koopmans, a Dutch virologist and epidemiologist: “The SARS CoV-2 virus was circulating in the Wuhan market market in December 2019, but it was also circulating elsewhere in the city, in cases unrelated to each other,” she noted at the press briefing. . The team also noted that despite the multiple restrictions and barriers put up by Chinese governmental authorities – the atmosphere between scientists remained positive – creating what Ben Embarek called a “space” for the scientists to do their work. And despite considerable pressure from China to point the finger abroad, the team’s testimony makes it clear that the next research steps on the virus trail must be taken in Wuhan, China as well as in rural areas that harbor bat coronaviruses – rather than more far-flung parts of the world. Moving Ahead – Balancing Political and Scientific Pressure What remains is a long road ahead, requiring investment in more rigorous, and as some team members rightly noted – more expensive studies – based upon evidence-driven demands and requests to Chinese authorities for more detailed data – on both the food safety as well as the human epidemiological side of the virus coin. In light of the WHO Director General’s comments about the inadequate analysis of the laboratory biosafety risks – it is also likely that WHO member states in Europe or the Americas (read USA), may demand a fresh query into that hypothesis – involving actual biosafety experts who were not members of the original virus origins team. Ultimately, It will be up to the WHO member states that mandated the report, informed by outside, independent experts and observers, to nurse the origins study – or studies – through to more significant, and final conclusions. In that quest, Europe, the United States and their allies will need to steer a delicate course between exertion of the right amount of political pressure on the one hand – and alienating attacks that only foster anger and geopolitical tensions of the kind visibly on display during the era of former US President Donald Trump. And from the point of view of scientists – It is a process that may require months, if not several years – WHO’s Ben Embarek warned. “”How long will it take? That is always difficult to predict.” he said, pleading with the world to “please be patient.” Although, despite the heat that the WHO team has received, his appeal was shadowed with appreciation for the fact that a certain amount of vigilance – may also be constructive: “It’s an exciting adventure that I hope the whole world will continue to follow.. it’s a fascinating journey and a critical one because it’s the only way we can understand what happened, and more recently tried to prevent something similar for happening again.” Image Credits: Sputnik, WHO. Global Leaders Call For New Treaty To Bolster Resilience Against Future Pandemics 30/03/2021 Svĕt Lustig Vijay Charles Michel, President of the European Council After the COVID-19 pandemic exposed fundamental flaws in the global health architecture, a proposal for a new pandemic treaty that could strengthen the world’s capacity to contain the current pandemic and prepare for future ones, is gaining momentum. That was a key message at a World Health Organization (WHO) launch of an open letter by 25 global leaders calling for the world to negotiate such a treaty, featuring Charles Michel, President of the European Council, and two dozen other global leaders that are now backing the treaty initiative. Other signatories now include the United Kingdom’s Boris Johnson, Germany’s Angela Merkel, France’s Emmanuel Macron, along with the leaders of Indonesia, Kenya, Rwanda and South Africa’s Cyril Ramaphosa. But China, the United States and Russia have yet to sign the call. “Today, we are calling for an international treaty on pandemics [to] foster a comprehensive approach to better predict, prevent and respond to pandemics,” said Michel, who has championed the treaty since late last year saying that the treaty would support the principle of “health for all”. If ratified, the treaty will give the WHO the political clout to better carry out part of its mandate in terms of improved pandemic alert systems, better investments in coronavirus research, and sharing of crucial data on infectious pathogens, vaccine supply chains and vaccine formulas. WHO’s director-general Dr. Tedros Adhanom Ghebreyesus echoed Michel’s sentiments, saying: “The time to act is now”. “The world cannot afford to wait until the pandemic is over to start planning for the next one. We cannot do things the way we have done them before and expect a different result. Without an internationally coordinated response…we remain vulnerable,” said Dr Tedros. Pandemic Treaty Rooted In WHO Constitution No single country can address pandemics alone. An international #PandemicTreaty would promote a global system to better prevent, predict & recover from future pandemics like #COVID19. Find out more on why we need a new treaty on pandemics ➡️https://t.co/iY2qUGLcPn pic.twitter.com/YkEL0LEzKl — EU Council (@EUCouncil) March 30, 2021 The treaty “would be rooted in the constitution of the World Health Organisation, drawing in other relevant organizations key to this endeavour,” said the letter, also signed by the heads of: Albania, Chile, Costa Rica, Greece, Korea, Trinidad and Tobago, the Netherlands, Senegal, Spain, Norway, Serbia, Indonesia, and Ukraine. “Existing global health instruments, especially the International Health Regulations, would underpin such a treaty, ensuring a firm and tested foundation on which we can build and improve.” The Pandemic Treaty Will Strengthen WHO’s Mandate According to Michel, “Such a treaty [could] play an interesting role in order to make sure that we have more transparency on the supply chains [and] on the level of productions of vaccines and of tests; it will mean more rust and better cooperation.” Michel suggested that the treaty could also be used to expand vaccine production by facilitating technology transfer in low- and middle-income countries, referring to the “third way” initially proposed by the World Trade Organisation’s (WTO) new chief Ngozi Okonjo-Iweala. “Certainly there is a debate in the international community about how to improve our vaccine production capacities to improve vaccine coverage, particularly in the African continent,” said Michel, adding that “we are closely following the debate at the WTO for the ‘third way’ voiced by Ngozi”. US and China Didn’t Sign Call – But Sent Positive ‘Comments’ WHO’s director-general Dr. Tedros Adhanom Ghebreyesus Although China and the US did not sign Tuesday’s op-ed, Dr Tedros said that that both countries had voiced “positive” comments during informal discussions with Member States – and that it was not necessarily an issue that the op-ed had only been signed by two dozen countries. “It doesn’t need to be all 194 countries [to write an op-ed],” said Dr. Tedros. “I don’t want it to be seen as a problem, it wasn’t even a problem. When the discussion on the global pandemic treaty starts, all Member States will be represented.” The Pandemic Treaty Will Synergize With The International Health Regulations Meanwhile, Mike Ryan, WHO’s Director of Emergency Programmes, emphasised that the treaty would “by no means” undermine the existing global framework that governs WHO countries’ behaviour during health emergencies – the legally binding International Health Regulations (IHRs). These regulations set out the mandates under which countries are obliged to report on disease outbreak risks, and share epidemic information, with WHO and other member states. Rather, the pandemic treaty would generate the necessary political commitment to ensure that the IHRs are implemented; and bolster global pandemic preparedness and response by covering a broader set of issues than those covered by the IHRs, such as the sharing of crucial data. “The IHRs…is a really really good instrument,” said Ryan. “But in itself [it] is a piece of legislation that is without meaning unless countries are fully committed to its implementation.” “IHR only works if we have trust, if we have transparency, if we have accountability. Such a treaty would provide that political framework in which we in public health can do our work much more effectively.” “The proposed treaty will definitely bring strong political commitment and support for the IHR implementation,” added Jaouad Mahjour, WHO Regional Director for the Eastern Mediterranean region, who also spoke at Tuesday’s press conference. In an initial response to the initiative, the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) said that pharma partners should play a role in shaping such a treaty. The statement reflected IFPMA concerns over preserving what it described as the patent “incentive system” for developing new vaccines and medicines. “The discussions around a possible International Pandemic Treaty need to take into account the important role played by the innovative biopharmaceutical industry and its supply chain in fighting the virus,” said the IFPMA statement. “It will be important to acknowledge the critical role played by the incentive system in developing tests, therapeutics, and vaccines to contain and defeat the coronavirus. We hope that the discussions on an International Pandemic Treaty will address enablers for future pandemic preparedness – the importance of incentives for future innovation, the immediate and unrestricted access to pathogens, and the importance of the free flow of goods and workforce during the pandemic – in addition to continuing the multi stakeholder approach undertaken in ACT-A and COVAX.” Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
The Clock Is Ticking For Vaccine Equity, But WHO Remains Hopeful 01/04/2021 Svĕt Lustig Vijay Dr. Tedros Adhanom Ghebreyesus, WHO Director General, at the press briefing on Thursday. The World Health Organization (WHO) is hopeful that all healthcare workers can be vaccinated by mid-April, but the clock is ticking away, leaving rich countries only nine days to donate surplus COVID-19 vaccines to the global COVAX facility – which has run out of doses at a crucial time. So far, the WHO has not received any donations since it called on countries last week to donate surplus doses they have accumulated, said Dr. Tedros Adhanom Ghebreyesus at a press conference on Thursday. “Last week, I made an urgent request to countries with surplus vaccines that have WHO emergency use listings to share 10 million doses with COVAX,” said Dr. Tedros. “This challenge has been heard, but we’re yet to receive commitments for those. I’m still hopeful that some forward looking and enlightened leaders will step up.” COVAX Facing “Serious Challenges” Although the global COVAX facility has already delivered 35 million doses to more than 78 countries across the globe, it is facing “serious” shortfalls in doses – mainly because of India’s recent move to halt vaccine exports to the rest of the world as it attempts to fend off an outbreak that has grown to some 70,000 cases a day from only 15,000 since early March – an increase in cases by a factor of four in just a month. Despite the WHO’s call on rich countries and vaccine manufacturers to donate surplus vaccine doses last week, a whopping 100 countries still lack adequate access to vaccines, said Turkey’s Health Minister Fahrettin Koca, who also spoke at the press conference. Of those, two dozen countries that have signed up to the WHO co-sponsored COVAX initiative are ready to begin vaccinating healthcare workers – but they lack the supplies to begin before the 100th day of 2021 – the target date WHO had said for vaccine campaigns to start everywhere in the world. These include Cameroon, Haiti, Congo, Burkina Faso, Niger, Vanuatu, Papua New Guinea, Kyrgyzstan, the Dominican Republic and Mauritania, among others. “I know this is a challenging time for many countries as cases and hospitalization are spiking, but conversely, it’s when cases are spiking that it’s the most important time to share vaccines equitably and protect our workers, and at-risk communities,” Dr Tedros said. Going forward, the concerning gaps in equity “could be addressed” by increasing local and regional vaccine production capacity and by moving forward on the intellectual property waiver spearheaded by South Africa and India, said the WHO Director General. “I think we should be able to produce vaccines everywhere, all over the world without intellectual property rights being a problem,” added Koca. “So that’s why I think we need to be taking concrete steps about this issue.” Turkish Health Minister Fahrettin Koca at the press briefing on Thursday. Turkey Announces Digital Platform To Commemorate Healthcare Workers Meanwhile, in celebration of the International Year of Health and Care Workers, Koca announced the creation of a digital platform to tell the stories of the heroic and essential work carried out by healthcare workers since the pandemic began. The platform will be run in collaboration with WHO. “The whole of humanity is grateful to you right now,” said Koka. “[Your] stories need to be told in the common language of humanity. For this purpose, as a first step, we are working on creating a digital platform with WHO, to serve as a memorial dedicated to health and care workers.” Since the start of the pandemic, millions of healthcare workers have been infected with the coronavirus and thousands have died. Those that have survived are struggling with a range of mental health issues, including heightened stress, anxiety, depression, insomnia, and exhaustion. That toll, said Dr Tedros, has been far too great – but it can be reversed by strengthening the capacity of the healthcare workforce, improving salaries, and ensuring healthcare workers are equipped with adequate personal protective equipment so they can do their job safely and effectively. “Far too many health and care workers have died in the pandemic,” he said. “As we work to end the pandemic and recover together….We must ensure that they are trained, protected, and supported to do their job safely and effectively.” Image Credits: Our World In Data, WHO. DNDi Strategy For The Decade: Delivering And Developing Treatments For Neglected Tropical Diseases 01/04/2021 Raisa Santos A man with symptoms of the deadly NTD African trypanosomiasis (sleeping sickness), is examined by Dr Victor Kande in the Democratic Republic of Congo (DRC). Kande was principle investigator for clinical trials of fexinidazole, the first oral sleeping sickness treatment approved by the European Medicines Agency (EMA) in 2018. Developed by DNDi, it is being rolled out in DRC. Global health experts expressed their frustration with the lack of research and attention towards neglected tropical diseases (NTDs) and vulnerable populations, calling for health systems to address NTDs in a more sustainable and holistic way. Speaking at the launch of a new strategic plan for the Geneva-based Drugs for Neglected Diseases initiative (DNDi) on Tuesday, DNDi Executive Director Bernard Pécoul said greater emphasis should be placed on expanding access and developing treatments for patients in low- and middle-income countries (LMICs) affected by neglected tropical diseases (NTDs), as well as neglected viral diseases like HIV/AIDS, and also pandemic-prone and climate-sensitive diseases. “Treatments were abandoned for years or decades because they fell outside commercial markets,” said Pécoul, at the launch of the plan that charters an eight-year journey to 2028, aiming to deliver 15 – 18 additional treatments, in addition to eight already developed, for a total of 25 new or improved, and highly effective, NTD treatments. “The frustration is where the idea was born – from the experience of humanitarian doctors, frustrated, while treating patients with vaccines that were ineffective, unsafe, or unaffordable, or never developed at all because the research and development was abandoned,” Pecoul added, speaking of his own experience in the past working with Medecins Sans Frontieres (MSF). DNDi, a WHO-supported organization of private and public sector actors, has committed to five strategic imperatives for the next eight-years: to deliver new treatments and expand access for neglected patients of NTDs and related viral diseases; join with public health leaders and Research and Development (R&D) stakeholders in low- and middle-income countries to advance sustainable health systems; contribute to building a proactive agenda for maternal, child health, and gender-responsive R&D; champion open science and transparency; and leverage new technologies to accelerate R&D. “It is our hope that we will identify safe, effective, and affordable medicines to help countries fight the health and social burden put on them by COVID-19. While all global attention is focused on development and purchase of COVID-19 vaccines, we should not forget about treatment and diagnostics,” said Marie-Paule Kieny, Director of Research, INSERM and DNDi Board Chair, at the Tuesday DNDi launch. Challenging The Status Quo DNDi’s Strategic Plan launch event panel: clockwise: Patricia Amira, moderator; Dr Somya Swaminathan; Dr Marie-Paule Kieny; Dr Jeremy Farrar; Dr Bernard Pecoul; Dr Berhards Ogutu Also appearing at the event, Jeremy Farrar, director of the Wellcome Trust. also expressed frustration with the ‘status quo’ that has defined R&D for global health, and called for more attention to be brought to three areas that would ‘define the 21st century’ – neglected and infectious disease, climate change, and mental health. “These three things are going to define our time – which have a focus on youth, and which have an inequitable impact on societies around the world. [DNDi is committed to] not just doing the science, but making sure that science is shared equally with everybody in the world,” he said. Over the next decade, DNDi will work to accelerate sustainable disease elimination in diseases with existing treatments, such as sleeping sickness and Chagas disease, and increase access to lifesaving and safer treatments for HIV and leishmaniasis. DNDi – founded in 2003 to discover, develop, and deliver safe, effective, and affordable treatments for neglected and marginalized patients – will also work with leaders and institutions in LMICs to bolster research capacity and generate more sustainable production and supply of NTD treatments. The initiative has grown into a network of over 200 partner institutions, and has so far delivered eight new treatments for people with sleeping sickness, visceral leishmaniasis, Chagas disease, HIV, and malaria. Clinical Trials for Mild COVID Cases Launching in 13 African Countries Africa launches largest COVID clinical trial COVID-19 has highlighted the need to prioritize and finance research in LMICs, as well as government preparedness to ensure both transparency and equitable access. In addition to working on NTDs and viral illnesses, DNDi will also address unmet medical needs, utilizing its ‘dynamic portfolio’ approach to explore new interventions in diseases with clear R&D gaps, including snakebite, dengue fever, schistosomiasis, and pandemic-prone diseases. At the start of the strategic planning period, DNDi also is coordinating ANTICOV – the largest African-led clinical trial testing for mild-to-moderate COVID-19. The ANTICOV platform deals with the outpatient population, which is the majority of people with COVID, and is trying to answer the question of how to treat people to prevent them from getting ill and needing hospitalization, said Dr Soumya Swaminathan, WHO Chief Scientist. Carried out by a group of 26 prominent African and global R&D organizations in 13 countries, ANTICOV will simultaneously test and adjust treatments for COVID-19, and identify new treatments, fast-tracking research for patients and health systems in resource-limited settings. Swaminathan said that the high costs of the COVID-19 pandemic should not come at the expense of cutting or reducing budgets for NTDs, saying that the ‘collaborative science’ seen over the past year as proof that knowledge could be shared openly and freely. “Because of this vision, and the collective mission to solve the problem of COVID and develop new tools, it is possible to [share knowledge more widely].” Though DNDi is primarily focused on R&D, the organization will also identify gaps in access to care, and build the partnerships needed to overcome them, laying the groundwork for more affordable care. Said Swaminathan: “When there’s a new technology, which can make a big impact, especially when it’s related to health and disease, it should be considered a global public good, and be made available to people who need it, regardless of their ability to pay.” Image Credits: DNDi, DNDi, ClimateWed/Twitter. France Enters Third Lockdown, While Europe’s Vaccine Rollout Is Critiqued As “Unacceptably Slow” 01/04/2021 Madeleine Hoecklin A patient getting tested for COVID-19 at the Paris Charles de Gaulle Airport in January 2021. French President Emmanuel Macron imposed strict lockdown measures amid of surge of new coronavirus cases. France is going into its third national lockdown since the start of the COVID-19 pandemic, after a deadly third wave hit Europe, causing soaring infection and death rates. With an average of more than 37,000 daily new cases over the past week, tougher restrictions have become inevitable. French President Emmanuel Macron announced the new restrictions in a televised address on Wednesday, saying that the government had waited “until the last moment” to impose the latest lockdown. The daily death toll reached 355 on Wednesday and health authorities recorded 569 new intensive care patients in 24 hours on Tuesday, the highest since April 2020. Over 5,000 COVID-19 patients are currently in intensive care units. Infections have doubled since February, likely due to the spread of the more transmissible B.1.1.7 SARS-CoV2 variant, first detected in the United Kingdom. France “risks losing control” without strict measures, said Macron. France is approaching the grim milestone of 100,000 total COVID deaths, with 95,798 deaths recorded as of Wednesday. Lockdown Measures Put in Place Lockdown restrictions include classes being taught remotely for the next three weeks, non-essential businesses will be closed, and travel within the country will be banned for a month after the Easter weekend (2-4 April). Residents will be limited to a 10 kilometer radius from their homes and will be subject to a curfew between 7pm and 6am. “We must limit all contact as much as we can, including family gatherings. We know now: these are where the virus spreads,” said Macron. Some 3,000 additional intensive care beds will be added to hospitals in the hardest-hit regions in an attempt to prevent health systems from becoming overwhelmed. The national lockdown will begin on Saturday and will last four weeks. Emmanuel Macron, the French President, in a televised address on Wednesday announcing the country’s third COVID-19 lockdown. Over a dozen regions were put under partial lockdown in early March with night-time curfews. The regional restrictions avoided closing schools or stores in an effort to keep the economy open. The existing restrictions at the regional level, which were implemented in early March in an attempt to avoid stricter measures, were unable to curb the spread of the virus. Macron was hesitant to impose nationwide restrictions, resisting calls from experts for tougher measures since January. “The outlook is worse than frightening. We’re already at the level of the second wave, and we’re quickly getting close to the threshold of the first wave,” said Jean-Michel Constantin, head of the intensive care unit at the Pitié-Salpêtrière hospital in Paris, in an interview on RMC radio on Monday. According to the French Health Minister, Olivier Veran, France could reach the peak of the epidemic in seven to 10 days, “then we need two extra weeks to reach a peak in intensive care units (ICUs) that could occur at the end of April,” he told Inter radio on Thursday. “We have endured a year of suffering and sacrifice, but if we stay united and organized, we will reach the end of the tunnel,” said Macron. “April will be a critical month.” France’s vaccination campaign is seen as the path out of the pandemic and will be accelerated in the coming weeks, according to Macron. France, along with the rest of the European Union, was plagued by a slow rollout of vaccines due both to shortages as well as a lack of a well-coordinated health sector response in many countries, with systems that are either highly fragmented or else too centralized to permit for smooth and efficient rollouts at the local level. WHO Calls Europe’s Vaccination Program “Unacceptably Slow” Amidst rising infection and death rates in the WHO European region, which encompasses 53 countries, the region’s vaccine “rollout is unacceptably slow,” said Hans Kluge, the WHO Regional Director for Europe, in a statement released on Wednesday. Europe has recorded 1.6 million new cases and close to 24,000 deaths in the last week, quickly nearing one million total deaths. It is the second most affected region by SARS-CoV2 in the world. The B.1.1.7 variant has a greater public health impact and requires numerous measures in place to control it, said the statement. Currently, 27 countries in Europe are under partial or nationwide lockdown and 23 have tightened restrictions over the past two weeks. However, some 13 countries have ease measures and nine plan to follow suit. “My message to governments in the region is…that now is not the time to relax measures. We can’t afford not to heed the danger,” said Kluge. “We must keep reining in the virus.” Hans Kluge, WHO Regional Director for Europe. “Vaccines present our best way out of this pandemic,” Kluge said. However, “as long as coverage remains low, we need to apply the same public health and social measures as we have in the past to compensate for delayed schedules.” In addition to implementing public health measures to limit transmission, efforts must be made to scale up vaccine production and administer as many jabs as possible, as quickly as possible. “We must speed up the process by ramping up manufacturing, reducing barriers to administering vaccines, and using every single vial we have in stock, now,” said Kluge. Only 10% of the region’s population have received one dose of a COVID-19 vaccine. While there has been a shortage of vaccines, countries must avoid vaccine nationalism and hoarding supplies, the statement said. Once a nation’s healthcare workers and vulnerable individuals have been vaccinated, Kluge urged governments to “share excess doses of WHO-approved vaccines with COVAX or with countries in need” in order to ensure that healthcare workers and older individuals in every country are inoculated. This message was echoed by Dr Tedros Adhanom Ghebreyesus, WHO Director-General, at a press conference on Thursday, who made an “urgent request to countries with surplus vaccines that have WHO emergency use listings to share 10 million doses with COVAX.” In order to reach the goal of vaccinating all healthcare workers in the first 100 days of 2021, rich countries have nine days remaining to to donate excess doses to the COVAX facility, which has run out of doses at a critical time. WTO Head Says Pharma Companies Should Either Scale Up Manufacturing Or Share Know-How with LMICs Meanwhile, the new Director-General of the World Trade Organization (WTO), Ngozi Okonjo-Iweala, called it “unacceptable” that low- and middle-income countries (LMICs) were being left at the “end of the queue” for COVID-19 vaccines. “The kind of inequities we see in vaccine access are really not acceptable, you can’t have a situation in which…10 countries have administered 70% of vaccine doses in the world, and there are countries that don’t have one single dose,” said Okonjo-Iweala at a WTO trade forecast press conference on Thursday. Ngozi Okonjo-Iweala, Director-General of the WTO, at a press conference on Thursday. She urged pharma companies to follow AstraZeneca’s lead in making deals with production facilities in LMICs to expand the manufacturing capacity for their vaccines. “Let’s have the same kind of arrangement that AstraZeneca has with the Serum Institute of India,” the world’s largest vaccine manufacturer and the main source of COVID-19 vaccines for LMICs, Okonjo-Iweala said. Voluntary licensing of technology could begin to address the inequity in access to vaccines, she said. While an intellectual property waiver for certain COVID-19 tools and technology – designed to allow more drug manufacturers to make the vaccines and improve access – is under consideration by WTO member states, Okonjo-Iweala said this was an issue for the next pandemic. Instead of pursuing the WTO TRIPS waiver, the focus now to meet the threat from COVID should be put on enlarging manufacturing capacity, she said. Image Credits: France24, Flickr – International Monetary Fund, BBC. A Good Place To Start To Beat The COVID Obesity Pandemic – Warning Labels on Unhealthy Foods 01/04/2021 Svĕt Lustig Vijay The obesity pandemic is in “the same room” as the COVID pandemic in terms of its threats to health – putting people at greater risk of premature death from multiple causes, including SARS-CoV-2, the virus that leads to COVID-19. And ever since stay-at-home measures became routine, people have gained even more weight – up to 1.5 pounds a month according to one recent US study. Yet countries have the tools to address obesity, note Trish Cotter and Dr. Nandita Murukutla at Vital Strategies, a global public health NGO. We spoke to Ms. Cotter and Dr. Murukutla to find out more: Health Policy Watch (HPW): A third of the global population now suffers from overweight, and rates of obesity are growing across the world, including in poor countries. How can we explain these trends? Vital Strategies (VS): Over the last 40 years, obesity rates around the world have ballooned. High-income countries, like the United States, were the first to experience substantial weight gains of their populations, but the 21st century has seen that phenomenon spread to all parts of the globe. Now, the average adult is three times as likely to be overweight as the average adult in the 1970s. There are a number of reasons for this alarming trend, which began well before COVID-19, starting with the environments in which people live, as well as poverty, discrimination, increasing availability of unhealthy foods in schools, dwindling levels of physical activity, and a lack of knowledge of unhealthy diets and products. However, the fundamental reason is the rapid change in our diets and the broader food environment. Ultra-processed products or “junk food”, such as soft drinks, ice creams, or prepared frozen dishes, are one of the key drivers of growing obesity worldwide. They are high in sugar, salt and fat and, unfortunately, widespread in most societies. Yet their harmful effects are poorly understood. One in three people worldwide are overweight HPW: Why are ultra-processed foods so ubiquitous? VS: They are cheap, easily available, and because of additives and preservatives, they have a long shelf-life. They’re made to feel and look attractive, and they’re made to taste good. Importantly, they’re also hyper-marketed by the food industry. Advertising campaigns are very good at making unhealthy products seem part of the fabric of society: unhealthy foods are made to seem crucial to family gatherings and entertainment, so they become part of the social norm that normalizes unhealthy foods. And much of the advertising around unhealthy foods is so enticing that it gets children hooked at a young age. In what ways is advertising of ultra-processed products misleading? Unhealthy products are often marketed cleverly as convenient substitutes for healthy, minimally processed options that include whole grains, fruits and vegetables. They are marketed as convenient breakfast foods, snacks, juices, and sometimes they are also marketed as being more sanitary than fresh fruits and vegetables. But that’s misleading, because current evidence demonstrates that ultra-processed products result in worse diets and ultimately overweight and obesity, which exacerbates the risk of contracting a range of chronic diseases as well as suffering poorer outcomes from infectious diseases like COVID-19. Claims that ultra-processed products are healthy alternatives are untrue. Can you give a concrete example of a strategy that misleads customers into thinking they’re buying healthy products? Labels on the front and back of food packages are often really hard to accurately decode. And many of these labels use clever algorithms to hide unhealthy levels of sugar, salt, and saturated fat. Customers may not always realize that the product they are buying is unhealthy. Late last year, you co-authored a guide to help policymakers introduce clear, yet highly effective warning labels on foods and beverages to nudge customers away from unhealthy foods. How do these warning labels work? Front-of-Package (FOP) nutrient labels, sometimes called warning labels, tell consumers immediately, on the front of products, and simply when a product contains high levels of unhealthy nutrients. That means customers don’t need to spend several minutes trying to work out whether each product is healthy or not. This system is simple, visual, and easy to understand. And it is effective, as seen from studies across the world, in triggering immediate behavior change. The front-of-package labels serve as behavioral nudges, protecting people from making unintended unhealthy purchases. In other words, the warning labels work by reminding consumers that the products they are purchasing are unhealthy, thus nudging them to make healthier choices. But they also have important knock-on effects: they help change social norms around unhealthy eating. Example of warning labels on food products in Chile to nudge customers away from unhealthy foods. Translation from top-left to bottom-right: high in calories; high in sugars; high in sodium; high in saturated fats. Source: Ministry of Health of Chile. You mentioned that warning labels can help change social norms that promote the consumption of unhealthy foods. Can you unpack that? One study found that children pestered their parents to buy healthier products that did not have warning labels, partially because teachers at school would not accept unhealthy snacks. In some cases, teachers would even confiscate unhealthy snacks brought by children. This suggests that something as simple as a warning label can challenge the idea that ultra-processed products are desirable, and start to change the social norm. It’s also important to reiterate that warning labels are a highly cost-efficient approach because you’re able to target consumers rapidly, constantly, and at the point of decision making to make a purchase or not, with little to no cost to the government. And the costs of not addressing obesity during the pandemic could amount to $US 7 trillion by 2025, according to the latest review by the World Obesity Federation. Furthermore, out of a total of 2.5 million deaths from COVID reported as of February, 2021, 2.2 million were in countries where over half of the population is overweight. Countries with high proportions of overweight people had coronavirus death toll that were ten times higher than those with low proportions of overwheight people So far, six countries including Chile have legally mandated warning labels, although many have put in place “voluntary” systems. How well do the voluntary systems work ? The voluntary systems, which do not legally mandate warning labels on every single food product, are not effective. As warning labels may reduce sales of unhealthy foods, the food industry is unlikely to take them up. That’s why mandatory regulations on warning labels are crucial if we want to make a real dent into obesity and overweight. We’ve seen these warning labels work very well in Chile where they contributed to a decrease in the consumption of sugar-sweetened beverages by almost 25%. This was achieved through a comprehensive approach to addressing obesity, which also included: restrictions on child-directed marketing of unhealthy foods and beverages on the radio, television, cinema, and internet; a ban of unhealthy foods and beverages in schools and daycare; and a tax on sugary drinks. What kinds of labels work best? There are two broad categories of labels. The first category, the so-called “reductive” labels, outline how much of each nutrient is contained in foods, but they don’t help the consumer decide whether the product is healthy or not. These labels are less effective. The second category of labels, the so-called “interpretive” labels, are much more effective. They draw attention to the nutrients of concern or summarize the overall healthfulness of the product. Thus, they can help consumers distinguish between healthy and unhealthy products immediately through clear visual cues. The so-called “interpretive” labels can help consumers quickly identify nutrients of concern in food products to make healthier decisions What are the challenges to getting countries to act? Although a number of high-level commitments have been made to fight obesity, including the inclusion of a target in the SDGs , The UN High-Level Meetings on NCDs as well as the UN Decade of Action on Nutrition, a lot more can and needs to be done. But that said, there is very strong industry pushback, and that’s also not surprising. We have seen decades of this with regard to other issues like tobacco control. Industry pressure cannot be underestimated and industry interference is often what holds governments back. However, governments should not feel powerless to take on food policy. The tools are out there to help them do this effectively and cheaply. Are there any other policies that can be used alongside mandatory warning labels to cut obesity and overweight? Sugary drinks taxes are among the most effective and cost-efficient ways to reduce access to unhealthy foods. Marketing restrictions and the removal of misleading advertising, especially in schools and environments in which children reside, is crucial. Bans on unhealthy products in schools can also help. We also need to ensure that healthy food becomes the default option by making sure that it’s easily available and cheap enough to buy – and at the same time ensure that unhealthy foods like ultra-processed foods are less available. And as mentioned earlier, it’s important to change those social norms around unhealthy foods so that they’re not associated with what marketers want you to associate them with – families, warmth, love, sports – and all of the things that bring people together. Where do we go from here? And let’s be honest that food labels are not a panacea – what about access to healthier diets generally, which are often more expensive than unhealthy diets. And what about environments where people can be physically active? With more than one-third of the world’s population overweight or obese, and the COVID-19 pandemic revealing deep structural inequities in food environments, the push to combat obesity has become more urgent than ever. Many individuals are powerless in the face of food shortages and the over-availability of cheap ultra-processed foods. The onus is on governments to act, and to act now. There were a number of factors, from environmental, structural to social, that brought us where we are today, and we will likewise need a concerted and cohesive set of actions to reverse these trends. FoP warning labels are a strong place to start. Read more here on Vital Strategies’ new guide to help policymakers design and implement warning labels on foods and beverages. Trish Cotter, MPH, Global Lead, Food Policy Program and Senior Advisor, Vital Strategies Dr. Nandita Murukutla, Vice President for Global Policy and Research, Vital Strategies Image Credits: University of Michigan, World Obesity Federation, Vital Strategies, Food Standard Agency, Vital Strateggies, Vital Strategies. Nigeria Pivots From AstraZeneca To Johnson & Johnson COVID-19 Vaccine 31/03/2021 Paul Adepoju The Nigerian government has ditched the AstraZeneca COVID-19 vaccine and will soon shift to the Johnson & Johnson’s one-shot vaccine. EXCLUSIVE – IBADAN – The Nigerian government has quietly ditched the AstraZeneca COVID-19 vaccine meant to vaccinate tens of millions of citizens, and will gradually shift to the Johnson & Johnson’s one-shot vaccine, saying it is easier to administer. Documents from the Nigerian Primary Healthcare Development Agency (NPHCDA) obtained by Health Policy Watch show that the agency intends to begin rolling out the J&J vaccine to almost 30 million people as soon as it can obtain the vaccine supplies. While denying that safety concerns are an issue, the Nigerian government’s move also comes amidst growing global concerns about AstraZeneca’s efficacy against the SARS-CoV2 virus variant first identified in South Africa, as well as safety concerns that have led to the suspension of AstraZeneca vaccines for people under the age of 60 in Germany, and elsewhere (see related story). Nigeria had already commenced the rollout of the AstraZeneca vaccine, with vaccines supplied by the WHO co-sponsored COVAX initiative. The country was meant to get more AstraZeneca supplies though the African Medical Supplies Platform (AMSP) – having already placed the largest order on the continent through the AMSP, as previously confirmed by the Africa Centres for Disease Control (CDC). However, according to the documents, the AstraZeneca vaccine doses reserved through the AMSP will be replaced with Johnson & Johnson vaccines. “Based on this, Nigeria’s total allocation is now 29,850,000 of Johnson & Johnson (Janssen) COVID-19 vaccine which is one dose shot to cover 29,850,000 eligible Nigerians as originally planned,” the agency stated. That would be enough to cover about 15% of Nigeria’s population of 200 million people. Government Says J&J ‘One Jab’ Vaccine, not Safety Worries, Are Behind Shift Government officials in Nigeria attributed the shift to J&J’s to the vaccine’s single jab technology – which will make it much easier to administer as compared to AstraZeneca’s two-dose shot – as well as ensuring the vaccine coverage stretches even further. They denied that it was linked to issues of safety and efficacy. However, behind the scenes, another factor is the J&J vaccine’s documented efficacy against the B.1351 virus variant identified in South Africa – and now spread to some 16 other countries on the continent, including nearby Ghana. South Africa on Monday announced that it has secured 30 million J&J vaccines after a small clinical trial and genomic surveillance showed the AstraZeneca vaccine was not strongly effective against that variant. In an earlier advisory, the Africa CDC stated that African countries where the B.1351 variant is the predominant SARS-CoV-2 strain should consider swapping the AstraZeneca vaccine for others that have shown more efficacy. Neither the AMSP or the Africa CDC could confirm when the J&J doses will become available. A recently announced J&J commitment to supply some 400 million vaccines to Africa is only scheduled to get into motion in the third quarter of 2021. Meanwhile, the continent continues to call for vaccine equality, fair distribution and local vaccine production. Nigerian Regulator’s Nod Government officials have continued to assure citizens of the safety of the vaccine despite global concerns – as it continues to roll-out the available AstraZeneca doses while it awaits the J&J vaccines. On Feb 18, just a few days after Nigeria received its first shipment of the AstraZeneca vaccine, the country’s drug regulator, the National Agency for Food and Drug Administration and Control (NAFDAC) approved the vaccine for emergency use. “The recommendation for Emergency Use Authorization was based on rigorous scientific considerations,” NAFDAC stated. Addressing a recent webinar on COVID-19 Vaccines, Dr. Faisal Shuaib, Executive Director/CEO of NPHCDA, acknowledged that the controversy around the vaccine’s safety, but urged countries in Europe and globally to continue vaccine administration as it is safe and effective. Prof Mojisola Christianah Adeyeye, NAFDAC’s Director General added that safety of the vaccine is primary to the agency and that it would be using its Med Safety App for Active Pharmacovigilance of the vaccine. Immunisation Drive Continues As at March 31, over 718,000 Nigerians had received the first doses of the available AstraZeneca vaccine supplies; coverage ranges from an over-the-top 104% target of priority patients reached in Kwara state to none at all in Kogi state – where a vaccine-hesitant government is only just now succumbing to pressure to allow citizens to receive the vaccine. But a cross section of health experts speaking at the recent Nigerian Academy of Science webinar said the bad publicity around the AstraZeneca vaccine might also have harmed vaccination in general. Recent news emanating from Europe has made the general public more suspicious of the potential lethal effects of the jabs – in addition to widespread misinformation circulating on social media. Dr Yahya Disu, Head of Risk Communication at the Nigeria Center for Disease Control (NCDC), said recent surveys show broad acceptance of vaccines among Nigerians and this is expected to ensure the country quickly achieves herd immunity – provided sufficient vaccines are made available. Disu said 86% of respondents of the surveys said they would still continue preventive measures such as wearing face masks, handwashing and social distancing even after receiving the vaccines. Pfizer Vaccine ‘Safe and Protective’ for Adolescents – Early Data Release 31/03/2021 Chandre Prince Pfizer and its German partner BioNTech say their COVID-19 vaccine is safe and protective in children as young as 12. The Pfizer-BioNTech COVID-19 vaccine is safe and protective in children as young as 12 with no serious side effects in adolescents who received the vaccination, the company said on Wednesday. Interim results of a recent clinical trial of some 2,260 adolescents ages 12-15 years old was published by the pharma company – although it has not yet undergone peer review. The adolescents who participated in the trial produced strong antibody responses and experienced no serious side effects, the company said, saying the vaccine had demonstrated “100 % efficacy”. Pfizer and its German partner BioNTech plan to ask the U.S. Food and Drug Administration and European regulators to allow emergency use of the shots among adolescents, beginning at age 12. Pfizer’s vaccine is already authorised by regulatory authorities for teens ages 16 and older.“We share th e urgency to expand the use of our vaccine,” Pfizer CEO Albert Bourla said in a statement. He expressed “the hope of starting to vaccinate this age group before the start of the next school year” in the United States. Pfizer isn’t the only company seeking to lower the age limit for its vaccine. Results also are expected soon from a U.S. study of Moderna’s vaccine in 12- to 17-year-olds. Another vaccine study of safety and efficacy in children ages 6 months to 11 years is also underway, but that has yet to yield preliminary results. See the full release here. Germany Suspends Use of AstraZeneca For Younger Population Over Reports of Rare Blood Cloth Cases 31/03/2021 Chandre Prince German Health Minister Jens Spahn and German Chancellor Angela Merkel during a joint press conference announcing the suspension of the use of the AstraZeneca COVID-19 vaccine. Germany has suspended the use of the AstraZeneca coronavirus vaccine for people under the age of 60 amidst fresh concerns of unusual blood clot cases among some people receiving the vaccine, particularly women, and leading to the deaths of nine people in all. German Chancellor Angela Merkel and Health Minister Jens Spahn made the announcement on Tuesday after the country’s Standing Committee on Vaccination (STIKO) reviewed more data on emerging cases of rare blood clots in people immunised with the vaccine, produced by the Anglo-Swedish drug maker. Germany’s medical regulator made the call after researchers at the federal government’s Paul Ehrlich Institute, said they had recorded 31 cases of rare blot clot abnormalities, among the 2.7-million Germans who have thus far received the AstraZeneca vaccine. All cases were younger than 63, and all but two were women. The cases involved cerebral venous thrombosis (CSVT), a rare clot in blood draining from the brain, but also related to abnormally low levels of platelets, which help blood clot, and bleeding near the site of vaccination. “The experts of the Paul-Ehrlich-Institut now see a striking accumulation of a special form of very rare cerebral vein thrombosis (sinus vein thrombosis) in connection with a deficiency of blood platelets (thrombocytopenia) and bleeding in temporal proximity to vaccinations with the COVID-19 vaccine AstraZeneca,” said a news release of PEI, the Federal Institute for Vaccines and Biomedicines. Several German regions — including the capital Berlin and the country’s most populous state, North Rhine-Westphalia — had already suspended use of the shots in younger people earlier on Tuesday. Merkel said that the government “cannot ignore” STIKO’s recommendation or the data about blood clots developing following shots with the vaccine. Germany Has Other Vaccine Options For Younger People Germany has suspended the use of the AstraZeneca vaccine in people under 60 years of age. “We all know that vaccination is the most important tool against the coronavirus,” said Merkel, adding there were other options for younger people. “We are not faced with the question of AstraZeneca or no vaccine,” she said. “Instead we have several vaccines at our disposal.” Spahn said the vaccine would only be administered to people aged 60 or older, unless they belong to a high-risk category for serious illness from COVID-19 and have agreed to take the vaccine despite the small risk of a serious side-effect. “In sum it’s about weighing the risk of a side effect that is statistically small, but needs to be taken seriously, and the risk of falling ill with corona,” Spahn said during a press briefing. He said the decision was taken “on the basis of currently available data on the occurrence of rare, but very serious thrombosis-related side-effects.” The commission said that it would issue guidelines on what to do for adults under 60 who had received a first AstraZeneca shot and were due another by the end of April. Suspension – A Blow To Germany’s Vaccine Roll-out The decision to suspend use of the vaccine for under-60s was “without doubt a setback” for the vaccination campaign, in which the AstraZeneca vaccine was a centrepiece, Spahn acknowledged. It comes as Germany, along with other European countries, scrambles to ramp up its vaccine programme, which lags far behind those in Britain and the United States. By Monday, some 13.2 million people in Germany, a country of some 83 million people, had received at least one dose of one of Europe’s approved vaccines, while only 4 million had received two vaccine doses. Germany is due to receive 15 million more AstraZeneca doses in the second quarter of 2021. Spahn said the new supply would be made available to people over 60 who might otherwise have had to wait longer, reducing their risk of falling seriously ill with COVID-19. Germany’s U-turn On AstraZeneca Use of the AstraZeneca vaccine was temporarily halted in Germany, as well as in several other European countries, earlier this month when concerns about occurrences of the rare blood clots first emerged. Then, just under two weeks ago, the European Medicines Agency said that the vaccine is safe and that its benefits outweigh the risks, and the vaccine rollout in Germany and elsewhere in Europe resumed. Paradoxically, earlier in the vaccine rollout, Germany had refrained from administering the AstraZeneca vaccine to people 65 and over, citing insufficient evidence of its efficacy in that age group at the time. Other Countries Restrict Use of AstraZeneca On March 29, Canada’s vaccination committee also recommended suspending the AstraZeneca jab for people under 55, citing reports coming out of Europe of blood clotting incidents. France limited its use to people older than 55. Norway, where regulators say four people died of blood clots among about 120,000 people who received the AstraZeneca jab, has also suspended the vaccine. Sweden has resumed AstraZeneca use for people older than 65. The vaccine is not yet cleared for use in the United States. An independent panel of medical experts overseeing the US trials took the unusual move last week of accusing the company of providing an “incomplete view” of efficacy data in its U.S. trials. On Monday, Canada also recommended halting the use of the jab for people under 55 “pending further analysis”. Researchers Find Association with Clots; AstraZeneca says Vaccine is “safe and effective” The suspensions also come in the wake of a March 28 pre-print report from researchers in Germany, Canada and Austria, including a scientist at the Paul-Ehrlich-Institute, which linked the vaccine to the development of a blood clotting disorder. However, some academics have said that the paper’s implication of a causal association isn’t backed up by evidence. In a statement ahead of the announcement, AstraZeneca said tens of millions of people worldwide have received its vaccines. The company said it would would analyse its own records to understand whether the rare blood clots reported occur more commonly “than would be expected naturally in a population of millions of people.” Image Credits: Clemens Bilan. SARS-CoV2 Virus Origins Report – Only Beginning Of Process Says WHO; 14 Member States Call For More Transparency 30/03/2021 Elaine Ruth Fletcher The most important takeaway about the just-released WHO report on the origins of the SARS-CoV2 virus that has infected over 100 million people to date may not be its initial findings, which need to be held under the microscope, but the fact that it has been issued at all. Speaking at a press conference on Tuesday, WHO’s Peter Ben Embarek, who coordinated the politically fraught WHO mission to Wuhan, China in January and the report produced after the visit – stressed that it was the beginning of a process – and a quest. It will take much more time for the 17 members of the international expert committee – and the world – to unravel. Glass Half Full – Half Empty WHO press briefing Tuesday with members of the international team tasked with tracing the origins of SARS-CoV2 The weaknesses of the report are already apparent, say experts, whose views were shared confidentially with Health Policy Watch. The committee’s methodology for ranking some scenarios, like transmission through food products, as very likely, while ranking others, like a laboratory biosafety incident, as “extremely unlikely” was foggy, with no real objective criteria measurement cited. The team discounted too rapidly the possibility that the virus could have emerged from a lab biosafety accident at the Wuhan Virology Institute – world-famous for its study of bat coronaviruses that are the closest known relatives of SARS-CoV2. WHO’s Peter Ben Embarek, head of the SARS CoV2 origins task team. Asked at the press briefing, how the team decided to rank the probability of the four different theories it considered, Ben Embarek said that the method was debate and discussion among the team members until they reached a consensus. And so it was also no surprise that WHO DIrector General Dr Tedros Adhanom Ghebreyesus, was already walking back on one of the report’s key conclusions. In a closed-door briefing to WHO member states, that preceded the report’s public release, the WHO Director General stated: “Although the team has concluded that a laboratory leak is the least likely hypothesis, this requires further investigation, potentially with additional missions involving specialist experts, which I am ready to deploy… I do not believe that this assessment was extensive enough. Further data and studies will be needed to reach more robust conclusions.” Significantly, Tedros himself also did not appear at the WHO media briefing – but rather let Ben Embarek, a WHO food safety expert who coordinated the mission by the international expert team to China, appear as the single WHO interlocutor on the public stage. And not long after the press conference was finished, some 14 governments led by the United States, Australia and Canada, but also including Denmark, Japan, Norway, Korea and the United Kingdom, issued a joint statement expressing, “shared concerns regarding the recent WHO-convened study in China, while at the same time reinforcing the importance of working together towards the development and use of a swift, effective, transparent, science-based, and independent process for international evaluations of such outbreaks of unknown origin in the future.” The group of 14 member states complained about the fact that the study was “significantly delayed and lacked access to complete, original data and samples”, stating that going forward, there is a need for “further studies of animals to find the means of introduction into humans. “Going forward,” the member states added,”it is critical for independent experts to have full access to all pertinent human, animal, and environmental data, research, and personnel involved in the early stages of the outbreak relevant to determining how this pandemic emerged. With all data in hand, the international community may independently assess COVID-19 origins, learn valuable lessons from this pandemic, and prevent future devastating consequences from outbreaks of disease.” Half Empty -missing and incomplete data Among the specifics being raised by experts and observers in the wake of the report’s release are the following: Weak rationale for the team’s dismissal of a coronavirus laboratory escape. As the international team members admitted themselves in the WHO press briefing, they lacked the competencies to carry out a ful-fledged laboratory investigation. The Wuhan Virology Institute staff, told the WHO team that although researchers at the institute had sequenced the genome of the RaTG13 horseshoe bat virus, which is the closest known relative to SARS CoV2, researchers did not maintain live samples of the virus on hand at the institute. that claim sounds disingenuous, because such samples were indeed collected by the institute in 2013 from a horseshoe-bat colony in Yunnan province, where a group of miners had died in 2012 from a mysterious SARS-like illness. And the institute’s research into those same coronaviruses is a matter of scientific record. In addition, the WHO team did not have access to raw data on the virology institute’s inventory samples or to data on the health status of institute employees, or serological testing, was made available to the investigators. Early spread of the coronavirus in Wuhan – the WHO-mandated team did not get full access to clinical patient data from the earliest known patients, or to the genomic sequences of the viruses with whch they were infected. Serological data available from blood banks, which could have been examined in retrospective studies similar to those carried out on Italy to identify asymptomatic virus carriers, also was not made available by the Chinese authorities. Such data would be critical to understanding where and how widely the virus was circulating prior to December 2019. Despite that, as team member Marion Kooperman’s noted at the WHO press briefing – data that the team did access suggested that as of December, there were already several coronavirus strains circulating in the city. Spread through the food cold chain – the theory touted by the Chinese government of virus spread through imported frozen food products is termed as a “possible pathway” in the report – when in fact little real evidence exists that such contamination could have triggered the Wuhan pandemic, and the conclusion that it is even “plausible” lacks analytical rigour. Evidence about spread through an intermediate wild animal host -while highly plausible as a theory, remains very incomplete, with the mapping of animal supply chains and products only at the initial stages. Half Full – Key insights gleaned Dr. Peter Daszak – President of the EcoHealth Alliance Despite the shortcomings, committee members at the briefing stressed the new evidence that they had gathered, which provides a basis to push ahead with more studies. Chief among those is a direct line of supply chain provision of wild animal products from regions such as Yunnan province, which are known to harbour bat coronaviruses similar to the SARS-CoV2 – to the Huanan Market in Wuhan – where the most intensive cluster of initial cases first appeared. Mapping of stalls in Wuhan’s Huanan market that sold farmed wildlife products from rural regions that are coronavirus hotspots. “Some of the market stalls in the (Huanan Seafood) market in Wuhan were selling [wild animal] foods foods originating from wildlife farms in known coronavirus hotspots” elsewhere in China, said Ben Embarek, citing what is perhaps one of the most important findings of the study. “From the animal side, … the events began to fit together when we looked at the molecular data the epi data and the animal data – they all seemed to fit to form a big picture story about what likely happened, and I think that’s quite exciting,” added Peter Daszak, a leading team member and president of the EcoHealth Alliance. “From the outside, it would have been incredible to have a bat with the exact same lineage of viruses, we didn’t see that yet – that will come in the future I think. “What we did see on the animal side is clear evidence… that there was a pathway to that market and animals that we know are Coronavirus carriers, from places where the nearest related viruses are. What that does is it shows you there is a pathway, that this virus could have taken to move 800-1000 miles from the rural parts of South China, Southeast Asia, into this market, that was exciting to see.” Those insights are all the more critical as the world grapples with a rapid pace of ecosystem deterioration, and more industrialized forms of animal food production, which present considerable risks of virus emergence that need to be better understood by the public at large. Dr. Marion Koopmans, Dutch virologist and epidemiologist On the patient side, despite the Chinese authorities’ fragmented provision of patient and epidemiological data, the evidence culled by the team still remains clear. Already in December 2019, there were diverse strains of the SARS-CoV2 virus already circulating in the city – suggesting that that the infection had already made its way into the city’s population some time before. Said Marion Koopmans, a Dutch virologist and epidemiologist: “The SARS CoV-2 virus was circulating in the Wuhan market market in December 2019, but it was also circulating elsewhere in the city, in cases unrelated to each other,” she noted at the press briefing. . The team also noted that despite the multiple restrictions and barriers put up by Chinese governmental authorities – the atmosphere between scientists remained positive – creating what Ben Embarek called a “space” for the scientists to do their work. And despite considerable pressure from China to point the finger abroad, the team’s testimony makes it clear that the next research steps on the virus trail must be taken in Wuhan, China as well as in rural areas that harbor bat coronaviruses – rather than more far-flung parts of the world. Moving Ahead – Balancing Political and Scientific Pressure What remains is a long road ahead, requiring investment in more rigorous, and as some team members rightly noted – more expensive studies – based upon evidence-driven demands and requests to Chinese authorities for more detailed data – on both the food safety as well as the human epidemiological side of the virus coin. In light of the WHO Director General’s comments about the inadequate analysis of the laboratory biosafety risks – it is also likely that WHO member states in Europe or the Americas (read USA), may demand a fresh query into that hypothesis – involving actual biosafety experts who were not members of the original virus origins team. Ultimately, It will be up to the WHO member states that mandated the report, informed by outside, independent experts and observers, to nurse the origins study – or studies – through to more significant, and final conclusions. In that quest, Europe, the United States and their allies will need to steer a delicate course between exertion of the right amount of political pressure on the one hand – and alienating attacks that only foster anger and geopolitical tensions of the kind visibly on display during the era of former US President Donald Trump. And from the point of view of scientists – It is a process that may require months, if not several years – WHO’s Ben Embarek warned. “”How long will it take? That is always difficult to predict.” he said, pleading with the world to “please be patient.” Although, despite the heat that the WHO team has received, his appeal was shadowed with appreciation for the fact that a certain amount of vigilance – may also be constructive: “It’s an exciting adventure that I hope the whole world will continue to follow.. it’s a fascinating journey and a critical one because it’s the only way we can understand what happened, and more recently tried to prevent something similar for happening again.” Image Credits: Sputnik, WHO. Global Leaders Call For New Treaty To Bolster Resilience Against Future Pandemics 30/03/2021 Svĕt Lustig Vijay Charles Michel, President of the European Council After the COVID-19 pandemic exposed fundamental flaws in the global health architecture, a proposal for a new pandemic treaty that could strengthen the world’s capacity to contain the current pandemic and prepare for future ones, is gaining momentum. That was a key message at a World Health Organization (WHO) launch of an open letter by 25 global leaders calling for the world to negotiate such a treaty, featuring Charles Michel, President of the European Council, and two dozen other global leaders that are now backing the treaty initiative. Other signatories now include the United Kingdom’s Boris Johnson, Germany’s Angela Merkel, France’s Emmanuel Macron, along with the leaders of Indonesia, Kenya, Rwanda and South Africa’s Cyril Ramaphosa. But China, the United States and Russia have yet to sign the call. “Today, we are calling for an international treaty on pandemics [to] foster a comprehensive approach to better predict, prevent and respond to pandemics,” said Michel, who has championed the treaty since late last year saying that the treaty would support the principle of “health for all”. If ratified, the treaty will give the WHO the political clout to better carry out part of its mandate in terms of improved pandemic alert systems, better investments in coronavirus research, and sharing of crucial data on infectious pathogens, vaccine supply chains and vaccine formulas. WHO’s director-general Dr. Tedros Adhanom Ghebreyesus echoed Michel’s sentiments, saying: “The time to act is now”. “The world cannot afford to wait until the pandemic is over to start planning for the next one. We cannot do things the way we have done them before and expect a different result. Without an internationally coordinated response…we remain vulnerable,” said Dr Tedros. Pandemic Treaty Rooted In WHO Constitution No single country can address pandemics alone. An international #PandemicTreaty would promote a global system to better prevent, predict & recover from future pandemics like #COVID19. Find out more on why we need a new treaty on pandemics ➡️https://t.co/iY2qUGLcPn pic.twitter.com/YkEL0LEzKl — EU Council (@EUCouncil) March 30, 2021 The treaty “would be rooted in the constitution of the World Health Organisation, drawing in other relevant organizations key to this endeavour,” said the letter, also signed by the heads of: Albania, Chile, Costa Rica, Greece, Korea, Trinidad and Tobago, the Netherlands, Senegal, Spain, Norway, Serbia, Indonesia, and Ukraine. “Existing global health instruments, especially the International Health Regulations, would underpin such a treaty, ensuring a firm and tested foundation on which we can build and improve.” The Pandemic Treaty Will Strengthen WHO’s Mandate According to Michel, “Such a treaty [could] play an interesting role in order to make sure that we have more transparency on the supply chains [and] on the level of productions of vaccines and of tests; it will mean more rust and better cooperation.” Michel suggested that the treaty could also be used to expand vaccine production by facilitating technology transfer in low- and middle-income countries, referring to the “third way” initially proposed by the World Trade Organisation’s (WTO) new chief Ngozi Okonjo-Iweala. “Certainly there is a debate in the international community about how to improve our vaccine production capacities to improve vaccine coverage, particularly in the African continent,” said Michel, adding that “we are closely following the debate at the WTO for the ‘third way’ voiced by Ngozi”. US and China Didn’t Sign Call – But Sent Positive ‘Comments’ WHO’s director-general Dr. Tedros Adhanom Ghebreyesus Although China and the US did not sign Tuesday’s op-ed, Dr Tedros said that that both countries had voiced “positive” comments during informal discussions with Member States – and that it was not necessarily an issue that the op-ed had only been signed by two dozen countries. “It doesn’t need to be all 194 countries [to write an op-ed],” said Dr. Tedros. “I don’t want it to be seen as a problem, it wasn’t even a problem. When the discussion on the global pandemic treaty starts, all Member States will be represented.” The Pandemic Treaty Will Synergize With The International Health Regulations Meanwhile, Mike Ryan, WHO’s Director of Emergency Programmes, emphasised that the treaty would “by no means” undermine the existing global framework that governs WHO countries’ behaviour during health emergencies – the legally binding International Health Regulations (IHRs). These regulations set out the mandates under which countries are obliged to report on disease outbreak risks, and share epidemic information, with WHO and other member states. Rather, the pandemic treaty would generate the necessary political commitment to ensure that the IHRs are implemented; and bolster global pandemic preparedness and response by covering a broader set of issues than those covered by the IHRs, such as the sharing of crucial data. “The IHRs…is a really really good instrument,” said Ryan. “But in itself [it] is a piece of legislation that is without meaning unless countries are fully committed to its implementation.” “IHR only works if we have trust, if we have transparency, if we have accountability. Such a treaty would provide that political framework in which we in public health can do our work much more effectively.” “The proposed treaty will definitely bring strong political commitment and support for the IHR implementation,” added Jaouad Mahjour, WHO Regional Director for the Eastern Mediterranean region, who also spoke at Tuesday’s press conference. In an initial response to the initiative, the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) said that pharma partners should play a role in shaping such a treaty. The statement reflected IFPMA concerns over preserving what it described as the patent “incentive system” for developing new vaccines and medicines. “The discussions around a possible International Pandemic Treaty need to take into account the important role played by the innovative biopharmaceutical industry and its supply chain in fighting the virus,” said the IFPMA statement. “It will be important to acknowledge the critical role played by the incentive system in developing tests, therapeutics, and vaccines to contain and defeat the coronavirus. We hope that the discussions on an International Pandemic Treaty will address enablers for future pandemic preparedness – the importance of incentives for future innovation, the immediate and unrestricted access to pathogens, and the importance of the free flow of goods and workforce during the pandemic – in addition to continuing the multi stakeholder approach undertaken in ACT-A and COVAX.” Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
DNDi Strategy For The Decade: Delivering And Developing Treatments For Neglected Tropical Diseases 01/04/2021 Raisa Santos A man with symptoms of the deadly NTD African trypanosomiasis (sleeping sickness), is examined by Dr Victor Kande in the Democratic Republic of Congo (DRC). Kande was principle investigator for clinical trials of fexinidazole, the first oral sleeping sickness treatment approved by the European Medicines Agency (EMA) in 2018. Developed by DNDi, it is being rolled out in DRC. Global health experts expressed their frustration with the lack of research and attention towards neglected tropical diseases (NTDs) and vulnerable populations, calling for health systems to address NTDs in a more sustainable and holistic way. Speaking at the launch of a new strategic plan for the Geneva-based Drugs for Neglected Diseases initiative (DNDi) on Tuesday, DNDi Executive Director Bernard Pécoul said greater emphasis should be placed on expanding access and developing treatments for patients in low- and middle-income countries (LMICs) affected by neglected tropical diseases (NTDs), as well as neglected viral diseases like HIV/AIDS, and also pandemic-prone and climate-sensitive diseases. “Treatments were abandoned for years or decades because they fell outside commercial markets,” said Pécoul, at the launch of the plan that charters an eight-year journey to 2028, aiming to deliver 15 – 18 additional treatments, in addition to eight already developed, for a total of 25 new or improved, and highly effective, NTD treatments. “The frustration is where the idea was born – from the experience of humanitarian doctors, frustrated, while treating patients with vaccines that were ineffective, unsafe, or unaffordable, or never developed at all because the research and development was abandoned,” Pecoul added, speaking of his own experience in the past working with Medecins Sans Frontieres (MSF). DNDi, a WHO-supported organization of private and public sector actors, has committed to five strategic imperatives for the next eight-years: to deliver new treatments and expand access for neglected patients of NTDs and related viral diseases; join with public health leaders and Research and Development (R&D) stakeholders in low- and middle-income countries to advance sustainable health systems; contribute to building a proactive agenda for maternal, child health, and gender-responsive R&D; champion open science and transparency; and leverage new technologies to accelerate R&D. “It is our hope that we will identify safe, effective, and affordable medicines to help countries fight the health and social burden put on them by COVID-19. While all global attention is focused on development and purchase of COVID-19 vaccines, we should not forget about treatment and diagnostics,” said Marie-Paule Kieny, Director of Research, INSERM and DNDi Board Chair, at the Tuesday DNDi launch. Challenging The Status Quo DNDi’s Strategic Plan launch event panel: clockwise: Patricia Amira, moderator; Dr Somya Swaminathan; Dr Marie-Paule Kieny; Dr Jeremy Farrar; Dr Bernard Pecoul; Dr Berhards Ogutu Also appearing at the event, Jeremy Farrar, director of the Wellcome Trust. also expressed frustration with the ‘status quo’ that has defined R&D for global health, and called for more attention to be brought to three areas that would ‘define the 21st century’ – neglected and infectious disease, climate change, and mental health. “These three things are going to define our time – which have a focus on youth, and which have an inequitable impact on societies around the world. [DNDi is committed to] not just doing the science, but making sure that science is shared equally with everybody in the world,” he said. Over the next decade, DNDi will work to accelerate sustainable disease elimination in diseases with existing treatments, such as sleeping sickness and Chagas disease, and increase access to lifesaving and safer treatments for HIV and leishmaniasis. DNDi – founded in 2003 to discover, develop, and deliver safe, effective, and affordable treatments for neglected and marginalized patients – will also work with leaders and institutions in LMICs to bolster research capacity and generate more sustainable production and supply of NTD treatments. The initiative has grown into a network of over 200 partner institutions, and has so far delivered eight new treatments for people with sleeping sickness, visceral leishmaniasis, Chagas disease, HIV, and malaria. Clinical Trials for Mild COVID Cases Launching in 13 African Countries Africa launches largest COVID clinical trial COVID-19 has highlighted the need to prioritize and finance research in LMICs, as well as government preparedness to ensure both transparency and equitable access. In addition to working on NTDs and viral illnesses, DNDi will also address unmet medical needs, utilizing its ‘dynamic portfolio’ approach to explore new interventions in diseases with clear R&D gaps, including snakebite, dengue fever, schistosomiasis, and pandemic-prone diseases. At the start of the strategic planning period, DNDi also is coordinating ANTICOV – the largest African-led clinical trial testing for mild-to-moderate COVID-19. The ANTICOV platform deals with the outpatient population, which is the majority of people with COVID, and is trying to answer the question of how to treat people to prevent them from getting ill and needing hospitalization, said Dr Soumya Swaminathan, WHO Chief Scientist. Carried out by a group of 26 prominent African and global R&D organizations in 13 countries, ANTICOV will simultaneously test and adjust treatments for COVID-19, and identify new treatments, fast-tracking research for patients and health systems in resource-limited settings. Swaminathan said that the high costs of the COVID-19 pandemic should not come at the expense of cutting or reducing budgets for NTDs, saying that the ‘collaborative science’ seen over the past year as proof that knowledge could be shared openly and freely. “Because of this vision, and the collective mission to solve the problem of COVID and develop new tools, it is possible to [share knowledge more widely].” Though DNDi is primarily focused on R&D, the organization will also identify gaps in access to care, and build the partnerships needed to overcome them, laying the groundwork for more affordable care. Said Swaminathan: “When there’s a new technology, which can make a big impact, especially when it’s related to health and disease, it should be considered a global public good, and be made available to people who need it, regardless of their ability to pay.” Image Credits: DNDi, DNDi, ClimateWed/Twitter. France Enters Third Lockdown, While Europe’s Vaccine Rollout Is Critiqued As “Unacceptably Slow” 01/04/2021 Madeleine Hoecklin A patient getting tested for COVID-19 at the Paris Charles de Gaulle Airport in January 2021. French President Emmanuel Macron imposed strict lockdown measures amid of surge of new coronavirus cases. France is going into its third national lockdown since the start of the COVID-19 pandemic, after a deadly third wave hit Europe, causing soaring infection and death rates. With an average of more than 37,000 daily new cases over the past week, tougher restrictions have become inevitable. French President Emmanuel Macron announced the new restrictions in a televised address on Wednesday, saying that the government had waited “until the last moment” to impose the latest lockdown. The daily death toll reached 355 on Wednesday and health authorities recorded 569 new intensive care patients in 24 hours on Tuesday, the highest since April 2020. Over 5,000 COVID-19 patients are currently in intensive care units. Infections have doubled since February, likely due to the spread of the more transmissible B.1.1.7 SARS-CoV2 variant, first detected in the United Kingdom. France “risks losing control” without strict measures, said Macron. France is approaching the grim milestone of 100,000 total COVID deaths, with 95,798 deaths recorded as of Wednesday. Lockdown Measures Put in Place Lockdown restrictions include classes being taught remotely for the next three weeks, non-essential businesses will be closed, and travel within the country will be banned for a month after the Easter weekend (2-4 April). Residents will be limited to a 10 kilometer radius from their homes and will be subject to a curfew between 7pm and 6am. “We must limit all contact as much as we can, including family gatherings. We know now: these are where the virus spreads,” said Macron. Some 3,000 additional intensive care beds will be added to hospitals in the hardest-hit regions in an attempt to prevent health systems from becoming overwhelmed. The national lockdown will begin on Saturday and will last four weeks. Emmanuel Macron, the French President, in a televised address on Wednesday announcing the country’s third COVID-19 lockdown. Over a dozen regions were put under partial lockdown in early March with night-time curfews. The regional restrictions avoided closing schools or stores in an effort to keep the economy open. The existing restrictions at the regional level, which were implemented in early March in an attempt to avoid stricter measures, were unable to curb the spread of the virus. Macron was hesitant to impose nationwide restrictions, resisting calls from experts for tougher measures since January. “The outlook is worse than frightening. We’re already at the level of the second wave, and we’re quickly getting close to the threshold of the first wave,” said Jean-Michel Constantin, head of the intensive care unit at the Pitié-Salpêtrière hospital in Paris, in an interview on RMC radio on Monday. According to the French Health Minister, Olivier Veran, France could reach the peak of the epidemic in seven to 10 days, “then we need two extra weeks to reach a peak in intensive care units (ICUs) that could occur at the end of April,” he told Inter radio on Thursday. “We have endured a year of suffering and sacrifice, but if we stay united and organized, we will reach the end of the tunnel,” said Macron. “April will be a critical month.” France’s vaccination campaign is seen as the path out of the pandemic and will be accelerated in the coming weeks, according to Macron. France, along with the rest of the European Union, was plagued by a slow rollout of vaccines due both to shortages as well as a lack of a well-coordinated health sector response in many countries, with systems that are either highly fragmented or else too centralized to permit for smooth and efficient rollouts at the local level. WHO Calls Europe’s Vaccination Program “Unacceptably Slow” Amidst rising infection and death rates in the WHO European region, which encompasses 53 countries, the region’s vaccine “rollout is unacceptably slow,” said Hans Kluge, the WHO Regional Director for Europe, in a statement released on Wednesday. Europe has recorded 1.6 million new cases and close to 24,000 deaths in the last week, quickly nearing one million total deaths. It is the second most affected region by SARS-CoV2 in the world. The B.1.1.7 variant has a greater public health impact and requires numerous measures in place to control it, said the statement. Currently, 27 countries in Europe are under partial or nationwide lockdown and 23 have tightened restrictions over the past two weeks. However, some 13 countries have ease measures and nine plan to follow suit. “My message to governments in the region is…that now is not the time to relax measures. We can’t afford not to heed the danger,” said Kluge. “We must keep reining in the virus.” Hans Kluge, WHO Regional Director for Europe. “Vaccines present our best way out of this pandemic,” Kluge said. However, “as long as coverage remains low, we need to apply the same public health and social measures as we have in the past to compensate for delayed schedules.” In addition to implementing public health measures to limit transmission, efforts must be made to scale up vaccine production and administer as many jabs as possible, as quickly as possible. “We must speed up the process by ramping up manufacturing, reducing barriers to administering vaccines, and using every single vial we have in stock, now,” said Kluge. Only 10% of the region’s population have received one dose of a COVID-19 vaccine. While there has been a shortage of vaccines, countries must avoid vaccine nationalism and hoarding supplies, the statement said. Once a nation’s healthcare workers and vulnerable individuals have been vaccinated, Kluge urged governments to “share excess doses of WHO-approved vaccines with COVAX or with countries in need” in order to ensure that healthcare workers and older individuals in every country are inoculated. This message was echoed by Dr Tedros Adhanom Ghebreyesus, WHO Director-General, at a press conference on Thursday, who made an “urgent request to countries with surplus vaccines that have WHO emergency use listings to share 10 million doses with COVAX.” In order to reach the goal of vaccinating all healthcare workers in the first 100 days of 2021, rich countries have nine days remaining to to donate excess doses to the COVAX facility, which has run out of doses at a critical time. WTO Head Says Pharma Companies Should Either Scale Up Manufacturing Or Share Know-How with LMICs Meanwhile, the new Director-General of the World Trade Organization (WTO), Ngozi Okonjo-Iweala, called it “unacceptable” that low- and middle-income countries (LMICs) were being left at the “end of the queue” for COVID-19 vaccines. “The kind of inequities we see in vaccine access are really not acceptable, you can’t have a situation in which…10 countries have administered 70% of vaccine doses in the world, and there are countries that don’t have one single dose,” said Okonjo-Iweala at a WTO trade forecast press conference on Thursday. Ngozi Okonjo-Iweala, Director-General of the WTO, at a press conference on Thursday. She urged pharma companies to follow AstraZeneca’s lead in making deals with production facilities in LMICs to expand the manufacturing capacity for their vaccines. “Let’s have the same kind of arrangement that AstraZeneca has with the Serum Institute of India,” the world’s largest vaccine manufacturer and the main source of COVID-19 vaccines for LMICs, Okonjo-Iweala said. Voluntary licensing of technology could begin to address the inequity in access to vaccines, she said. While an intellectual property waiver for certain COVID-19 tools and technology – designed to allow more drug manufacturers to make the vaccines and improve access – is under consideration by WTO member states, Okonjo-Iweala said this was an issue for the next pandemic. Instead of pursuing the WTO TRIPS waiver, the focus now to meet the threat from COVID should be put on enlarging manufacturing capacity, she said. Image Credits: France24, Flickr – International Monetary Fund, BBC. A Good Place To Start To Beat The COVID Obesity Pandemic – Warning Labels on Unhealthy Foods 01/04/2021 Svĕt Lustig Vijay The obesity pandemic is in “the same room” as the COVID pandemic in terms of its threats to health – putting people at greater risk of premature death from multiple causes, including SARS-CoV-2, the virus that leads to COVID-19. And ever since stay-at-home measures became routine, people have gained even more weight – up to 1.5 pounds a month according to one recent US study. Yet countries have the tools to address obesity, note Trish Cotter and Dr. Nandita Murukutla at Vital Strategies, a global public health NGO. We spoke to Ms. Cotter and Dr. Murukutla to find out more: Health Policy Watch (HPW): A third of the global population now suffers from overweight, and rates of obesity are growing across the world, including in poor countries. How can we explain these trends? Vital Strategies (VS): Over the last 40 years, obesity rates around the world have ballooned. High-income countries, like the United States, were the first to experience substantial weight gains of their populations, but the 21st century has seen that phenomenon spread to all parts of the globe. Now, the average adult is three times as likely to be overweight as the average adult in the 1970s. There are a number of reasons for this alarming trend, which began well before COVID-19, starting with the environments in which people live, as well as poverty, discrimination, increasing availability of unhealthy foods in schools, dwindling levels of physical activity, and a lack of knowledge of unhealthy diets and products. However, the fundamental reason is the rapid change in our diets and the broader food environment. Ultra-processed products or “junk food”, such as soft drinks, ice creams, or prepared frozen dishes, are one of the key drivers of growing obesity worldwide. They are high in sugar, salt and fat and, unfortunately, widespread in most societies. Yet their harmful effects are poorly understood. One in three people worldwide are overweight HPW: Why are ultra-processed foods so ubiquitous? VS: They are cheap, easily available, and because of additives and preservatives, they have a long shelf-life. They’re made to feel and look attractive, and they’re made to taste good. Importantly, they’re also hyper-marketed by the food industry. Advertising campaigns are very good at making unhealthy products seem part of the fabric of society: unhealthy foods are made to seem crucial to family gatherings and entertainment, so they become part of the social norm that normalizes unhealthy foods. And much of the advertising around unhealthy foods is so enticing that it gets children hooked at a young age. In what ways is advertising of ultra-processed products misleading? Unhealthy products are often marketed cleverly as convenient substitutes for healthy, minimally processed options that include whole grains, fruits and vegetables. They are marketed as convenient breakfast foods, snacks, juices, and sometimes they are also marketed as being more sanitary than fresh fruits and vegetables. But that’s misleading, because current evidence demonstrates that ultra-processed products result in worse diets and ultimately overweight and obesity, which exacerbates the risk of contracting a range of chronic diseases as well as suffering poorer outcomes from infectious diseases like COVID-19. Claims that ultra-processed products are healthy alternatives are untrue. Can you give a concrete example of a strategy that misleads customers into thinking they’re buying healthy products? Labels on the front and back of food packages are often really hard to accurately decode. And many of these labels use clever algorithms to hide unhealthy levels of sugar, salt, and saturated fat. Customers may not always realize that the product they are buying is unhealthy. Late last year, you co-authored a guide to help policymakers introduce clear, yet highly effective warning labels on foods and beverages to nudge customers away from unhealthy foods. How do these warning labels work? Front-of-Package (FOP) nutrient labels, sometimes called warning labels, tell consumers immediately, on the front of products, and simply when a product contains high levels of unhealthy nutrients. That means customers don’t need to spend several minutes trying to work out whether each product is healthy or not. This system is simple, visual, and easy to understand. And it is effective, as seen from studies across the world, in triggering immediate behavior change. The front-of-package labels serve as behavioral nudges, protecting people from making unintended unhealthy purchases. In other words, the warning labels work by reminding consumers that the products they are purchasing are unhealthy, thus nudging them to make healthier choices. But they also have important knock-on effects: they help change social norms around unhealthy eating. Example of warning labels on food products in Chile to nudge customers away from unhealthy foods. Translation from top-left to bottom-right: high in calories; high in sugars; high in sodium; high in saturated fats. Source: Ministry of Health of Chile. You mentioned that warning labels can help change social norms that promote the consumption of unhealthy foods. Can you unpack that? One study found that children pestered their parents to buy healthier products that did not have warning labels, partially because teachers at school would not accept unhealthy snacks. In some cases, teachers would even confiscate unhealthy snacks brought by children. This suggests that something as simple as a warning label can challenge the idea that ultra-processed products are desirable, and start to change the social norm. It’s also important to reiterate that warning labels are a highly cost-efficient approach because you’re able to target consumers rapidly, constantly, and at the point of decision making to make a purchase or not, with little to no cost to the government. And the costs of not addressing obesity during the pandemic could amount to $US 7 trillion by 2025, according to the latest review by the World Obesity Federation. Furthermore, out of a total of 2.5 million deaths from COVID reported as of February, 2021, 2.2 million were in countries where over half of the population is overweight. Countries with high proportions of overweight people had coronavirus death toll that were ten times higher than those with low proportions of overwheight people So far, six countries including Chile have legally mandated warning labels, although many have put in place “voluntary” systems. How well do the voluntary systems work ? The voluntary systems, which do not legally mandate warning labels on every single food product, are not effective. As warning labels may reduce sales of unhealthy foods, the food industry is unlikely to take them up. That’s why mandatory regulations on warning labels are crucial if we want to make a real dent into obesity and overweight. We’ve seen these warning labels work very well in Chile where they contributed to a decrease in the consumption of sugar-sweetened beverages by almost 25%. This was achieved through a comprehensive approach to addressing obesity, which also included: restrictions on child-directed marketing of unhealthy foods and beverages on the radio, television, cinema, and internet; a ban of unhealthy foods and beverages in schools and daycare; and a tax on sugary drinks. What kinds of labels work best? There are two broad categories of labels. The first category, the so-called “reductive” labels, outline how much of each nutrient is contained in foods, but they don’t help the consumer decide whether the product is healthy or not. These labels are less effective. The second category of labels, the so-called “interpretive” labels, are much more effective. They draw attention to the nutrients of concern or summarize the overall healthfulness of the product. Thus, they can help consumers distinguish between healthy and unhealthy products immediately through clear visual cues. The so-called “interpretive” labels can help consumers quickly identify nutrients of concern in food products to make healthier decisions What are the challenges to getting countries to act? Although a number of high-level commitments have been made to fight obesity, including the inclusion of a target in the SDGs , The UN High-Level Meetings on NCDs as well as the UN Decade of Action on Nutrition, a lot more can and needs to be done. But that said, there is very strong industry pushback, and that’s also not surprising. We have seen decades of this with regard to other issues like tobacco control. Industry pressure cannot be underestimated and industry interference is often what holds governments back. However, governments should not feel powerless to take on food policy. The tools are out there to help them do this effectively and cheaply. Are there any other policies that can be used alongside mandatory warning labels to cut obesity and overweight? Sugary drinks taxes are among the most effective and cost-efficient ways to reduce access to unhealthy foods. Marketing restrictions and the removal of misleading advertising, especially in schools and environments in which children reside, is crucial. Bans on unhealthy products in schools can also help. We also need to ensure that healthy food becomes the default option by making sure that it’s easily available and cheap enough to buy – and at the same time ensure that unhealthy foods like ultra-processed foods are less available. And as mentioned earlier, it’s important to change those social norms around unhealthy foods so that they’re not associated with what marketers want you to associate them with – families, warmth, love, sports – and all of the things that bring people together. Where do we go from here? And let’s be honest that food labels are not a panacea – what about access to healthier diets generally, which are often more expensive than unhealthy diets. And what about environments where people can be physically active? With more than one-third of the world’s population overweight or obese, and the COVID-19 pandemic revealing deep structural inequities in food environments, the push to combat obesity has become more urgent than ever. Many individuals are powerless in the face of food shortages and the over-availability of cheap ultra-processed foods. The onus is on governments to act, and to act now. There were a number of factors, from environmental, structural to social, that brought us where we are today, and we will likewise need a concerted and cohesive set of actions to reverse these trends. FoP warning labels are a strong place to start. Read more here on Vital Strategies’ new guide to help policymakers design and implement warning labels on foods and beverages. Trish Cotter, MPH, Global Lead, Food Policy Program and Senior Advisor, Vital Strategies Dr. Nandita Murukutla, Vice President for Global Policy and Research, Vital Strategies Image Credits: University of Michigan, World Obesity Federation, Vital Strategies, Food Standard Agency, Vital Strateggies, Vital Strategies. Nigeria Pivots From AstraZeneca To Johnson & Johnson COVID-19 Vaccine 31/03/2021 Paul Adepoju The Nigerian government has ditched the AstraZeneca COVID-19 vaccine and will soon shift to the Johnson & Johnson’s one-shot vaccine. EXCLUSIVE – IBADAN – The Nigerian government has quietly ditched the AstraZeneca COVID-19 vaccine meant to vaccinate tens of millions of citizens, and will gradually shift to the Johnson & Johnson’s one-shot vaccine, saying it is easier to administer. Documents from the Nigerian Primary Healthcare Development Agency (NPHCDA) obtained by Health Policy Watch show that the agency intends to begin rolling out the J&J vaccine to almost 30 million people as soon as it can obtain the vaccine supplies. While denying that safety concerns are an issue, the Nigerian government’s move also comes amidst growing global concerns about AstraZeneca’s efficacy against the SARS-CoV2 virus variant first identified in South Africa, as well as safety concerns that have led to the suspension of AstraZeneca vaccines for people under the age of 60 in Germany, and elsewhere (see related story). Nigeria had already commenced the rollout of the AstraZeneca vaccine, with vaccines supplied by the WHO co-sponsored COVAX initiative. The country was meant to get more AstraZeneca supplies though the African Medical Supplies Platform (AMSP) – having already placed the largest order on the continent through the AMSP, as previously confirmed by the Africa Centres for Disease Control (CDC). However, according to the documents, the AstraZeneca vaccine doses reserved through the AMSP will be replaced with Johnson & Johnson vaccines. “Based on this, Nigeria’s total allocation is now 29,850,000 of Johnson & Johnson (Janssen) COVID-19 vaccine which is one dose shot to cover 29,850,000 eligible Nigerians as originally planned,” the agency stated. That would be enough to cover about 15% of Nigeria’s population of 200 million people. Government Says J&J ‘One Jab’ Vaccine, not Safety Worries, Are Behind Shift Government officials in Nigeria attributed the shift to J&J’s to the vaccine’s single jab technology – which will make it much easier to administer as compared to AstraZeneca’s two-dose shot – as well as ensuring the vaccine coverage stretches even further. They denied that it was linked to issues of safety and efficacy. However, behind the scenes, another factor is the J&J vaccine’s documented efficacy against the B.1351 virus variant identified in South Africa – and now spread to some 16 other countries on the continent, including nearby Ghana. South Africa on Monday announced that it has secured 30 million J&J vaccines after a small clinical trial and genomic surveillance showed the AstraZeneca vaccine was not strongly effective against that variant. In an earlier advisory, the Africa CDC stated that African countries where the B.1351 variant is the predominant SARS-CoV-2 strain should consider swapping the AstraZeneca vaccine for others that have shown more efficacy. Neither the AMSP or the Africa CDC could confirm when the J&J doses will become available. A recently announced J&J commitment to supply some 400 million vaccines to Africa is only scheduled to get into motion in the third quarter of 2021. Meanwhile, the continent continues to call for vaccine equality, fair distribution and local vaccine production. Nigerian Regulator’s Nod Government officials have continued to assure citizens of the safety of the vaccine despite global concerns – as it continues to roll-out the available AstraZeneca doses while it awaits the J&J vaccines. On Feb 18, just a few days after Nigeria received its first shipment of the AstraZeneca vaccine, the country’s drug regulator, the National Agency for Food and Drug Administration and Control (NAFDAC) approved the vaccine for emergency use. “The recommendation for Emergency Use Authorization was based on rigorous scientific considerations,” NAFDAC stated. Addressing a recent webinar on COVID-19 Vaccines, Dr. Faisal Shuaib, Executive Director/CEO of NPHCDA, acknowledged that the controversy around the vaccine’s safety, but urged countries in Europe and globally to continue vaccine administration as it is safe and effective. Prof Mojisola Christianah Adeyeye, NAFDAC’s Director General added that safety of the vaccine is primary to the agency and that it would be using its Med Safety App for Active Pharmacovigilance of the vaccine. Immunisation Drive Continues As at March 31, over 718,000 Nigerians had received the first doses of the available AstraZeneca vaccine supplies; coverage ranges from an over-the-top 104% target of priority patients reached in Kwara state to none at all in Kogi state – where a vaccine-hesitant government is only just now succumbing to pressure to allow citizens to receive the vaccine. But a cross section of health experts speaking at the recent Nigerian Academy of Science webinar said the bad publicity around the AstraZeneca vaccine might also have harmed vaccination in general. Recent news emanating from Europe has made the general public more suspicious of the potential lethal effects of the jabs – in addition to widespread misinformation circulating on social media. Dr Yahya Disu, Head of Risk Communication at the Nigeria Center for Disease Control (NCDC), said recent surveys show broad acceptance of vaccines among Nigerians and this is expected to ensure the country quickly achieves herd immunity – provided sufficient vaccines are made available. Disu said 86% of respondents of the surveys said they would still continue preventive measures such as wearing face masks, handwashing and social distancing even after receiving the vaccines. Pfizer Vaccine ‘Safe and Protective’ for Adolescents – Early Data Release 31/03/2021 Chandre Prince Pfizer and its German partner BioNTech say their COVID-19 vaccine is safe and protective in children as young as 12. The Pfizer-BioNTech COVID-19 vaccine is safe and protective in children as young as 12 with no serious side effects in adolescents who received the vaccination, the company said on Wednesday. Interim results of a recent clinical trial of some 2,260 adolescents ages 12-15 years old was published by the pharma company – although it has not yet undergone peer review. The adolescents who participated in the trial produced strong antibody responses and experienced no serious side effects, the company said, saying the vaccine had demonstrated “100 % efficacy”. Pfizer and its German partner BioNTech plan to ask the U.S. Food and Drug Administration and European regulators to allow emergency use of the shots among adolescents, beginning at age 12. Pfizer’s vaccine is already authorised by regulatory authorities for teens ages 16 and older.“We share th e urgency to expand the use of our vaccine,” Pfizer CEO Albert Bourla said in a statement. He expressed “the hope of starting to vaccinate this age group before the start of the next school year” in the United States. Pfizer isn’t the only company seeking to lower the age limit for its vaccine. Results also are expected soon from a U.S. study of Moderna’s vaccine in 12- to 17-year-olds. Another vaccine study of safety and efficacy in children ages 6 months to 11 years is also underway, but that has yet to yield preliminary results. See the full release here. Germany Suspends Use of AstraZeneca For Younger Population Over Reports of Rare Blood Cloth Cases 31/03/2021 Chandre Prince German Health Minister Jens Spahn and German Chancellor Angela Merkel during a joint press conference announcing the suspension of the use of the AstraZeneca COVID-19 vaccine. Germany has suspended the use of the AstraZeneca coronavirus vaccine for people under the age of 60 amidst fresh concerns of unusual blood clot cases among some people receiving the vaccine, particularly women, and leading to the deaths of nine people in all. German Chancellor Angela Merkel and Health Minister Jens Spahn made the announcement on Tuesday after the country’s Standing Committee on Vaccination (STIKO) reviewed more data on emerging cases of rare blood clots in people immunised with the vaccine, produced by the Anglo-Swedish drug maker. Germany’s medical regulator made the call after researchers at the federal government’s Paul Ehrlich Institute, said they had recorded 31 cases of rare blot clot abnormalities, among the 2.7-million Germans who have thus far received the AstraZeneca vaccine. All cases were younger than 63, and all but two were women. The cases involved cerebral venous thrombosis (CSVT), a rare clot in blood draining from the brain, but also related to abnormally low levels of platelets, which help blood clot, and bleeding near the site of vaccination. “The experts of the Paul-Ehrlich-Institut now see a striking accumulation of a special form of very rare cerebral vein thrombosis (sinus vein thrombosis) in connection with a deficiency of blood platelets (thrombocytopenia) and bleeding in temporal proximity to vaccinations with the COVID-19 vaccine AstraZeneca,” said a news release of PEI, the Federal Institute for Vaccines and Biomedicines. Several German regions — including the capital Berlin and the country’s most populous state, North Rhine-Westphalia — had already suspended use of the shots in younger people earlier on Tuesday. Merkel said that the government “cannot ignore” STIKO’s recommendation or the data about blood clots developing following shots with the vaccine. Germany Has Other Vaccine Options For Younger People Germany has suspended the use of the AstraZeneca vaccine in people under 60 years of age. “We all know that vaccination is the most important tool against the coronavirus,” said Merkel, adding there were other options for younger people. “We are not faced with the question of AstraZeneca or no vaccine,” she said. “Instead we have several vaccines at our disposal.” Spahn said the vaccine would only be administered to people aged 60 or older, unless they belong to a high-risk category for serious illness from COVID-19 and have agreed to take the vaccine despite the small risk of a serious side-effect. “In sum it’s about weighing the risk of a side effect that is statistically small, but needs to be taken seriously, and the risk of falling ill with corona,” Spahn said during a press briefing. He said the decision was taken “on the basis of currently available data on the occurrence of rare, but very serious thrombosis-related side-effects.” The commission said that it would issue guidelines on what to do for adults under 60 who had received a first AstraZeneca shot and were due another by the end of April. Suspension – A Blow To Germany’s Vaccine Roll-out The decision to suspend use of the vaccine for under-60s was “without doubt a setback” for the vaccination campaign, in which the AstraZeneca vaccine was a centrepiece, Spahn acknowledged. It comes as Germany, along with other European countries, scrambles to ramp up its vaccine programme, which lags far behind those in Britain and the United States. By Monday, some 13.2 million people in Germany, a country of some 83 million people, had received at least one dose of one of Europe’s approved vaccines, while only 4 million had received two vaccine doses. Germany is due to receive 15 million more AstraZeneca doses in the second quarter of 2021. Spahn said the new supply would be made available to people over 60 who might otherwise have had to wait longer, reducing their risk of falling seriously ill with COVID-19. Germany’s U-turn On AstraZeneca Use of the AstraZeneca vaccine was temporarily halted in Germany, as well as in several other European countries, earlier this month when concerns about occurrences of the rare blood clots first emerged. Then, just under two weeks ago, the European Medicines Agency said that the vaccine is safe and that its benefits outweigh the risks, and the vaccine rollout in Germany and elsewhere in Europe resumed. Paradoxically, earlier in the vaccine rollout, Germany had refrained from administering the AstraZeneca vaccine to people 65 and over, citing insufficient evidence of its efficacy in that age group at the time. Other Countries Restrict Use of AstraZeneca On March 29, Canada’s vaccination committee also recommended suspending the AstraZeneca jab for people under 55, citing reports coming out of Europe of blood clotting incidents. France limited its use to people older than 55. Norway, where regulators say four people died of blood clots among about 120,000 people who received the AstraZeneca jab, has also suspended the vaccine. Sweden has resumed AstraZeneca use for people older than 65. The vaccine is not yet cleared for use in the United States. An independent panel of medical experts overseeing the US trials took the unusual move last week of accusing the company of providing an “incomplete view” of efficacy data in its U.S. trials. On Monday, Canada also recommended halting the use of the jab for people under 55 “pending further analysis”. Researchers Find Association with Clots; AstraZeneca says Vaccine is “safe and effective” The suspensions also come in the wake of a March 28 pre-print report from researchers in Germany, Canada and Austria, including a scientist at the Paul-Ehrlich-Institute, which linked the vaccine to the development of a blood clotting disorder. However, some academics have said that the paper’s implication of a causal association isn’t backed up by evidence. In a statement ahead of the announcement, AstraZeneca said tens of millions of people worldwide have received its vaccines. The company said it would would analyse its own records to understand whether the rare blood clots reported occur more commonly “than would be expected naturally in a population of millions of people.” Image Credits: Clemens Bilan. SARS-CoV2 Virus Origins Report – Only Beginning Of Process Says WHO; 14 Member States Call For More Transparency 30/03/2021 Elaine Ruth Fletcher The most important takeaway about the just-released WHO report on the origins of the SARS-CoV2 virus that has infected over 100 million people to date may not be its initial findings, which need to be held under the microscope, but the fact that it has been issued at all. Speaking at a press conference on Tuesday, WHO’s Peter Ben Embarek, who coordinated the politically fraught WHO mission to Wuhan, China in January and the report produced after the visit – stressed that it was the beginning of a process – and a quest. It will take much more time for the 17 members of the international expert committee – and the world – to unravel. Glass Half Full – Half Empty WHO press briefing Tuesday with members of the international team tasked with tracing the origins of SARS-CoV2 The weaknesses of the report are already apparent, say experts, whose views were shared confidentially with Health Policy Watch. The committee’s methodology for ranking some scenarios, like transmission through food products, as very likely, while ranking others, like a laboratory biosafety incident, as “extremely unlikely” was foggy, with no real objective criteria measurement cited. The team discounted too rapidly the possibility that the virus could have emerged from a lab biosafety accident at the Wuhan Virology Institute – world-famous for its study of bat coronaviruses that are the closest known relatives of SARS-CoV2. WHO’s Peter Ben Embarek, head of the SARS CoV2 origins task team. Asked at the press briefing, how the team decided to rank the probability of the four different theories it considered, Ben Embarek said that the method was debate and discussion among the team members until they reached a consensus. And so it was also no surprise that WHO DIrector General Dr Tedros Adhanom Ghebreyesus, was already walking back on one of the report’s key conclusions. In a closed-door briefing to WHO member states, that preceded the report’s public release, the WHO Director General stated: “Although the team has concluded that a laboratory leak is the least likely hypothesis, this requires further investigation, potentially with additional missions involving specialist experts, which I am ready to deploy… I do not believe that this assessment was extensive enough. Further data and studies will be needed to reach more robust conclusions.” Significantly, Tedros himself also did not appear at the WHO media briefing – but rather let Ben Embarek, a WHO food safety expert who coordinated the mission by the international expert team to China, appear as the single WHO interlocutor on the public stage. And not long after the press conference was finished, some 14 governments led by the United States, Australia and Canada, but also including Denmark, Japan, Norway, Korea and the United Kingdom, issued a joint statement expressing, “shared concerns regarding the recent WHO-convened study in China, while at the same time reinforcing the importance of working together towards the development and use of a swift, effective, transparent, science-based, and independent process for international evaluations of such outbreaks of unknown origin in the future.” The group of 14 member states complained about the fact that the study was “significantly delayed and lacked access to complete, original data and samples”, stating that going forward, there is a need for “further studies of animals to find the means of introduction into humans. “Going forward,” the member states added,”it is critical for independent experts to have full access to all pertinent human, animal, and environmental data, research, and personnel involved in the early stages of the outbreak relevant to determining how this pandemic emerged. With all data in hand, the international community may independently assess COVID-19 origins, learn valuable lessons from this pandemic, and prevent future devastating consequences from outbreaks of disease.” Half Empty -missing and incomplete data Among the specifics being raised by experts and observers in the wake of the report’s release are the following: Weak rationale for the team’s dismissal of a coronavirus laboratory escape. As the international team members admitted themselves in the WHO press briefing, they lacked the competencies to carry out a ful-fledged laboratory investigation. The Wuhan Virology Institute staff, told the WHO team that although researchers at the institute had sequenced the genome of the RaTG13 horseshoe bat virus, which is the closest known relative to SARS CoV2, researchers did not maintain live samples of the virus on hand at the institute. that claim sounds disingenuous, because such samples were indeed collected by the institute in 2013 from a horseshoe-bat colony in Yunnan province, where a group of miners had died in 2012 from a mysterious SARS-like illness. And the institute’s research into those same coronaviruses is a matter of scientific record. In addition, the WHO team did not have access to raw data on the virology institute’s inventory samples or to data on the health status of institute employees, or serological testing, was made available to the investigators. Early spread of the coronavirus in Wuhan – the WHO-mandated team did not get full access to clinical patient data from the earliest known patients, or to the genomic sequences of the viruses with whch they were infected. Serological data available from blood banks, which could have been examined in retrospective studies similar to those carried out on Italy to identify asymptomatic virus carriers, also was not made available by the Chinese authorities. Such data would be critical to understanding where and how widely the virus was circulating prior to December 2019. Despite that, as team member Marion Kooperman’s noted at the WHO press briefing – data that the team did access suggested that as of December, there were already several coronavirus strains circulating in the city. Spread through the food cold chain – the theory touted by the Chinese government of virus spread through imported frozen food products is termed as a “possible pathway” in the report – when in fact little real evidence exists that such contamination could have triggered the Wuhan pandemic, and the conclusion that it is even “plausible” lacks analytical rigour. Evidence about spread through an intermediate wild animal host -while highly plausible as a theory, remains very incomplete, with the mapping of animal supply chains and products only at the initial stages. Half Full – Key insights gleaned Dr. Peter Daszak – President of the EcoHealth Alliance Despite the shortcomings, committee members at the briefing stressed the new evidence that they had gathered, which provides a basis to push ahead with more studies. Chief among those is a direct line of supply chain provision of wild animal products from regions such as Yunnan province, which are known to harbour bat coronaviruses similar to the SARS-CoV2 – to the Huanan Market in Wuhan – where the most intensive cluster of initial cases first appeared. Mapping of stalls in Wuhan’s Huanan market that sold farmed wildlife products from rural regions that are coronavirus hotspots. “Some of the market stalls in the (Huanan Seafood) market in Wuhan were selling [wild animal] foods foods originating from wildlife farms in known coronavirus hotspots” elsewhere in China, said Ben Embarek, citing what is perhaps one of the most important findings of the study. “From the animal side, … the events began to fit together when we looked at the molecular data the epi data and the animal data – they all seemed to fit to form a big picture story about what likely happened, and I think that’s quite exciting,” added Peter Daszak, a leading team member and president of the EcoHealth Alliance. “From the outside, it would have been incredible to have a bat with the exact same lineage of viruses, we didn’t see that yet – that will come in the future I think. “What we did see on the animal side is clear evidence… that there was a pathway to that market and animals that we know are Coronavirus carriers, from places where the nearest related viruses are. What that does is it shows you there is a pathway, that this virus could have taken to move 800-1000 miles from the rural parts of South China, Southeast Asia, into this market, that was exciting to see.” Those insights are all the more critical as the world grapples with a rapid pace of ecosystem deterioration, and more industrialized forms of animal food production, which present considerable risks of virus emergence that need to be better understood by the public at large. Dr. Marion Koopmans, Dutch virologist and epidemiologist On the patient side, despite the Chinese authorities’ fragmented provision of patient and epidemiological data, the evidence culled by the team still remains clear. Already in December 2019, there were diverse strains of the SARS-CoV2 virus already circulating in the city – suggesting that that the infection had already made its way into the city’s population some time before. Said Marion Koopmans, a Dutch virologist and epidemiologist: “The SARS CoV-2 virus was circulating in the Wuhan market market in December 2019, but it was also circulating elsewhere in the city, in cases unrelated to each other,” she noted at the press briefing. . The team also noted that despite the multiple restrictions and barriers put up by Chinese governmental authorities – the atmosphere between scientists remained positive – creating what Ben Embarek called a “space” for the scientists to do their work. And despite considerable pressure from China to point the finger abroad, the team’s testimony makes it clear that the next research steps on the virus trail must be taken in Wuhan, China as well as in rural areas that harbor bat coronaviruses – rather than more far-flung parts of the world. Moving Ahead – Balancing Political and Scientific Pressure What remains is a long road ahead, requiring investment in more rigorous, and as some team members rightly noted – more expensive studies – based upon evidence-driven demands and requests to Chinese authorities for more detailed data – on both the food safety as well as the human epidemiological side of the virus coin. In light of the WHO Director General’s comments about the inadequate analysis of the laboratory biosafety risks – it is also likely that WHO member states in Europe or the Americas (read USA), may demand a fresh query into that hypothesis – involving actual biosafety experts who were not members of the original virus origins team. Ultimately, It will be up to the WHO member states that mandated the report, informed by outside, independent experts and observers, to nurse the origins study – or studies – through to more significant, and final conclusions. In that quest, Europe, the United States and their allies will need to steer a delicate course between exertion of the right amount of political pressure on the one hand – and alienating attacks that only foster anger and geopolitical tensions of the kind visibly on display during the era of former US President Donald Trump. And from the point of view of scientists – It is a process that may require months, if not several years – WHO’s Ben Embarek warned. “”How long will it take? That is always difficult to predict.” he said, pleading with the world to “please be patient.” Although, despite the heat that the WHO team has received, his appeal was shadowed with appreciation for the fact that a certain amount of vigilance – may also be constructive: “It’s an exciting adventure that I hope the whole world will continue to follow.. it’s a fascinating journey and a critical one because it’s the only way we can understand what happened, and more recently tried to prevent something similar for happening again.” Image Credits: Sputnik, WHO. Global Leaders Call For New Treaty To Bolster Resilience Against Future Pandemics 30/03/2021 Svĕt Lustig Vijay Charles Michel, President of the European Council After the COVID-19 pandemic exposed fundamental flaws in the global health architecture, a proposal for a new pandemic treaty that could strengthen the world’s capacity to contain the current pandemic and prepare for future ones, is gaining momentum. That was a key message at a World Health Organization (WHO) launch of an open letter by 25 global leaders calling for the world to negotiate such a treaty, featuring Charles Michel, President of the European Council, and two dozen other global leaders that are now backing the treaty initiative. Other signatories now include the United Kingdom’s Boris Johnson, Germany’s Angela Merkel, France’s Emmanuel Macron, along with the leaders of Indonesia, Kenya, Rwanda and South Africa’s Cyril Ramaphosa. But China, the United States and Russia have yet to sign the call. “Today, we are calling for an international treaty on pandemics [to] foster a comprehensive approach to better predict, prevent and respond to pandemics,” said Michel, who has championed the treaty since late last year saying that the treaty would support the principle of “health for all”. If ratified, the treaty will give the WHO the political clout to better carry out part of its mandate in terms of improved pandemic alert systems, better investments in coronavirus research, and sharing of crucial data on infectious pathogens, vaccine supply chains and vaccine formulas. WHO’s director-general Dr. Tedros Adhanom Ghebreyesus echoed Michel’s sentiments, saying: “The time to act is now”. “The world cannot afford to wait until the pandemic is over to start planning for the next one. We cannot do things the way we have done them before and expect a different result. Without an internationally coordinated response…we remain vulnerable,” said Dr Tedros. Pandemic Treaty Rooted In WHO Constitution No single country can address pandemics alone. An international #PandemicTreaty would promote a global system to better prevent, predict & recover from future pandemics like #COVID19. Find out more on why we need a new treaty on pandemics ➡️https://t.co/iY2qUGLcPn pic.twitter.com/YkEL0LEzKl — EU Council (@EUCouncil) March 30, 2021 The treaty “would be rooted in the constitution of the World Health Organisation, drawing in other relevant organizations key to this endeavour,” said the letter, also signed by the heads of: Albania, Chile, Costa Rica, Greece, Korea, Trinidad and Tobago, the Netherlands, Senegal, Spain, Norway, Serbia, Indonesia, and Ukraine. “Existing global health instruments, especially the International Health Regulations, would underpin such a treaty, ensuring a firm and tested foundation on which we can build and improve.” The Pandemic Treaty Will Strengthen WHO’s Mandate According to Michel, “Such a treaty [could] play an interesting role in order to make sure that we have more transparency on the supply chains [and] on the level of productions of vaccines and of tests; it will mean more rust and better cooperation.” Michel suggested that the treaty could also be used to expand vaccine production by facilitating technology transfer in low- and middle-income countries, referring to the “third way” initially proposed by the World Trade Organisation’s (WTO) new chief Ngozi Okonjo-Iweala. “Certainly there is a debate in the international community about how to improve our vaccine production capacities to improve vaccine coverage, particularly in the African continent,” said Michel, adding that “we are closely following the debate at the WTO for the ‘third way’ voiced by Ngozi”. US and China Didn’t Sign Call – But Sent Positive ‘Comments’ WHO’s director-general Dr. Tedros Adhanom Ghebreyesus Although China and the US did not sign Tuesday’s op-ed, Dr Tedros said that that both countries had voiced “positive” comments during informal discussions with Member States – and that it was not necessarily an issue that the op-ed had only been signed by two dozen countries. “It doesn’t need to be all 194 countries [to write an op-ed],” said Dr. Tedros. “I don’t want it to be seen as a problem, it wasn’t even a problem. When the discussion on the global pandemic treaty starts, all Member States will be represented.” The Pandemic Treaty Will Synergize With The International Health Regulations Meanwhile, Mike Ryan, WHO’s Director of Emergency Programmes, emphasised that the treaty would “by no means” undermine the existing global framework that governs WHO countries’ behaviour during health emergencies – the legally binding International Health Regulations (IHRs). These regulations set out the mandates under which countries are obliged to report on disease outbreak risks, and share epidemic information, with WHO and other member states. Rather, the pandemic treaty would generate the necessary political commitment to ensure that the IHRs are implemented; and bolster global pandemic preparedness and response by covering a broader set of issues than those covered by the IHRs, such as the sharing of crucial data. “The IHRs…is a really really good instrument,” said Ryan. “But in itself [it] is a piece of legislation that is without meaning unless countries are fully committed to its implementation.” “IHR only works if we have trust, if we have transparency, if we have accountability. Such a treaty would provide that political framework in which we in public health can do our work much more effectively.” “The proposed treaty will definitely bring strong political commitment and support for the IHR implementation,” added Jaouad Mahjour, WHO Regional Director for the Eastern Mediterranean region, who also spoke at Tuesday’s press conference. In an initial response to the initiative, the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) said that pharma partners should play a role in shaping such a treaty. The statement reflected IFPMA concerns over preserving what it described as the patent “incentive system” for developing new vaccines and medicines. “The discussions around a possible International Pandemic Treaty need to take into account the important role played by the innovative biopharmaceutical industry and its supply chain in fighting the virus,” said the IFPMA statement. “It will be important to acknowledge the critical role played by the incentive system in developing tests, therapeutics, and vaccines to contain and defeat the coronavirus. We hope that the discussions on an International Pandemic Treaty will address enablers for future pandemic preparedness – the importance of incentives for future innovation, the immediate and unrestricted access to pathogens, and the importance of the free flow of goods and workforce during the pandemic – in addition to continuing the multi stakeholder approach undertaken in ACT-A and COVAX.” Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
France Enters Third Lockdown, While Europe’s Vaccine Rollout Is Critiqued As “Unacceptably Slow” 01/04/2021 Madeleine Hoecklin A patient getting tested for COVID-19 at the Paris Charles de Gaulle Airport in January 2021. French President Emmanuel Macron imposed strict lockdown measures amid of surge of new coronavirus cases. France is going into its third national lockdown since the start of the COVID-19 pandemic, after a deadly third wave hit Europe, causing soaring infection and death rates. With an average of more than 37,000 daily new cases over the past week, tougher restrictions have become inevitable. French President Emmanuel Macron announced the new restrictions in a televised address on Wednesday, saying that the government had waited “until the last moment” to impose the latest lockdown. The daily death toll reached 355 on Wednesday and health authorities recorded 569 new intensive care patients in 24 hours on Tuesday, the highest since April 2020. Over 5,000 COVID-19 patients are currently in intensive care units. Infections have doubled since February, likely due to the spread of the more transmissible B.1.1.7 SARS-CoV2 variant, first detected in the United Kingdom. France “risks losing control” without strict measures, said Macron. France is approaching the grim milestone of 100,000 total COVID deaths, with 95,798 deaths recorded as of Wednesday. Lockdown Measures Put in Place Lockdown restrictions include classes being taught remotely for the next three weeks, non-essential businesses will be closed, and travel within the country will be banned for a month after the Easter weekend (2-4 April). Residents will be limited to a 10 kilometer radius from their homes and will be subject to a curfew between 7pm and 6am. “We must limit all contact as much as we can, including family gatherings. We know now: these are where the virus spreads,” said Macron. Some 3,000 additional intensive care beds will be added to hospitals in the hardest-hit regions in an attempt to prevent health systems from becoming overwhelmed. The national lockdown will begin on Saturday and will last four weeks. Emmanuel Macron, the French President, in a televised address on Wednesday announcing the country’s third COVID-19 lockdown. Over a dozen regions were put under partial lockdown in early March with night-time curfews. The regional restrictions avoided closing schools or stores in an effort to keep the economy open. The existing restrictions at the regional level, which were implemented in early March in an attempt to avoid stricter measures, were unable to curb the spread of the virus. Macron was hesitant to impose nationwide restrictions, resisting calls from experts for tougher measures since January. “The outlook is worse than frightening. We’re already at the level of the second wave, and we’re quickly getting close to the threshold of the first wave,” said Jean-Michel Constantin, head of the intensive care unit at the Pitié-Salpêtrière hospital in Paris, in an interview on RMC radio on Monday. According to the French Health Minister, Olivier Veran, France could reach the peak of the epidemic in seven to 10 days, “then we need two extra weeks to reach a peak in intensive care units (ICUs) that could occur at the end of April,” he told Inter radio on Thursday. “We have endured a year of suffering and sacrifice, but if we stay united and organized, we will reach the end of the tunnel,” said Macron. “April will be a critical month.” France’s vaccination campaign is seen as the path out of the pandemic and will be accelerated in the coming weeks, according to Macron. France, along with the rest of the European Union, was plagued by a slow rollout of vaccines due both to shortages as well as a lack of a well-coordinated health sector response in many countries, with systems that are either highly fragmented or else too centralized to permit for smooth and efficient rollouts at the local level. WHO Calls Europe’s Vaccination Program “Unacceptably Slow” Amidst rising infection and death rates in the WHO European region, which encompasses 53 countries, the region’s vaccine “rollout is unacceptably slow,” said Hans Kluge, the WHO Regional Director for Europe, in a statement released on Wednesday. Europe has recorded 1.6 million new cases and close to 24,000 deaths in the last week, quickly nearing one million total deaths. It is the second most affected region by SARS-CoV2 in the world. The B.1.1.7 variant has a greater public health impact and requires numerous measures in place to control it, said the statement. Currently, 27 countries in Europe are under partial or nationwide lockdown and 23 have tightened restrictions over the past two weeks. However, some 13 countries have ease measures and nine plan to follow suit. “My message to governments in the region is…that now is not the time to relax measures. We can’t afford not to heed the danger,” said Kluge. “We must keep reining in the virus.” Hans Kluge, WHO Regional Director for Europe. “Vaccines present our best way out of this pandemic,” Kluge said. However, “as long as coverage remains low, we need to apply the same public health and social measures as we have in the past to compensate for delayed schedules.” In addition to implementing public health measures to limit transmission, efforts must be made to scale up vaccine production and administer as many jabs as possible, as quickly as possible. “We must speed up the process by ramping up manufacturing, reducing barriers to administering vaccines, and using every single vial we have in stock, now,” said Kluge. Only 10% of the region’s population have received one dose of a COVID-19 vaccine. While there has been a shortage of vaccines, countries must avoid vaccine nationalism and hoarding supplies, the statement said. Once a nation’s healthcare workers and vulnerable individuals have been vaccinated, Kluge urged governments to “share excess doses of WHO-approved vaccines with COVAX or with countries in need” in order to ensure that healthcare workers and older individuals in every country are inoculated. This message was echoed by Dr Tedros Adhanom Ghebreyesus, WHO Director-General, at a press conference on Thursday, who made an “urgent request to countries with surplus vaccines that have WHO emergency use listings to share 10 million doses with COVAX.” In order to reach the goal of vaccinating all healthcare workers in the first 100 days of 2021, rich countries have nine days remaining to to donate excess doses to the COVAX facility, which has run out of doses at a critical time. WTO Head Says Pharma Companies Should Either Scale Up Manufacturing Or Share Know-How with LMICs Meanwhile, the new Director-General of the World Trade Organization (WTO), Ngozi Okonjo-Iweala, called it “unacceptable” that low- and middle-income countries (LMICs) were being left at the “end of the queue” for COVID-19 vaccines. “The kind of inequities we see in vaccine access are really not acceptable, you can’t have a situation in which…10 countries have administered 70% of vaccine doses in the world, and there are countries that don’t have one single dose,” said Okonjo-Iweala at a WTO trade forecast press conference on Thursday. Ngozi Okonjo-Iweala, Director-General of the WTO, at a press conference on Thursday. She urged pharma companies to follow AstraZeneca’s lead in making deals with production facilities in LMICs to expand the manufacturing capacity for their vaccines. “Let’s have the same kind of arrangement that AstraZeneca has with the Serum Institute of India,” the world’s largest vaccine manufacturer and the main source of COVID-19 vaccines for LMICs, Okonjo-Iweala said. Voluntary licensing of technology could begin to address the inequity in access to vaccines, she said. While an intellectual property waiver for certain COVID-19 tools and technology – designed to allow more drug manufacturers to make the vaccines and improve access – is under consideration by WTO member states, Okonjo-Iweala said this was an issue for the next pandemic. Instead of pursuing the WTO TRIPS waiver, the focus now to meet the threat from COVID should be put on enlarging manufacturing capacity, she said. Image Credits: France24, Flickr – International Monetary Fund, BBC. A Good Place To Start To Beat The COVID Obesity Pandemic – Warning Labels on Unhealthy Foods 01/04/2021 Svĕt Lustig Vijay The obesity pandemic is in “the same room” as the COVID pandemic in terms of its threats to health – putting people at greater risk of premature death from multiple causes, including SARS-CoV-2, the virus that leads to COVID-19. And ever since stay-at-home measures became routine, people have gained even more weight – up to 1.5 pounds a month according to one recent US study. Yet countries have the tools to address obesity, note Trish Cotter and Dr. Nandita Murukutla at Vital Strategies, a global public health NGO. We spoke to Ms. Cotter and Dr. Murukutla to find out more: Health Policy Watch (HPW): A third of the global population now suffers from overweight, and rates of obesity are growing across the world, including in poor countries. How can we explain these trends? Vital Strategies (VS): Over the last 40 years, obesity rates around the world have ballooned. High-income countries, like the United States, were the first to experience substantial weight gains of their populations, but the 21st century has seen that phenomenon spread to all parts of the globe. Now, the average adult is three times as likely to be overweight as the average adult in the 1970s. There are a number of reasons for this alarming trend, which began well before COVID-19, starting with the environments in which people live, as well as poverty, discrimination, increasing availability of unhealthy foods in schools, dwindling levels of physical activity, and a lack of knowledge of unhealthy diets and products. However, the fundamental reason is the rapid change in our diets and the broader food environment. Ultra-processed products or “junk food”, such as soft drinks, ice creams, or prepared frozen dishes, are one of the key drivers of growing obesity worldwide. They are high in sugar, salt and fat and, unfortunately, widespread in most societies. Yet their harmful effects are poorly understood. One in three people worldwide are overweight HPW: Why are ultra-processed foods so ubiquitous? VS: They are cheap, easily available, and because of additives and preservatives, they have a long shelf-life. They’re made to feel and look attractive, and they’re made to taste good. Importantly, they’re also hyper-marketed by the food industry. Advertising campaigns are very good at making unhealthy products seem part of the fabric of society: unhealthy foods are made to seem crucial to family gatherings and entertainment, so they become part of the social norm that normalizes unhealthy foods. And much of the advertising around unhealthy foods is so enticing that it gets children hooked at a young age. In what ways is advertising of ultra-processed products misleading? Unhealthy products are often marketed cleverly as convenient substitutes for healthy, minimally processed options that include whole grains, fruits and vegetables. They are marketed as convenient breakfast foods, snacks, juices, and sometimes they are also marketed as being more sanitary than fresh fruits and vegetables. But that’s misleading, because current evidence demonstrates that ultra-processed products result in worse diets and ultimately overweight and obesity, which exacerbates the risk of contracting a range of chronic diseases as well as suffering poorer outcomes from infectious diseases like COVID-19. Claims that ultra-processed products are healthy alternatives are untrue. Can you give a concrete example of a strategy that misleads customers into thinking they’re buying healthy products? Labels on the front and back of food packages are often really hard to accurately decode. And many of these labels use clever algorithms to hide unhealthy levels of sugar, salt, and saturated fat. Customers may not always realize that the product they are buying is unhealthy. Late last year, you co-authored a guide to help policymakers introduce clear, yet highly effective warning labels on foods and beverages to nudge customers away from unhealthy foods. How do these warning labels work? Front-of-Package (FOP) nutrient labels, sometimes called warning labels, tell consumers immediately, on the front of products, and simply when a product contains high levels of unhealthy nutrients. That means customers don’t need to spend several minutes trying to work out whether each product is healthy or not. This system is simple, visual, and easy to understand. And it is effective, as seen from studies across the world, in triggering immediate behavior change. The front-of-package labels serve as behavioral nudges, protecting people from making unintended unhealthy purchases. In other words, the warning labels work by reminding consumers that the products they are purchasing are unhealthy, thus nudging them to make healthier choices. But they also have important knock-on effects: they help change social norms around unhealthy eating. Example of warning labels on food products in Chile to nudge customers away from unhealthy foods. Translation from top-left to bottom-right: high in calories; high in sugars; high in sodium; high in saturated fats. Source: Ministry of Health of Chile. You mentioned that warning labels can help change social norms that promote the consumption of unhealthy foods. Can you unpack that? One study found that children pestered their parents to buy healthier products that did not have warning labels, partially because teachers at school would not accept unhealthy snacks. In some cases, teachers would even confiscate unhealthy snacks brought by children. This suggests that something as simple as a warning label can challenge the idea that ultra-processed products are desirable, and start to change the social norm. It’s also important to reiterate that warning labels are a highly cost-efficient approach because you’re able to target consumers rapidly, constantly, and at the point of decision making to make a purchase or not, with little to no cost to the government. And the costs of not addressing obesity during the pandemic could amount to $US 7 trillion by 2025, according to the latest review by the World Obesity Federation. Furthermore, out of a total of 2.5 million deaths from COVID reported as of February, 2021, 2.2 million were in countries where over half of the population is overweight. Countries with high proportions of overweight people had coronavirus death toll that were ten times higher than those with low proportions of overwheight people So far, six countries including Chile have legally mandated warning labels, although many have put in place “voluntary” systems. How well do the voluntary systems work ? The voluntary systems, which do not legally mandate warning labels on every single food product, are not effective. As warning labels may reduce sales of unhealthy foods, the food industry is unlikely to take them up. That’s why mandatory regulations on warning labels are crucial if we want to make a real dent into obesity and overweight. We’ve seen these warning labels work very well in Chile where they contributed to a decrease in the consumption of sugar-sweetened beverages by almost 25%. This was achieved through a comprehensive approach to addressing obesity, which also included: restrictions on child-directed marketing of unhealthy foods and beverages on the radio, television, cinema, and internet; a ban of unhealthy foods and beverages in schools and daycare; and a tax on sugary drinks. What kinds of labels work best? There are two broad categories of labels. The first category, the so-called “reductive” labels, outline how much of each nutrient is contained in foods, but they don’t help the consumer decide whether the product is healthy or not. These labels are less effective. The second category of labels, the so-called “interpretive” labels, are much more effective. They draw attention to the nutrients of concern or summarize the overall healthfulness of the product. Thus, they can help consumers distinguish between healthy and unhealthy products immediately through clear visual cues. The so-called “interpretive” labels can help consumers quickly identify nutrients of concern in food products to make healthier decisions What are the challenges to getting countries to act? Although a number of high-level commitments have been made to fight obesity, including the inclusion of a target in the SDGs , The UN High-Level Meetings on NCDs as well as the UN Decade of Action on Nutrition, a lot more can and needs to be done. But that said, there is very strong industry pushback, and that’s also not surprising. We have seen decades of this with regard to other issues like tobacco control. Industry pressure cannot be underestimated and industry interference is often what holds governments back. However, governments should not feel powerless to take on food policy. The tools are out there to help them do this effectively and cheaply. Are there any other policies that can be used alongside mandatory warning labels to cut obesity and overweight? Sugary drinks taxes are among the most effective and cost-efficient ways to reduce access to unhealthy foods. Marketing restrictions and the removal of misleading advertising, especially in schools and environments in which children reside, is crucial. Bans on unhealthy products in schools can also help. We also need to ensure that healthy food becomes the default option by making sure that it’s easily available and cheap enough to buy – and at the same time ensure that unhealthy foods like ultra-processed foods are less available. And as mentioned earlier, it’s important to change those social norms around unhealthy foods so that they’re not associated with what marketers want you to associate them with – families, warmth, love, sports – and all of the things that bring people together. Where do we go from here? And let’s be honest that food labels are not a panacea – what about access to healthier diets generally, which are often more expensive than unhealthy diets. And what about environments where people can be physically active? With more than one-third of the world’s population overweight or obese, and the COVID-19 pandemic revealing deep structural inequities in food environments, the push to combat obesity has become more urgent than ever. Many individuals are powerless in the face of food shortages and the over-availability of cheap ultra-processed foods. The onus is on governments to act, and to act now. There were a number of factors, from environmental, structural to social, that brought us where we are today, and we will likewise need a concerted and cohesive set of actions to reverse these trends. FoP warning labels are a strong place to start. Read more here on Vital Strategies’ new guide to help policymakers design and implement warning labels on foods and beverages. Trish Cotter, MPH, Global Lead, Food Policy Program and Senior Advisor, Vital Strategies Dr. Nandita Murukutla, Vice President for Global Policy and Research, Vital Strategies Image Credits: University of Michigan, World Obesity Federation, Vital Strategies, Food Standard Agency, Vital Strateggies, Vital Strategies. Nigeria Pivots From AstraZeneca To Johnson & Johnson COVID-19 Vaccine 31/03/2021 Paul Adepoju The Nigerian government has ditched the AstraZeneca COVID-19 vaccine and will soon shift to the Johnson & Johnson’s one-shot vaccine. EXCLUSIVE – IBADAN – The Nigerian government has quietly ditched the AstraZeneca COVID-19 vaccine meant to vaccinate tens of millions of citizens, and will gradually shift to the Johnson & Johnson’s one-shot vaccine, saying it is easier to administer. Documents from the Nigerian Primary Healthcare Development Agency (NPHCDA) obtained by Health Policy Watch show that the agency intends to begin rolling out the J&J vaccine to almost 30 million people as soon as it can obtain the vaccine supplies. While denying that safety concerns are an issue, the Nigerian government’s move also comes amidst growing global concerns about AstraZeneca’s efficacy against the SARS-CoV2 virus variant first identified in South Africa, as well as safety concerns that have led to the suspension of AstraZeneca vaccines for people under the age of 60 in Germany, and elsewhere (see related story). Nigeria had already commenced the rollout of the AstraZeneca vaccine, with vaccines supplied by the WHO co-sponsored COVAX initiative. The country was meant to get more AstraZeneca supplies though the African Medical Supplies Platform (AMSP) – having already placed the largest order on the continent through the AMSP, as previously confirmed by the Africa Centres for Disease Control (CDC). However, according to the documents, the AstraZeneca vaccine doses reserved through the AMSP will be replaced with Johnson & Johnson vaccines. “Based on this, Nigeria’s total allocation is now 29,850,000 of Johnson & Johnson (Janssen) COVID-19 vaccine which is one dose shot to cover 29,850,000 eligible Nigerians as originally planned,” the agency stated. That would be enough to cover about 15% of Nigeria’s population of 200 million people. Government Says J&J ‘One Jab’ Vaccine, not Safety Worries, Are Behind Shift Government officials in Nigeria attributed the shift to J&J’s to the vaccine’s single jab technology – which will make it much easier to administer as compared to AstraZeneca’s two-dose shot – as well as ensuring the vaccine coverage stretches even further. They denied that it was linked to issues of safety and efficacy. However, behind the scenes, another factor is the J&J vaccine’s documented efficacy against the B.1351 virus variant identified in South Africa – and now spread to some 16 other countries on the continent, including nearby Ghana. South Africa on Monday announced that it has secured 30 million J&J vaccines after a small clinical trial and genomic surveillance showed the AstraZeneca vaccine was not strongly effective against that variant. In an earlier advisory, the Africa CDC stated that African countries where the B.1351 variant is the predominant SARS-CoV-2 strain should consider swapping the AstraZeneca vaccine for others that have shown more efficacy. Neither the AMSP or the Africa CDC could confirm when the J&J doses will become available. A recently announced J&J commitment to supply some 400 million vaccines to Africa is only scheduled to get into motion in the third quarter of 2021. Meanwhile, the continent continues to call for vaccine equality, fair distribution and local vaccine production. Nigerian Regulator’s Nod Government officials have continued to assure citizens of the safety of the vaccine despite global concerns – as it continues to roll-out the available AstraZeneca doses while it awaits the J&J vaccines. On Feb 18, just a few days after Nigeria received its first shipment of the AstraZeneca vaccine, the country’s drug regulator, the National Agency for Food and Drug Administration and Control (NAFDAC) approved the vaccine for emergency use. “The recommendation for Emergency Use Authorization was based on rigorous scientific considerations,” NAFDAC stated. Addressing a recent webinar on COVID-19 Vaccines, Dr. Faisal Shuaib, Executive Director/CEO of NPHCDA, acknowledged that the controversy around the vaccine’s safety, but urged countries in Europe and globally to continue vaccine administration as it is safe and effective. Prof Mojisola Christianah Adeyeye, NAFDAC’s Director General added that safety of the vaccine is primary to the agency and that it would be using its Med Safety App for Active Pharmacovigilance of the vaccine. Immunisation Drive Continues As at March 31, over 718,000 Nigerians had received the first doses of the available AstraZeneca vaccine supplies; coverage ranges from an over-the-top 104% target of priority patients reached in Kwara state to none at all in Kogi state – where a vaccine-hesitant government is only just now succumbing to pressure to allow citizens to receive the vaccine. But a cross section of health experts speaking at the recent Nigerian Academy of Science webinar said the bad publicity around the AstraZeneca vaccine might also have harmed vaccination in general. Recent news emanating from Europe has made the general public more suspicious of the potential lethal effects of the jabs – in addition to widespread misinformation circulating on social media. Dr Yahya Disu, Head of Risk Communication at the Nigeria Center for Disease Control (NCDC), said recent surveys show broad acceptance of vaccines among Nigerians and this is expected to ensure the country quickly achieves herd immunity – provided sufficient vaccines are made available. Disu said 86% of respondents of the surveys said they would still continue preventive measures such as wearing face masks, handwashing and social distancing even after receiving the vaccines. Pfizer Vaccine ‘Safe and Protective’ for Adolescents – Early Data Release 31/03/2021 Chandre Prince Pfizer and its German partner BioNTech say their COVID-19 vaccine is safe and protective in children as young as 12. The Pfizer-BioNTech COVID-19 vaccine is safe and protective in children as young as 12 with no serious side effects in adolescents who received the vaccination, the company said on Wednesday. Interim results of a recent clinical trial of some 2,260 adolescents ages 12-15 years old was published by the pharma company – although it has not yet undergone peer review. The adolescents who participated in the trial produced strong antibody responses and experienced no serious side effects, the company said, saying the vaccine had demonstrated “100 % efficacy”. Pfizer and its German partner BioNTech plan to ask the U.S. Food and Drug Administration and European regulators to allow emergency use of the shots among adolescents, beginning at age 12. Pfizer’s vaccine is already authorised by regulatory authorities for teens ages 16 and older.“We share th e urgency to expand the use of our vaccine,” Pfizer CEO Albert Bourla said in a statement. He expressed “the hope of starting to vaccinate this age group before the start of the next school year” in the United States. Pfizer isn’t the only company seeking to lower the age limit for its vaccine. Results also are expected soon from a U.S. study of Moderna’s vaccine in 12- to 17-year-olds. Another vaccine study of safety and efficacy in children ages 6 months to 11 years is also underway, but that has yet to yield preliminary results. See the full release here. Germany Suspends Use of AstraZeneca For Younger Population Over Reports of Rare Blood Cloth Cases 31/03/2021 Chandre Prince German Health Minister Jens Spahn and German Chancellor Angela Merkel during a joint press conference announcing the suspension of the use of the AstraZeneca COVID-19 vaccine. Germany has suspended the use of the AstraZeneca coronavirus vaccine for people under the age of 60 amidst fresh concerns of unusual blood clot cases among some people receiving the vaccine, particularly women, and leading to the deaths of nine people in all. German Chancellor Angela Merkel and Health Minister Jens Spahn made the announcement on Tuesday after the country’s Standing Committee on Vaccination (STIKO) reviewed more data on emerging cases of rare blood clots in people immunised with the vaccine, produced by the Anglo-Swedish drug maker. Germany’s medical regulator made the call after researchers at the federal government’s Paul Ehrlich Institute, said they had recorded 31 cases of rare blot clot abnormalities, among the 2.7-million Germans who have thus far received the AstraZeneca vaccine. All cases were younger than 63, and all but two were women. The cases involved cerebral venous thrombosis (CSVT), a rare clot in blood draining from the brain, but also related to abnormally low levels of platelets, which help blood clot, and bleeding near the site of vaccination. “The experts of the Paul-Ehrlich-Institut now see a striking accumulation of a special form of very rare cerebral vein thrombosis (sinus vein thrombosis) in connection with a deficiency of blood platelets (thrombocytopenia) and bleeding in temporal proximity to vaccinations with the COVID-19 vaccine AstraZeneca,” said a news release of PEI, the Federal Institute for Vaccines and Biomedicines. Several German regions — including the capital Berlin and the country’s most populous state, North Rhine-Westphalia — had already suspended use of the shots in younger people earlier on Tuesday. Merkel said that the government “cannot ignore” STIKO’s recommendation or the data about blood clots developing following shots with the vaccine. Germany Has Other Vaccine Options For Younger People Germany has suspended the use of the AstraZeneca vaccine in people under 60 years of age. “We all know that vaccination is the most important tool against the coronavirus,” said Merkel, adding there were other options for younger people. “We are not faced with the question of AstraZeneca or no vaccine,” she said. “Instead we have several vaccines at our disposal.” Spahn said the vaccine would only be administered to people aged 60 or older, unless they belong to a high-risk category for serious illness from COVID-19 and have agreed to take the vaccine despite the small risk of a serious side-effect. “In sum it’s about weighing the risk of a side effect that is statistically small, but needs to be taken seriously, and the risk of falling ill with corona,” Spahn said during a press briefing. He said the decision was taken “on the basis of currently available data on the occurrence of rare, but very serious thrombosis-related side-effects.” The commission said that it would issue guidelines on what to do for adults under 60 who had received a first AstraZeneca shot and were due another by the end of April. Suspension – A Blow To Germany’s Vaccine Roll-out The decision to suspend use of the vaccine for under-60s was “without doubt a setback” for the vaccination campaign, in which the AstraZeneca vaccine was a centrepiece, Spahn acknowledged. It comes as Germany, along with other European countries, scrambles to ramp up its vaccine programme, which lags far behind those in Britain and the United States. By Monday, some 13.2 million people in Germany, a country of some 83 million people, had received at least one dose of one of Europe’s approved vaccines, while only 4 million had received two vaccine doses. Germany is due to receive 15 million more AstraZeneca doses in the second quarter of 2021. Spahn said the new supply would be made available to people over 60 who might otherwise have had to wait longer, reducing their risk of falling seriously ill with COVID-19. Germany’s U-turn On AstraZeneca Use of the AstraZeneca vaccine was temporarily halted in Germany, as well as in several other European countries, earlier this month when concerns about occurrences of the rare blood clots first emerged. Then, just under two weeks ago, the European Medicines Agency said that the vaccine is safe and that its benefits outweigh the risks, and the vaccine rollout in Germany and elsewhere in Europe resumed. Paradoxically, earlier in the vaccine rollout, Germany had refrained from administering the AstraZeneca vaccine to people 65 and over, citing insufficient evidence of its efficacy in that age group at the time. Other Countries Restrict Use of AstraZeneca On March 29, Canada’s vaccination committee also recommended suspending the AstraZeneca jab for people under 55, citing reports coming out of Europe of blood clotting incidents. France limited its use to people older than 55. Norway, where regulators say four people died of blood clots among about 120,000 people who received the AstraZeneca jab, has also suspended the vaccine. Sweden has resumed AstraZeneca use for people older than 65. The vaccine is not yet cleared for use in the United States. An independent panel of medical experts overseeing the US trials took the unusual move last week of accusing the company of providing an “incomplete view” of efficacy data in its U.S. trials. On Monday, Canada also recommended halting the use of the jab for people under 55 “pending further analysis”. Researchers Find Association with Clots; AstraZeneca says Vaccine is “safe and effective” The suspensions also come in the wake of a March 28 pre-print report from researchers in Germany, Canada and Austria, including a scientist at the Paul-Ehrlich-Institute, which linked the vaccine to the development of a blood clotting disorder. However, some academics have said that the paper’s implication of a causal association isn’t backed up by evidence. In a statement ahead of the announcement, AstraZeneca said tens of millions of people worldwide have received its vaccines. The company said it would would analyse its own records to understand whether the rare blood clots reported occur more commonly “than would be expected naturally in a population of millions of people.” Image Credits: Clemens Bilan. SARS-CoV2 Virus Origins Report – Only Beginning Of Process Says WHO; 14 Member States Call For More Transparency 30/03/2021 Elaine Ruth Fletcher The most important takeaway about the just-released WHO report on the origins of the SARS-CoV2 virus that has infected over 100 million people to date may not be its initial findings, which need to be held under the microscope, but the fact that it has been issued at all. Speaking at a press conference on Tuesday, WHO’s Peter Ben Embarek, who coordinated the politically fraught WHO mission to Wuhan, China in January and the report produced after the visit – stressed that it was the beginning of a process – and a quest. It will take much more time for the 17 members of the international expert committee – and the world – to unravel. Glass Half Full – Half Empty WHO press briefing Tuesday with members of the international team tasked with tracing the origins of SARS-CoV2 The weaknesses of the report are already apparent, say experts, whose views were shared confidentially with Health Policy Watch. The committee’s methodology for ranking some scenarios, like transmission through food products, as very likely, while ranking others, like a laboratory biosafety incident, as “extremely unlikely” was foggy, with no real objective criteria measurement cited. The team discounted too rapidly the possibility that the virus could have emerged from a lab biosafety accident at the Wuhan Virology Institute – world-famous for its study of bat coronaviruses that are the closest known relatives of SARS-CoV2. WHO’s Peter Ben Embarek, head of the SARS CoV2 origins task team. Asked at the press briefing, how the team decided to rank the probability of the four different theories it considered, Ben Embarek said that the method was debate and discussion among the team members until they reached a consensus. And so it was also no surprise that WHO DIrector General Dr Tedros Adhanom Ghebreyesus, was already walking back on one of the report’s key conclusions. In a closed-door briefing to WHO member states, that preceded the report’s public release, the WHO Director General stated: “Although the team has concluded that a laboratory leak is the least likely hypothesis, this requires further investigation, potentially with additional missions involving specialist experts, which I am ready to deploy… I do not believe that this assessment was extensive enough. Further data and studies will be needed to reach more robust conclusions.” Significantly, Tedros himself also did not appear at the WHO media briefing – but rather let Ben Embarek, a WHO food safety expert who coordinated the mission by the international expert team to China, appear as the single WHO interlocutor on the public stage. And not long after the press conference was finished, some 14 governments led by the United States, Australia and Canada, but also including Denmark, Japan, Norway, Korea and the United Kingdom, issued a joint statement expressing, “shared concerns regarding the recent WHO-convened study in China, while at the same time reinforcing the importance of working together towards the development and use of a swift, effective, transparent, science-based, and independent process for international evaluations of such outbreaks of unknown origin in the future.” The group of 14 member states complained about the fact that the study was “significantly delayed and lacked access to complete, original data and samples”, stating that going forward, there is a need for “further studies of animals to find the means of introduction into humans. “Going forward,” the member states added,”it is critical for independent experts to have full access to all pertinent human, animal, and environmental data, research, and personnel involved in the early stages of the outbreak relevant to determining how this pandemic emerged. With all data in hand, the international community may independently assess COVID-19 origins, learn valuable lessons from this pandemic, and prevent future devastating consequences from outbreaks of disease.” Half Empty -missing and incomplete data Among the specifics being raised by experts and observers in the wake of the report’s release are the following: Weak rationale for the team’s dismissal of a coronavirus laboratory escape. As the international team members admitted themselves in the WHO press briefing, they lacked the competencies to carry out a ful-fledged laboratory investigation. The Wuhan Virology Institute staff, told the WHO team that although researchers at the institute had sequenced the genome of the RaTG13 horseshoe bat virus, which is the closest known relative to SARS CoV2, researchers did not maintain live samples of the virus on hand at the institute. that claim sounds disingenuous, because such samples were indeed collected by the institute in 2013 from a horseshoe-bat colony in Yunnan province, where a group of miners had died in 2012 from a mysterious SARS-like illness. And the institute’s research into those same coronaviruses is a matter of scientific record. In addition, the WHO team did not have access to raw data on the virology institute’s inventory samples or to data on the health status of institute employees, or serological testing, was made available to the investigators. Early spread of the coronavirus in Wuhan – the WHO-mandated team did not get full access to clinical patient data from the earliest known patients, or to the genomic sequences of the viruses with whch they were infected. Serological data available from blood banks, which could have been examined in retrospective studies similar to those carried out on Italy to identify asymptomatic virus carriers, also was not made available by the Chinese authorities. Such data would be critical to understanding where and how widely the virus was circulating prior to December 2019. Despite that, as team member Marion Kooperman’s noted at the WHO press briefing – data that the team did access suggested that as of December, there were already several coronavirus strains circulating in the city. Spread through the food cold chain – the theory touted by the Chinese government of virus spread through imported frozen food products is termed as a “possible pathway” in the report – when in fact little real evidence exists that such contamination could have triggered the Wuhan pandemic, and the conclusion that it is even “plausible” lacks analytical rigour. Evidence about spread through an intermediate wild animal host -while highly plausible as a theory, remains very incomplete, with the mapping of animal supply chains and products only at the initial stages. Half Full – Key insights gleaned Dr. Peter Daszak – President of the EcoHealth Alliance Despite the shortcomings, committee members at the briefing stressed the new evidence that they had gathered, which provides a basis to push ahead with more studies. Chief among those is a direct line of supply chain provision of wild animal products from regions such as Yunnan province, which are known to harbour bat coronaviruses similar to the SARS-CoV2 – to the Huanan Market in Wuhan – where the most intensive cluster of initial cases first appeared. Mapping of stalls in Wuhan’s Huanan market that sold farmed wildlife products from rural regions that are coronavirus hotspots. “Some of the market stalls in the (Huanan Seafood) market in Wuhan were selling [wild animal] foods foods originating from wildlife farms in known coronavirus hotspots” elsewhere in China, said Ben Embarek, citing what is perhaps one of the most important findings of the study. “From the animal side, … the events began to fit together when we looked at the molecular data the epi data and the animal data – they all seemed to fit to form a big picture story about what likely happened, and I think that’s quite exciting,” added Peter Daszak, a leading team member and president of the EcoHealth Alliance. “From the outside, it would have been incredible to have a bat with the exact same lineage of viruses, we didn’t see that yet – that will come in the future I think. “What we did see on the animal side is clear evidence… that there was a pathway to that market and animals that we know are Coronavirus carriers, from places where the nearest related viruses are. What that does is it shows you there is a pathway, that this virus could have taken to move 800-1000 miles from the rural parts of South China, Southeast Asia, into this market, that was exciting to see.” Those insights are all the more critical as the world grapples with a rapid pace of ecosystem deterioration, and more industrialized forms of animal food production, which present considerable risks of virus emergence that need to be better understood by the public at large. Dr. Marion Koopmans, Dutch virologist and epidemiologist On the patient side, despite the Chinese authorities’ fragmented provision of patient and epidemiological data, the evidence culled by the team still remains clear. Already in December 2019, there were diverse strains of the SARS-CoV2 virus already circulating in the city – suggesting that that the infection had already made its way into the city’s population some time before. Said Marion Koopmans, a Dutch virologist and epidemiologist: “The SARS CoV-2 virus was circulating in the Wuhan market market in December 2019, but it was also circulating elsewhere in the city, in cases unrelated to each other,” she noted at the press briefing. . The team also noted that despite the multiple restrictions and barriers put up by Chinese governmental authorities – the atmosphere between scientists remained positive – creating what Ben Embarek called a “space” for the scientists to do their work. And despite considerable pressure from China to point the finger abroad, the team’s testimony makes it clear that the next research steps on the virus trail must be taken in Wuhan, China as well as in rural areas that harbor bat coronaviruses – rather than more far-flung parts of the world. Moving Ahead – Balancing Political and Scientific Pressure What remains is a long road ahead, requiring investment in more rigorous, and as some team members rightly noted – more expensive studies – based upon evidence-driven demands and requests to Chinese authorities for more detailed data – on both the food safety as well as the human epidemiological side of the virus coin. In light of the WHO Director General’s comments about the inadequate analysis of the laboratory biosafety risks – it is also likely that WHO member states in Europe or the Americas (read USA), may demand a fresh query into that hypothesis – involving actual biosafety experts who were not members of the original virus origins team. Ultimately, It will be up to the WHO member states that mandated the report, informed by outside, independent experts and observers, to nurse the origins study – or studies – through to more significant, and final conclusions. In that quest, Europe, the United States and their allies will need to steer a delicate course between exertion of the right amount of political pressure on the one hand – and alienating attacks that only foster anger and geopolitical tensions of the kind visibly on display during the era of former US President Donald Trump. And from the point of view of scientists – It is a process that may require months, if not several years – WHO’s Ben Embarek warned. “”How long will it take? That is always difficult to predict.” he said, pleading with the world to “please be patient.” Although, despite the heat that the WHO team has received, his appeal was shadowed with appreciation for the fact that a certain amount of vigilance – may also be constructive: “It’s an exciting adventure that I hope the whole world will continue to follow.. it’s a fascinating journey and a critical one because it’s the only way we can understand what happened, and more recently tried to prevent something similar for happening again.” Image Credits: Sputnik, WHO. Global Leaders Call For New Treaty To Bolster Resilience Against Future Pandemics 30/03/2021 Svĕt Lustig Vijay Charles Michel, President of the European Council After the COVID-19 pandemic exposed fundamental flaws in the global health architecture, a proposal for a new pandemic treaty that could strengthen the world’s capacity to contain the current pandemic and prepare for future ones, is gaining momentum. That was a key message at a World Health Organization (WHO) launch of an open letter by 25 global leaders calling for the world to negotiate such a treaty, featuring Charles Michel, President of the European Council, and two dozen other global leaders that are now backing the treaty initiative. Other signatories now include the United Kingdom’s Boris Johnson, Germany’s Angela Merkel, France’s Emmanuel Macron, along with the leaders of Indonesia, Kenya, Rwanda and South Africa’s Cyril Ramaphosa. But China, the United States and Russia have yet to sign the call. “Today, we are calling for an international treaty on pandemics [to] foster a comprehensive approach to better predict, prevent and respond to pandemics,” said Michel, who has championed the treaty since late last year saying that the treaty would support the principle of “health for all”. If ratified, the treaty will give the WHO the political clout to better carry out part of its mandate in terms of improved pandemic alert systems, better investments in coronavirus research, and sharing of crucial data on infectious pathogens, vaccine supply chains and vaccine formulas. WHO’s director-general Dr. Tedros Adhanom Ghebreyesus echoed Michel’s sentiments, saying: “The time to act is now”. “The world cannot afford to wait until the pandemic is over to start planning for the next one. We cannot do things the way we have done them before and expect a different result. Without an internationally coordinated response…we remain vulnerable,” said Dr Tedros. Pandemic Treaty Rooted In WHO Constitution No single country can address pandemics alone. An international #PandemicTreaty would promote a global system to better prevent, predict & recover from future pandemics like #COVID19. Find out more on why we need a new treaty on pandemics ➡️https://t.co/iY2qUGLcPn pic.twitter.com/YkEL0LEzKl — EU Council (@EUCouncil) March 30, 2021 The treaty “would be rooted in the constitution of the World Health Organisation, drawing in other relevant organizations key to this endeavour,” said the letter, also signed by the heads of: Albania, Chile, Costa Rica, Greece, Korea, Trinidad and Tobago, the Netherlands, Senegal, Spain, Norway, Serbia, Indonesia, and Ukraine. “Existing global health instruments, especially the International Health Regulations, would underpin such a treaty, ensuring a firm and tested foundation on which we can build and improve.” The Pandemic Treaty Will Strengthen WHO’s Mandate According to Michel, “Such a treaty [could] play an interesting role in order to make sure that we have more transparency on the supply chains [and] on the level of productions of vaccines and of tests; it will mean more rust and better cooperation.” Michel suggested that the treaty could also be used to expand vaccine production by facilitating technology transfer in low- and middle-income countries, referring to the “third way” initially proposed by the World Trade Organisation’s (WTO) new chief Ngozi Okonjo-Iweala. “Certainly there is a debate in the international community about how to improve our vaccine production capacities to improve vaccine coverage, particularly in the African continent,” said Michel, adding that “we are closely following the debate at the WTO for the ‘third way’ voiced by Ngozi”. US and China Didn’t Sign Call – But Sent Positive ‘Comments’ WHO’s director-general Dr. Tedros Adhanom Ghebreyesus Although China and the US did not sign Tuesday’s op-ed, Dr Tedros said that that both countries had voiced “positive” comments during informal discussions with Member States – and that it was not necessarily an issue that the op-ed had only been signed by two dozen countries. “It doesn’t need to be all 194 countries [to write an op-ed],” said Dr. Tedros. “I don’t want it to be seen as a problem, it wasn’t even a problem. When the discussion on the global pandemic treaty starts, all Member States will be represented.” The Pandemic Treaty Will Synergize With The International Health Regulations Meanwhile, Mike Ryan, WHO’s Director of Emergency Programmes, emphasised that the treaty would “by no means” undermine the existing global framework that governs WHO countries’ behaviour during health emergencies – the legally binding International Health Regulations (IHRs). These regulations set out the mandates under which countries are obliged to report on disease outbreak risks, and share epidemic information, with WHO and other member states. Rather, the pandemic treaty would generate the necessary political commitment to ensure that the IHRs are implemented; and bolster global pandemic preparedness and response by covering a broader set of issues than those covered by the IHRs, such as the sharing of crucial data. “The IHRs…is a really really good instrument,” said Ryan. “But in itself [it] is a piece of legislation that is without meaning unless countries are fully committed to its implementation.” “IHR only works if we have trust, if we have transparency, if we have accountability. Such a treaty would provide that political framework in which we in public health can do our work much more effectively.” “The proposed treaty will definitely bring strong political commitment and support for the IHR implementation,” added Jaouad Mahjour, WHO Regional Director for the Eastern Mediterranean region, who also spoke at Tuesday’s press conference. In an initial response to the initiative, the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) said that pharma partners should play a role in shaping such a treaty. The statement reflected IFPMA concerns over preserving what it described as the patent “incentive system” for developing new vaccines and medicines. “The discussions around a possible International Pandemic Treaty need to take into account the important role played by the innovative biopharmaceutical industry and its supply chain in fighting the virus,” said the IFPMA statement. “It will be important to acknowledge the critical role played by the incentive system in developing tests, therapeutics, and vaccines to contain and defeat the coronavirus. We hope that the discussions on an International Pandemic Treaty will address enablers for future pandemic preparedness – the importance of incentives for future innovation, the immediate and unrestricted access to pathogens, and the importance of the free flow of goods and workforce during the pandemic – in addition to continuing the multi stakeholder approach undertaken in ACT-A and COVAX.” Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
A Good Place To Start To Beat The COVID Obesity Pandemic – Warning Labels on Unhealthy Foods 01/04/2021 Svĕt Lustig Vijay The obesity pandemic is in “the same room” as the COVID pandemic in terms of its threats to health – putting people at greater risk of premature death from multiple causes, including SARS-CoV-2, the virus that leads to COVID-19. And ever since stay-at-home measures became routine, people have gained even more weight – up to 1.5 pounds a month according to one recent US study. Yet countries have the tools to address obesity, note Trish Cotter and Dr. Nandita Murukutla at Vital Strategies, a global public health NGO. We spoke to Ms. Cotter and Dr. Murukutla to find out more: Health Policy Watch (HPW): A third of the global population now suffers from overweight, and rates of obesity are growing across the world, including in poor countries. How can we explain these trends? Vital Strategies (VS): Over the last 40 years, obesity rates around the world have ballooned. High-income countries, like the United States, were the first to experience substantial weight gains of their populations, but the 21st century has seen that phenomenon spread to all parts of the globe. Now, the average adult is three times as likely to be overweight as the average adult in the 1970s. There are a number of reasons for this alarming trend, which began well before COVID-19, starting with the environments in which people live, as well as poverty, discrimination, increasing availability of unhealthy foods in schools, dwindling levels of physical activity, and a lack of knowledge of unhealthy diets and products. However, the fundamental reason is the rapid change in our diets and the broader food environment. Ultra-processed products or “junk food”, such as soft drinks, ice creams, or prepared frozen dishes, are one of the key drivers of growing obesity worldwide. They are high in sugar, salt and fat and, unfortunately, widespread in most societies. Yet their harmful effects are poorly understood. One in three people worldwide are overweight HPW: Why are ultra-processed foods so ubiquitous? VS: They are cheap, easily available, and because of additives and preservatives, they have a long shelf-life. They’re made to feel and look attractive, and they’re made to taste good. Importantly, they’re also hyper-marketed by the food industry. Advertising campaigns are very good at making unhealthy products seem part of the fabric of society: unhealthy foods are made to seem crucial to family gatherings and entertainment, so they become part of the social norm that normalizes unhealthy foods. And much of the advertising around unhealthy foods is so enticing that it gets children hooked at a young age. In what ways is advertising of ultra-processed products misleading? Unhealthy products are often marketed cleverly as convenient substitutes for healthy, minimally processed options that include whole grains, fruits and vegetables. They are marketed as convenient breakfast foods, snacks, juices, and sometimes they are also marketed as being more sanitary than fresh fruits and vegetables. But that’s misleading, because current evidence demonstrates that ultra-processed products result in worse diets and ultimately overweight and obesity, which exacerbates the risk of contracting a range of chronic diseases as well as suffering poorer outcomes from infectious diseases like COVID-19. Claims that ultra-processed products are healthy alternatives are untrue. Can you give a concrete example of a strategy that misleads customers into thinking they’re buying healthy products? Labels on the front and back of food packages are often really hard to accurately decode. And many of these labels use clever algorithms to hide unhealthy levels of sugar, salt, and saturated fat. Customers may not always realize that the product they are buying is unhealthy. Late last year, you co-authored a guide to help policymakers introduce clear, yet highly effective warning labels on foods and beverages to nudge customers away from unhealthy foods. How do these warning labels work? Front-of-Package (FOP) nutrient labels, sometimes called warning labels, tell consumers immediately, on the front of products, and simply when a product contains high levels of unhealthy nutrients. That means customers don’t need to spend several minutes trying to work out whether each product is healthy or not. This system is simple, visual, and easy to understand. And it is effective, as seen from studies across the world, in triggering immediate behavior change. The front-of-package labels serve as behavioral nudges, protecting people from making unintended unhealthy purchases. In other words, the warning labels work by reminding consumers that the products they are purchasing are unhealthy, thus nudging them to make healthier choices. But they also have important knock-on effects: they help change social norms around unhealthy eating. Example of warning labels on food products in Chile to nudge customers away from unhealthy foods. Translation from top-left to bottom-right: high in calories; high in sugars; high in sodium; high in saturated fats. Source: Ministry of Health of Chile. You mentioned that warning labels can help change social norms that promote the consumption of unhealthy foods. Can you unpack that? One study found that children pestered their parents to buy healthier products that did not have warning labels, partially because teachers at school would not accept unhealthy snacks. In some cases, teachers would even confiscate unhealthy snacks brought by children. This suggests that something as simple as a warning label can challenge the idea that ultra-processed products are desirable, and start to change the social norm. It’s also important to reiterate that warning labels are a highly cost-efficient approach because you’re able to target consumers rapidly, constantly, and at the point of decision making to make a purchase or not, with little to no cost to the government. And the costs of not addressing obesity during the pandemic could amount to $US 7 trillion by 2025, according to the latest review by the World Obesity Federation. Furthermore, out of a total of 2.5 million deaths from COVID reported as of February, 2021, 2.2 million were in countries where over half of the population is overweight. Countries with high proportions of overweight people had coronavirus death toll that were ten times higher than those with low proportions of overwheight people So far, six countries including Chile have legally mandated warning labels, although many have put in place “voluntary” systems. How well do the voluntary systems work ? The voluntary systems, which do not legally mandate warning labels on every single food product, are not effective. As warning labels may reduce sales of unhealthy foods, the food industry is unlikely to take them up. That’s why mandatory regulations on warning labels are crucial if we want to make a real dent into obesity and overweight. We’ve seen these warning labels work very well in Chile where they contributed to a decrease in the consumption of sugar-sweetened beverages by almost 25%. This was achieved through a comprehensive approach to addressing obesity, which also included: restrictions on child-directed marketing of unhealthy foods and beverages on the radio, television, cinema, and internet; a ban of unhealthy foods and beverages in schools and daycare; and a tax on sugary drinks. What kinds of labels work best? There are two broad categories of labels. The first category, the so-called “reductive” labels, outline how much of each nutrient is contained in foods, but they don’t help the consumer decide whether the product is healthy or not. These labels are less effective. The second category of labels, the so-called “interpretive” labels, are much more effective. They draw attention to the nutrients of concern or summarize the overall healthfulness of the product. Thus, they can help consumers distinguish between healthy and unhealthy products immediately through clear visual cues. The so-called “interpretive” labels can help consumers quickly identify nutrients of concern in food products to make healthier decisions What are the challenges to getting countries to act? Although a number of high-level commitments have been made to fight obesity, including the inclusion of a target in the SDGs , The UN High-Level Meetings on NCDs as well as the UN Decade of Action on Nutrition, a lot more can and needs to be done. But that said, there is very strong industry pushback, and that’s also not surprising. We have seen decades of this with regard to other issues like tobacco control. Industry pressure cannot be underestimated and industry interference is often what holds governments back. However, governments should not feel powerless to take on food policy. The tools are out there to help them do this effectively and cheaply. Are there any other policies that can be used alongside mandatory warning labels to cut obesity and overweight? Sugary drinks taxes are among the most effective and cost-efficient ways to reduce access to unhealthy foods. Marketing restrictions and the removal of misleading advertising, especially in schools and environments in which children reside, is crucial. Bans on unhealthy products in schools can also help. We also need to ensure that healthy food becomes the default option by making sure that it’s easily available and cheap enough to buy – and at the same time ensure that unhealthy foods like ultra-processed foods are less available. And as mentioned earlier, it’s important to change those social norms around unhealthy foods so that they’re not associated with what marketers want you to associate them with – families, warmth, love, sports – and all of the things that bring people together. Where do we go from here? And let’s be honest that food labels are not a panacea – what about access to healthier diets generally, which are often more expensive than unhealthy diets. And what about environments where people can be physically active? With more than one-third of the world’s population overweight or obese, and the COVID-19 pandemic revealing deep structural inequities in food environments, the push to combat obesity has become more urgent than ever. Many individuals are powerless in the face of food shortages and the over-availability of cheap ultra-processed foods. The onus is on governments to act, and to act now. There were a number of factors, from environmental, structural to social, that brought us where we are today, and we will likewise need a concerted and cohesive set of actions to reverse these trends. FoP warning labels are a strong place to start. Read more here on Vital Strategies’ new guide to help policymakers design and implement warning labels on foods and beverages. Trish Cotter, MPH, Global Lead, Food Policy Program and Senior Advisor, Vital Strategies Dr. Nandita Murukutla, Vice President for Global Policy and Research, Vital Strategies Image Credits: University of Michigan, World Obesity Federation, Vital Strategies, Food Standard Agency, Vital Strateggies, Vital Strategies. Nigeria Pivots From AstraZeneca To Johnson & Johnson COVID-19 Vaccine 31/03/2021 Paul Adepoju The Nigerian government has ditched the AstraZeneca COVID-19 vaccine and will soon shift to the Johnson & Johnson’s one-shot vaccine. EXCLUSIVE – IBADAN – The Nigerian government has quietly ditched the AstraZeneca COVID-19 vaccine meant to vaccinate tens of millions of citizens, and will gradually shift to the Johnson & Johnson’s one-shot vaccine, saying it is easier to administer. Documents from the Nigerian Primary Healthcare Development Agency (NPHCDA) obtained by Health Policy Watch show that the agency intends to begin rolling out the J&J vaccine to almost 30 million people as soon as it can obtain the vaccine supplies. While denying that safety concerns are an issue, the Nigerian government’s move also comes amidst growing global concerns about AstraZeneca’s efficacy against the SARS-CoV2 virus variant first identified in South Africa, as well as safety concerns that have led to the suspension of AstraZeneca vaccines for people under the age of 60 in Germany, and elsewhere (see related story). Nigeria had already commenced the rollout of the AstraZeneca vaccine, with vaccines supplied by the WHO co-sponsored COVAX initiative. The country was meant to get more AstraZeneca supplies though the African Medical Supplies Platform (AMSP) – having already placed the largest order on the continent through the AMSP, as previously confirmed by the Africa Centres for Disease Control (CDC). However, according to the documents, the AstraZeneca vaccine doses reserved through the AMSP will be replaced with Johnson & Johnson vaccines. “Based on this, Nigeria’s total allocation is now 29,850,000 of Johnson & Johnson (Janssen) COVID-19 vaccine which is one dose shot to cover 29,850,000 eligible Nigerians as originally planned,” the agency stated. That would be enough to cover about 15% of Nigeria’s population of 200 million people. Government Says J&J ‘One Jab’ Vaccine, not Safety Worries, Are Behind Shift Government officials in Nigeria attributed the shift to J&J’s to the vaccine’s single jab technology – which will make it much easier to administer as compared to AstraZeneca’s two-dose shot – as well as ensuring the vaccine coverage stretches even further. They denied that it was linked to issues of safety and efficacy. However, behind the scenes, another factor is the J&J vaccine’s documented efficacy against the B.1351 virus variant identified in South Africa – and now spread to some 16 other countries on the continent, including nearby Ghana. South Africa on Monday announced that it has secured 30 million J&J vaccines after a small clinical trial and genomic surveillance showed the AstraZeneca vaccine was not strongly effective against that variant. In an earlier advisory, the Africa CDC stated that African countries where the B.1351 variant is the predominant SARS-CoV-2 strain should consider swapping the AstraZeneca vaccine for others that have shown more efficacy. Neither the AMSP or the Africa CDC could confirm when the J&J doses will become available. A recently announced J&J commitment to supply some 400 million vaccines to Africa is only scheduled to get into motion in the third quarter of 2021. Meanwhile, the continent continues to call for vaccine equality, fair distribution and local vaccine production. Nigerian Regulator’s Nod Government officials have continued to assure citizens of the safety of the vaccine despite global concerns – as it continues to roll-out the available AstraZeneca doses while it awaits the J&J vaccines. On Feb 18, just a few days after Nigeria received its first shipment of the AstraZeneca vaccine, the country’s drug regulator, the National Agency for Food and Drug Administration and Control (NAFDAC) approved the vaccine for emergency use. “The recommendation for Emergency Use Authorization was based on rigorous scientific considerations,” NAFDAC stated. Addressing a recent webinar on COVID-19 Vaccines, Dr. Faisal Shuaib, Executive Director/CEO of NPHCDA, acknowledged that the controversy around the vaccine’s safety, but urged countries in Europe and globally to continue vaccine administration as it is safe and effective. Prof Mojisola Christianah Adeyeye, NAFDAC’s Director General added that safety of the vaccine is primary to the agency and that it would be using its Med Safety App for Active Pharmacovigilance of the vaccine. Immunisation Drive Continues As at March 31, over 718,000 Nigerians had received the first doses of the available AstraZeneca vaccine supplies; coverage ranges from an over-the-top 104% target of priority patients reached in Kwara state to none at all in Kogi state – where a vaccine-hesitant government is only just now succumbing to pressure to allow citizens to receive the vaccine. But a cross section of health experts speaking at the recent Nigerian Academy of Science webinar said the bad publicity around the AstraZeneca vaccine might also have harmed vaccination in general. Recent news emanating from Europe has made the general public more suspicious of the potential lethal effects of the jabs – in addition to widespread misinformation circulating on social media. Dr Yahya Disu, Head of Risk Communication at the Nigeria Center for Disease Control (NCDC), said recent surveys show broad acceptance of vaccines among Nigerians and this is expected to ensure the country quickly achieves herd immunity – provided sufficient vaccines are made available. Disu said 86% of respondents of the surveys said they would still continue preventive measures such as wearing face masks, handwashing and social distancing even after receiving the vaccines. Pfizer Vaccine ‘Safe and Protective’ for Adolescents – Early Data Release 31/03/2021 Chandre Prince Pfizer and its German partner BioNTech say their COVID-19 vaccine is safe and protective in children as young as 12. The Pfizer-BioNTech COVID-19 vaccine is safe and protective in children as young as 12 with no serious side effects in adolescents who received the vaccination, the company said on Wednesday. Interim results of a recent clinical trial of some 2,260 adolescents ages 12-15 years old was published by the pharma company – although it has not yet undergone peer review. The adolescents who participated in the trial produced strong antibody responses and experienced no serious side effects, the company said, saying the vaccine had demonstrated “100 % efficacy”. Pfizer and its German partner BioNTech plan to ask the U.S. Food and Drug Administration and European regulators to allow emergency use of the shots among adolescents, beginning at age 12. Pfizer’s vaccine is already authorised by regulatory authorities for teens ages 16 and older.“We share th e urgency to expand the use of our vaccine,” Pfizer CEO Albert Bourla said in a statement. He expressed “the hope of starting to vaccinate this age group before the start of the next school year” in the United States. Pfizer isn’t the only company seeking to lower the age limit for its vaccine. Results also are expected soon from a U.S. study of Moderna’s vaccine in 12- to 17-year-olds. Another vaccine study of safety and efficacy in children ages 6 months to 11 years is also underway, but that has yet to yield preliminary results. See the full release here. Germany Suspends Use of AstraZeneca For Younger Population Over Reports of Rare Blood Cloth Cases 31/03/2021 Chandre Prince German Health Minister Jens Spahn and German Chancellor Angela Merkel during a joint press conference announcing the suspension of the use of the AstraZeneca COVID-19 vaccine. Germany has suspended the use of the AstraZeneca coronavirus vaccine for people under the age of 60 amidst fresh concerns of unusual blood clot cases among some people receiving the vaccine, particularly women, and leading to the deaths of nine people in all. German Chancellor Angela Merkel and Health Minister Jens Spahn made the announcement on Tuesday after the country’s Standing Committee on Vaccination (STIKO) reviewed more data on emerging cases of rare blood clots in people immunised with the vaccine, produced by the Anglo-Swedish drug maker. Germany’s medical regulator made the call after researchers at the federal government’s Paul Ehrlich Institute, said they had recorded 31 cases of rare blot clot abnormalities, among the 2.7-million Germans who have thus far received the AstraZeneca vaccine. All cases were younger than 63, and all but two were women. The cases involved cerebral venous thrombosis (CSVT), a rare clot in blood draining from the brain, but also related to abnormally low levels of platelets, which help blood clot, and bleeding near the site of vaccination. “The experts of the Paul-Ehrlich-Institut now see a striking accumulation of a special form of very rare cerebral vein thrombosis (sinus vein thrombosis) in connection with a deficiency of blood platelets (thrombocytopenia) and bleeding in temporal proximity to vaccinations with the COVID-19 vaccine AstraZeneca,” said a news release of PEI, the Federal Institute for Vaccines and Biomedicines. Several German regions — including the capital Berlin and the country’s most populous state, North Rhine-Westphalia — had already suspended use of the shots in younger people earlier on Tuesday. Merkel said that the government “cannot ignore” STIKO’s recommendation or the data about blood clots developing following shots with the vaccine. Germany Has Other Vaccine Options For Younger People Germany has suspended the use of the AstraZeneca vaccine in people under 60 years of age. “We all know that vaccination is the most important tool against the coronavirus,” said Merkel, adding there were other options for younger people. “We are not faced with the question of AstraZeneca or no vaccine,” she said. “Instead we have several vaccines at our disposal.” Spahn said the vaccine would only be administered to people aged 60 or older, unless they belong to a high-risk category for serious illness from COVID-19 and have agreed to take the vaccine despite the small risk of a serious side-effect. “In sum it’s about weighing the risk of a side effect that is statistically small, but needs to be taken seriously, and the risk of falling ill with corona,” Spahn said during a press briefing. He said the decision was taken “on the basis of currently available data on the occurrence of rare, but very serious thrombosis-related side-effects.” The commission said that it would issue guidelines on what to do for adults under 60 who had received a first AstraZeneca shot and were due another by the end of April. Suspension – A Blow To Germany’s Vaccine Roll-out The decision to suspend use of the vaccine for under-60s was “without doubt a setback” for the vaccination campaign, in which the AstraZeneca vaccine was a centrepiece, Spahn acknowledged. It comes as Germany, along with other European countries, scrambles to ramp up its vaccine programme, which lags far behind those in Britain and the United States. By Monday, some 13.2 million people in Germany, a country of some 83 million people, had received at least one dose of one of Europe’s approved vaccines, while only 4 million had received two vaccine doses. Germany is due to receive 15 million more AstraZeneca doses in the second quarter of 2021. Spahn said the new supply would be made available to people over 60 who might otherwise have had to wait longer, reducing their risk of falling seriously ill with COVID-19. Germany’s U-turn On AstraZeneca Use of the AstraZeneca vaccine was temporarily halted in Germany, as well as in several other European countries, earlier this month when concerns about occurrences of the rare blood clots first emerged. Then, just under two weeks ago, the European Medicines Agency said that the vaccine is safe and that its benefits outweigh the risks, and the vaccine rollout in Germany and elsewhere in Europe resumed. Paradoxically, earlier in the vaccine rollout, Germany had refrained from administering the AstraZeneca vaccine to people 65 and over, citing insufficient evidence of its efficacy in that age group at the time. Other Countries Restrict Use of AstraZeneca On March 29, Canada’s vaccination committee also recommended suspending the AstraZeneca jab for people under 55, citing reports coming out of Europe of blood clotting incidents. France limited its use to people older than 55. Norway, where regulators say four people died of blood clots among about 120,000 people who received the AstraZeneca jab, has also suspended the vaccine. Sweden has resumed AstraZeneca use for people older than 65. The vaccine is not yet cleared for use in the United States. An independent panel of medical experts overseeing the US trials took the unusual move last week of accusing the company of providing an “incomplete view” of efficacy data in its U.S. trials. On Monday, Canada also recommended halting the use of the jab for people under 55 “pending further analysis”. Researchers Find Association with Clots; AstraZeneca says Vaccine is “safe and effective” The suspensions also come in the wake of a March 28 pre-print report from researchers in Germany, Canada and Austria, including a scientist at the Paul-Ehrlich-Institute, which linked the vaccine to the development of a blood clotting disorder. However, some academics have said that the paper’s implication of a causal association isn’t backed up by evidence. In a statement ahead of the announcement, AstraZeneca said tens of millions of people worldwide have received its vaccines. The company said it would would analyse its own records to understand whether the rare blood clots reported occur more commonly “than would be expected naturally in a population of millions of people.” Image Credits: Clemens Bilan. SARS-CoV2 Virus Origins Report – Only Beginning Of Process Says WHO; 14 Member States Call For More Transparency 30/03/2021 Elaine Ruth Fletcher The most important takeaway about the just-released WHO report on the origins of the SARS-CoV2 virus that has infected over 100 million people to date may not be its initial findings, which need to be held under the microscope, but the fact that it has been issued at all. Speaking at a press conference on Tuesday, WHO’s Peter Ben Embarek, who coordinated the politically fraught WHO mission to Wuhan, China in January and the report produced after the visit – stressed that it was the beginning of a process – and a quest. It will take much more time for the 17 members of the international expert committee – and the world – to unravel. Glass Half Full – Half Empty WHO press briefing Tuesday with members of the international team tasked with tracing the origins of SARS-CoV2 The weaknesses of the report are already apparent, say experts, whose views were shared confidentially with Health Policy Watch. The committee’s methodology for ranking some scenarios, like transmission through food products, as very likely, while ranking others, like a laboratory biosafety incident, as “extremely unlikely” was foggy, with no real objective criteria measurement cited. The team discounted too rapidly the possibility that the virus could have emerged from a lab biosafety accident at the Wuhan Virology Institute – world-famous for its study of bat coronaviruses that are the closest known relatives of SARS-CoV2. WHO’s Peter Ben Embarek, head of the SARS CoV2 origins task team. Asked at the press briefing, how the team decided to rank the probability of the four different theories it considered, Ben Embarek said that the method was debate and discussion among the team members until they reached a consensus. And so it was also no surprise that WHO DIrector General Dr Tedros Adhanom Ghebreyesus, was already walking back on one of the report’s key conclusions. In a closed-door briefing to WHO member states, that preceded the report’s public release, the WHO Director General stated: “Although the team has concluded that a laboratory leak is the least likely hypothesis, this requires further investigation, potentially with additional missions involving specialist experts, which I am ready to deploy… I do not believe that this assessment was extensive enough. Further data and studies will be needed to reach more robust conclusions.” Significantly, Tedros himself also did not appear at the WHO media briefing – but rather let Ben Embarek, a WHO food safety expert who coordinated the mission by the international expert team to China, appear as the single WHO interlocutor on the public stage. And not long after the press conference was finished, some 14 governments led by the United States, Australia and Canada, but also including Denmark, Japan, Norway, Korea and the United Kingdom, issued a joint statement expressing, “shared concerns regarding the recent WHO-convened study in China, while at the same time reinforcing the importance of working together towards the development and use of a swift, effective, transparent, science-based, and independent process for international evaluations of such outbreaks of unknown origin in the future.” The group of 14 member states complained about the fact that the study was “significantly delayed and lacked access to complete, original data and samples”, stating that going forward, there is a need for “further studies of animals to find the means of introduction into humans. “Going forward,” the member states added,”it is critical for independent experts to have full access to all pertinent human, animal, and environmental data, research, and personnel involved in the early stages of the outbreak relevant to determining how this pandemic emerged. With all data in hand, the international community may independently assess COVID-19 origins, learn valuable lessons from this pandemic, and prevent future devastating consequences from outbreaks of disease.” Half Empty -missing and incomplete data Among the specifics being raised by experts and observers in the wake of the report’s release are the following: Weak rationale for the team’s dismissal of a coronavirus laboratory escape. As the international team members admitted themselves in the WHO press briefing, they lacked the competencies to carry out a ful-fledged laboratory investigation. The Wuhan Virology Institute staff, told the WHO team that although researchers at the institute had sequenced the genome of the RaTG13 horseshoe bat virus, which is the closest known relative to SARS CoV2, researchers did not maintain live samples of the virus on hand at the institute. that claim sounds disingenuous, because such samples were indeed collected by the institute in 2013 from a horseshoe-bat colony in Yunnan province, where a group of miners had died in 2012 from a mysterious SARS-like illness. And the institute’s research into those same coronaviruses is a matter of scientific record. In addition, the WHO team did not have access to raw data on the virology institute’s inventory samples or to data on the health status of institute employees, or serological testing, was made available to the investigators. Early spread of the coronavirus in Wuhan – the WHO-mandated team did not get full access to clinical patient data from the earliest known patients, or to the genomic sequences of the viruses with whch they were infected. Serological data available from blood banks, which could have been examined in retrospective studies similar to those carried out on Italy to identify asymptomatic virus carriers, also was not made available by the Chinese authorities. Such data would be critical to understanding where and how widely the virus was circulating prior to December 2019. Despite that, as team member Marion Kooperman’s noted at the WHO press briefing – data that the team did access suggested that as of December, there were already several coronavirus strains circulating in the city. Spread through the food cold chain – the theory touted by the Chinese government of virus spread through imported frozen food products is termed as a “possible pathway” in the report – when in fact little real evidence exists that such contamination could have triggered the Wuhan pandemic, and the conclusion that it is even “plausible” lacks analytical rigour. Evidence about spread through an intermediate wild animal host -while highly plausible as a theory, remains very incomplete, with the mapping of animal supply chains and products only at the initial stages. Half Full – Key insights gleaned Dr. Peter Daszak – President of the EcoHealth Alliance Despite the shortcomings, committee members at the briefing stressed the new evidence that they had gathered, which provides a basis to push ahead with more studies. Chief among those is a direct line of supply chain provision of wild animal products from regions such as Yunnan province, which are known to harbour bat coronaviruses similar to the SARS-CoV2 – to the Huanan Market in Wuhan – where the most intensive cluster of initial cases first appeared. Mapping of stalls in Wuhan’s Huanan market that sold farmed wildlife products from rural regions that are coronavirus hotspots. “Some of the market stalls in the (Huanan Seafood) market in Wuhan were selling [wild animal] foods foods originating from wildlife farms in known coronavirus hotspots” elsewhere in China, said Ben Embarek, citing what is perhaps one of the most important findings of the study. “From the animal side, … the events began to fit together when we looked at the molecular data the epi data and the animal data – they all seemed to fit to form a big picture story about what likely happened, and I think that’s quite exciting,” added Peter Daszak, a leading team member and president of the EcoHealth Alliance. “From the outside, it would have been incredible to have a bat with the exact same lineage of viruses, we didn’t see that yet – that will come in the future I think. “What we did see on the animal side is clear evidence… that there was a pathway to that market and animals that we know are Coronavirus carriers, from places where the nearest related viruses are. What that does is it shows you there is a pathway, that this virus could have taken to move 800-1000 miles from the rural parts of South China, Southeast Asia, into this market, that was exciting to see.” Those insights are all the more critical as the world grapples with a rapid pace of ecosystem deterioration, and more industrialized forms of animal food production, which present considerable risks of virus emergence that need to be better understood by the public at large. Dr. Marion Koopmans, Dutch virologist and epidemiologist On the patient side, despite the Chinese authorities’ fragmented provision of patient and epidemiological data, the evidence culled by the team still remains clear. Already in December 2019, there were diverse strains of the SARS-CoV2 virus already circulating in the city – suggesting that that the infection had already made its way into the city’s population some time before. Said Marion Koopmans, a Dutch virologist and epidemiologist: “The SARS CoV-2 virus was circulating in the Wuhan market market in December 2019, but it was also circulating elsewhere in the city, in cases unrelated to each other,” she noted at the press briefing. . The team also noted that despite the multiple restrictions and barriers put up by Chinese governmental authorities – the atmosphere between scientists remained positive – creating what Ben Embarek called a “space” for the scientists to do their work. And despite considerable pressure from China to point the finger abroad, the team’s testimony makes it clear that the next research steps on the virus trail must be taken in Wuhan, China as well as in rural areas that harbor bat coronaviruses – rather than more far-flung parts of the world. Moving Ahead – Balancing Political and Scientific Pressure What remains is a long road ahead, requiring investment in more rigorous, and as some team members rightly noted – more expensive studies – based upon evidence-driven demands and requests to Chinese authorities for more detailed data – on both the food safety as well as the human epidemiological side of the virus coin. In light of the WHO Director General’s comments about the inadequate analysis of the laboratory biosafety risks – it is also likely that WHO member states in Europe or the Americas (read USA), may demand a fresh query into that hypothesis – involving actual biosafety experts who were not members of the original virus origins team. Ultimately, It will be up to the WHO member states that mandated the report, informed by outside, independent experts and observers, to nurse the origins study – or studies – through to more significant, and final conclusions. In that quest, Europe, the United States and their allies will need to steer a delicate course between exertion of the right amount of political pressure on the one hand – and alienating attacks that only foster anger and geopolitical tensions of the kind visibly on display during the era of former US President Donald Trump. And from the point of view of scientists – It is a process that may require months, if not several years – WHO’s Ben Embarek warned. “”How long will it take? That is always difficult to predict.” he said, pleading with the world to “please be patient.” Although, despite the heat that the WHO team has received, his appeal was shadowed with appreciation for the fact that a certain amount of vigilance – may also be constructive: “It’s an exciting adventure that I hope the whole world will continue to follow.. it’s a fascinating journey and a critical one because it’s the only way we can understand what happened, and more recently tried to prevent something similar for happening again.” Image Credits: Sputnik, WHO. Global Leaders Call For New Treaty To Bolster Resilience Against Future Pandemics 30/03/2021 Svĕt Lustig Vijay Charles Michel, President of the European Council After the COVID-19 pandemic exposed fundamental flaws in the global health architecture, a proposal for a new pandemic treaty that could strengthen the world’s capacity to contain the current pandemic and prepare for future ones, is gaining momentum. That was a key message at a World Health Organization (WHO) launch of an open letter by 25 global leaders calling for the world to negotiate such a treaty, featuring Charles Michel, President of the European Council, and two dozen other global leaders that are now backing the treaty initiative. Other signatories now include the United Kingdom’s Boris Johnson, Germany’s Angela Merkel, France’s Emmanuel Macron, along with the leaders of Indonesia, Kenya, Rwanda and South Africa’s Cyril Ramaphosa. But China, the United States and Russia have yet to sign the call. “Today, we are calling for an international treaty on pandemics [to] foster a comprehensive approach to better predict, prevent and respond to pandemics,” said Michel, who has championed the treaty since late last year saying that the treaty would support the principle of “health for all”. If ratified, the treaty will give the WHO the political clout to better carry out part of its mandate in terms of improved pandemic alert systems, better investments in coronavirus research, and sharing of crucial data on infectious pathogens, vaccine supply chains and vaccine formulas. WHO’s director-general Dr. Tedros Adhanom Ghebreyesus echoed Michel’s sentiments, saying: “The time to act is now”. “The world cannot afford to wait until the pandemic is over to start planning for the next one. We cannot do things the way we have done them before and expect a different result. Without an internationally coordinated response…we remain vulnerable,” said Dr Tedros. Pandemic Treaty Rooted In WHO Constitution No single country can address pandemics alone. An international #PandemicTreaty would promote a global system to better prevent, predict & recover from future pandemics like #COVID19. Find out more on why we need a new treaty on pandemics ➡️https://t.co/iY2qUGLcPn pic.twitter.com/YkEL0LEzKl — EU Council (@EUCouncil) March 30, 2021 The treaty “would be rooted in the constitution of the World Health Organisation, drawing in other relevant organizations key to this endeavour,” said the letter, also signed by the heads of: Albania, Chile, Costa Rica, Greece, Korea, Trinidad and Tobago, the Netherlands, Senegal, Spain, Norway, Serbia, Indonesia, and Ukraine. “Existing global health instruments, especially the International Health Regulations, would underpin such a treaty, ensuring a firm and tested foundation on which we can build and improve.” The Pandemic Treaty Will Strengthen WHO’s Mandate According to Michel, “Such a treaty [could] play an interesting role in order to make sure that we have more transparency on the supply chains [and] on the level of productions of vaccines and of tests; it will mean more rust and better cooperation.” Michel suggested that the treaty could also be used to expand vaccine production by facilitating technology transfer in low- and middle-income countries, referring to the “third way” initially proposed by the World Trade Organisation’s (WTO) new chief Ngozi Okonjo-Iweala. “Certainly there is a debate in the international community about how to improve our vaccine production capacities to improve vaccine coverage, particularly in the African continent,” said Michel, adding that “we are closely following the debate at the WTO for the ‘third way’ voiced by Ngozi”. US and China Didn’t Sign Call – But Sent Positive ‘Comments’ WHO’s director-general Dr. Tedros Adhanom Ghebreyesus Although China and the US did not sign Tuesday’s op-ed, Dr Tedros said that that both countries had voiced “positive” comments during informal discussions with Member States – and that it was not necessarily an issue that the op-ed had only been signed by two dozen countries. “It doesn’t need to be all 194 countries [to write an op-ed],” said Dr. Tedros. “I don’t want it to be seen as a problem, it wasn’t even a problem. When the discussion on the global pandemic treaty starts, all Member States will be represented.” The Pandemic Treaty Will Synergize With The International Health Regulations Meanwhile, Mike Ryan, WHO’s Director of Emergency Programmes, emphasised that the treaty would “by no means” undermine the existing global framework that governs WHO countries’ behaviour during health emergencies – the legally binding International Health Regulations (IHRs). These regulations set out the mandates under which countries are obliged to report on disease outbreak risks, and share epidemic information, with WHO and other member states. Rather, the pandemic treaty would generate the necessary political commitment to ensure that the IHRs are implemented; and bolster global pandemic preparedness and response by covering a broader set of issues than those covered by the IHRs, such as the sharing of crucial data. “The IHRs…is a really really good instrument,” said Ryan. “But in itself [it] is a piece of legislation that is without meaning unless countries are fully committed to its implementation.” “IHR only works if we have trust, if we have transparency, if we have accountability. Such a treaty would provide that political framework in which we in public health can do our work much more effectively.” “The proposed treaty will definitely bring strong political commitment and support for the IHR implementation,” added Jaouad Mahjour, WHO Regional Director for the Eastern Mediterranean region, who also spoke at Tuesday’s press conference. In an initial response to the initiative, the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) said that pharma partners should play a role in shaping such a treaty. The statement reflected IFPMA concerns over preserving what it described as the patent “incentive system” for developing new vaccines and medicines. “The discussions around a possible International Pandemic Treaty need to take into account the important role played by the innovative biopharmaceutical industry and its supply chain in fighting the virus,” said the IFPMA statement. “It will be important to acknowledge the critical role played by the incentive system in developing tests, therapeutics, and vaccines to contain and defeat the coronavirus. We hope that the discussions on an International Pandemic Treaty will address enablers for future pandemic preparedness – the importance of incentives for future innovation, the immediate and unrestricted access to pathogens, and the importance of the free flow of goods and workforce during the pandemic – in addition to continuing the multi stakeholder approach undertaken in ACT-A and COVAX.” Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Nigeria Pivots From AstraZeneca To Johnson & Johnson COVID-19 Vaccine 31/03/2021 Paul Adepoju The Nigerian government has ditched the AstraZeneca COVID-19 vaccine and will soon shift to the Johnson & Johnson’s one-shot vaccine. EXCLUSIVE – IBADAN – The Nigerian government has quietly ditched the AstraZeneca COVID-19 vaccine meant to vaccinate tens of millions of citizens, and will gradually shift to the Johnson & Johnson’s one-shot vaccine, saying it is easier to administer. Documents from the Nigerian Primary Healthcare Development Agency (NPHCDA) obtained by Health Policy Watch show that the agency intends to begin rolling out the J&J vaccine to almost 30 million people as soon as it can obtain the vaccine supplies. While denying that safety concerns are an issue, the Nigerian government’s move also comes amidst growing global concerns about AstraZeneca’s efficacy against the SARS-CoV2 virus variant first identified in South Africa, as well as safety concerns that have led to the suspension of AstraZeneca vaccines for people under the age of 60 in Germany, and elsewhere (see related story). Nigeria had already commenced the rollout of the AstraZeneca vaccine, with vaccines supplied by the WHO co-sponsored COVAX initiative. The country was meant to get more AstraZeneca supplies though the African Medical Supplies Platform (AMSP) – having already placed the largest order on the continent through the AMSP, as previously confirmed by the Africa Centres for Disease Control (CDC). However, according to the documents, the AstraZeneca vaccine doses reserved through the AMSP will be replaced with Johnson & Johnson vaccines. “Based on this, Nigeria’s total allocation is now 29,850,000 of Johnson & Johnson (Janssen) COVID-19 vaccine which is one dose shot to cover 29,850,000 eligible Nigerians as originally planned,” the agency stated. That would be enough to cover about 15% of Nigeria’s population of 200 million people. Government Says J&J ‘One Jab’ Vaccine, not Safety Worries, Are Behind Shift Government officials in Nigeria attributed the shift to J&J’s to the vaccine’s single jab technology – which will make it much easier to administer as compared to AstraZeneca’s two-dose shot – as well as ensuring the vaccine coverage stretches even further. They denied that it was linked to issues of safety and efficacy. However, behind the scenes, another factor is the J&J vaccine’s documented efficacy against the B.1351 virus variant identified in South Africa – and now spread to some 16 other countries on the continent, including nearby Ghana. South Africa on Monday announced that it has secured 30 million J&J vaccines after a small clinical trial and genomic surveillance showed the AstraZeneca vaccine was not strongly effective against that variant. In an earlier advisory, the Africa CDC stated that African countries where the B.1351 variant is the predominant SARS-CoV-2 strain should consider swapping the AstraZeneca vaccine for others that have shown more efficacy. Neither the AMSP or the Africa CDC could confirm when the J&J doses will become available. A recently announced J&J commitment to supply some 400 million vaccines to Africa is only scheduled to get into motion in the third quarter of 2021. Meanwhile, the continent continues to call for vaccine equality, fair distribution and local vaccine production. Nigerian Regulator’s Nod Government officials have continued to assure citizens of the safety of the vaccine despite global concerns – as it continues to roll-out the available AstraZeneca doses while it awaits the J&J vaccines. On Feb 18, just a few days after Nigeria received its first shipment of the AstraZeneca vaccine, the country’s drug regulator, the National Agency for Food and Drug Administration and Control (NAFDAC) approved the vaccine for emergency use. “The recommendation for Emergency Use Authorization was based on rigorous scientific considerations,” NAFDAC stated. Addressing a recent webinar on COVID-19 Vaccines, Dr. Faisal Shuaib, Executive Director/CEO of NPHCDA, acknowledged that the controversy around the vaccine’s safety, but urged countries in Europe and globally to continue vaccine administration as it is safe and effective. Prof Mojisola Christianah Adeyeye, NAFDAC’s Director General added that safety of the vaccine is primary to the agency and that it would be using its Med Safety App for Active Pharmacovigilance of the vaccine. Immunisation Drive Continues As at March 31, over 718,000 Nigerians had received the first doses of the available AstraZeneca vaccine supplies; coverage ranges from an over-the-top 104% target of priority patients reached in Kwara state to none at all in Kogi state – where a vaccine-hesitant government is only just now succumbing to pressure to allow citizens to receive the vaccine. But a cross section of health experts speaking at the recent Nigerian Academy of Science webinar said the bad publicity around the AstraZeneca vaccine might also have harmed vaccination in general. Recent news emanating from Europe has made the general public more suspicious of the potential lethal effects of the jabs – in addition to widespread misinformation circulating on social media. Dr Yahya Disu, Head of Risk Communication at the Nigeria Center for Disease Control (NCDC), said recent surveys show broad acceptance of vaccines among Nigerians and this is expected to ensure the country quickly achieves herd immunity – provided sufficient vaccines are made available. Disu said 86% of respondents of the surveys said they would still continue preventive measures such as wearing face masks, handwashing and social distancing even after receiving the vaccines. Pfizer Vaccine ‘Safe and Protective’ for Adolescents – Early Data Release 31/03/2021 Chandre Prince Pfizer and its German partner BioNTech say their COVID-19 vaccine is safe and protective in children as young as 12. The Pfizer-BioNTech COVID-19 vaccine is safe and protective in children as young as 12 with no serious side effects in adolescents who received the vaccination, the company said on Wednesday. Interim results of a recent clinical trial of some 2,260 adolescents ages 12-15 years old was published by the pharma company – although it has not yet undergone peer review. The adolescents who participated in the trial produced strong antibody responses and experienced no serious side effects, the company said, saying the vaccine had demonstrated “100 % efficacy”. Pfizer and its German partner BioNTech plan to ask the U.S. Food and Drug Administration and European regulators to allow emergency use of the shots among adolescents, beginning at age 12. Pfizer’s vaccine is already authorised by regulatory authorities for teens ages 16 and older.“We share th e urgency to expand the use of our vaccine,” Pfizer CEO Albert Bourla said in a statement. He expressed “the hope of starting to vaccinate this age group before the start of the next school year” in the United States. Pfizer isn’t the only company seeking to lower the age limit for its vaccine. Results also are expected soon from a U.S. study of Moderna’s vaccine in 12- to 17-year-olds. Another vaccine study of safety and efficacy in children ages 6 months to 11 years is also underway, but that has yet to yield preliminary results. See the full release here. Germany Suspends Use of AstraZeneca For Younger Population Over Reports of Rare Blood Cloth Cases 31/03/2021 Chandre Prince German Health Minister Jens Spahn and German Chancellor Angela Merkel during a joint press conference announcing the suspension of the use of the AstraZeneca COVID-19 vaccine. Germany has suspended the use of the AstraZeneca coronavirus vaccine for people under the age of 60 amidst fresh concerns of unusual blood clot cases among some people receiving the vaccine, particularly women, and leading to the deaths of nine people in all. German Chancellor Angela Merkel and Health Minister Jens Spahn made the announcement on Tuesday after the country’s Standing Committee on Vaccination (STIKO) reviewed more data on emerging cases of rare blood clots in people immunised with the vaccine, produced by the Anglo-Swedish drug maker. Germany’s medical regulator made the call after researchers at the federal government’s Paul Ehrlich Institute, said they had recorded 31 cases of rare blot clot abnormalities, among the 2.7-million Germans who have thus far received the AstraZeneca vaccine. All cases were younger than 63, and all but two were women. The cases involved cerebral venous thrombosis (CSVT), a rare clot in blood draining from the brain, but also related to abnormally low levels of platelets, which help blood clot, and bleeding near the site of vaccination. “The experts of the Paul-Ehrlich-Institut now see a striking accumulation of a special form of very rare cerebral vein thrombosis (sinus vein thrombosis) in connection with a deficiency of blood platelets (thrombocytopenia) and bleeding in temporal proximity to vaccinations with the COVID-19 vaccine AstraZeneca,” said a news release of PEI, the Federal Institute for Vaccines and Biomedicines. Several German regions — including the capital Berlin and the country’s most populous state, North Rhine-Westphalia — had already suspended use of the shots in younger people earlier on Tuesday. Merkel said that the government “cannot ignore” STIKO’s recommendation or the data about blood clots developing following shots with the vaccine. Germany Has Other Vaccine Options For Younger People Germany has suspended the use of the AstraZeneca vaccine in people under 60 years of age. “We all know that vaccination is the most important tool against the coronavirus,” said Merkel, adding there were other options for younger people. “We are not faced with the question of AstraZeneca or no vaccine,” she said. “Instead we have several vaccines at our disposal.” Spahn said the vaccine would only be administered to people aged 60 or older, unless they belong to a high-risk category for serious illness from COVID-19 and have agreed to take the vaccine despite the small risk of a serious side-effect. “In sum it’s about weighing the risk of a side effect that is statistically small, but needs to be taken seriously, and the risk of falling ill with corona,” Spahn said during a press briefing. He said the decision was taken “on the basis of currently available data on the occurrence of rare, but very serious thrombosis-related side-effects.” The commission said that it would issue guidelines on what to do for adults under 60 who had received a first AstraZeneca shot and were due another by the end of April. Suspension – A Blow To Germany’s Vaccine Roll-out The decision to suspend use of the vaccine for under-60s was “without doubt a setback” for the vaccination campaign, in which the AstraZeneca vaccine was a centrepiece, Spahn acknowledged. It comes as Germany, along with other European countries, scrambles to ramp up its vaccine programme, which lags far behind those in Britain and the United States. By Monday, some 13.2 million people in Germany, a country of some 83 million people, had received at least one dose of one of Europe’s approved vaccines, while only 4 million had received two vaccine doses. Germany is due to receive 15 million more AstraZeneca doses in the second quarter of 2021. Spahn said the new supply would be made available to people over 60 who might otherwise have had to wait longer, reducing their risk of falling seriously ill with COVID-19. Germany’s U-turn On AstraZeneca Use of the AstraZeneca vaccine was temporarily halted in Germany, as well as in several other European countries, earlier this month when concerns about occurrences of the rare blood clots first emerged. Then, just under two weeks ago, the European Medicines Agency said that the vaccine is safe and that its benefits outweigh the risks, and the vaccine rollout in Germany and elsewhere in Europe resumed. Paradoxically, earlier in the vaccine rollout, Germany had refrained from administering the AstraZeneca vaccine to people 65 and over, citing insufficient evidence of its efficacy in that age group at the time. Other Countries Restrict Use of AstraZeneca On March 29, Canada’s vaccination committee also recommended suspending the AstraZeneca jab for people under 55, citing reports coming out of Europe of blood clotting incidents. France limited its use to people older than 55. Norway, where regulators say four people died of blood clots among about 120,000 people who received the AstraZeneca jab, has also suspended the vaccine. Sweden has resumed AstraZeneca use for people older than 65. The vaccine is not yet cleared for use in the United States. An independent panel of medical experts overseeing the US trials took the unusual move last week of accusing the company of providing an “incomplete view” of efficacy data in its U.S. trials. On Monday, Canada also recommended halting the use of the jab for people under 55 “pending further analysis”. Researchers Find Association with Clots; AstraZeneca says Vaccine is “safe and effective” The suspensions also come in the wake of a March 28 pre-print report from researchers in Germany, Canada and Austria, including a scientist at the Paul-Ehrlich-Institute, which linked the vaccine to the development of a blood clotting disorder. However, some academics have said that the paper’s implication of a causal association isn’t backed up by evidence. In a statement ahead of the announcement, AstraZeneca said tens of millions of people worldwide have received its vaccines. The company said it would would analyse its own records to understand whether the rare blood clots reported occur more commonly “than would be expected naturally in a population of millions of people.” Image Credits: Clemens Bilan. SARS-CoV2 Virus Origins Report – Only Beginning Of Process Says WHO; 14 Member States Call For More Transparency 30/03/2021 Elaine Ruth Fletcher The most important takeaway about the just-released WHO report on the origins of the SARS-CoV2 virus that has infected over 100 million people to date may not be its initial findings, which need to be held under the microscope, but the fact that it has been issued at all. Speaking at a press conference on Tuesday, WHO’s Peter Ben Embarek, who coordinated the politically fraught WHO mission to Wuhan, China in January and the report produced after the visit – stressed that it was the beginning of a process – and a quest. It will take much more time for the 17 members of the international expert committee – and the world – to unravel. Glass Half Full – Half Empty WHO press briefing Tuesday with members of the international team tasked with tracing the origins of SARS-CoV2 The weaknesses of the report are already apparent, say experts, whose views were shared confidentially with Health Policy Watch. The committee’s methodology for ranking some scenarios, like transmission through food products, as very likely, while ranking others, like a laboratory biosafety incident, as “extremely unlikely” was foggy, with no real objective criteria measurement cited. The team discounted too rapidly the possibility that the virus could have emerged from a lab biosafety accident at the Wuhan Virology Institute – world-famous for its study of bat coronaviruses that are the closest known relatives of SARS-CoV2. WHO’s Peter Ben Embarek, head of the SARS CoV2 origins task team. Asked at the press briefing, how the team decided to rank the probability of the four different theories it considered, Ben Embarek said that the method was debate and discussion among the team members until they reached a consensus. And so it was also no surprise that WHO DIrector General Dr Tedros Adhanom Ghebreyesus, was already walking back on one of the report’s key conclusions. In a closed-door briefing to WHO member states, that preceded the report’s public release, the WHO Director General stated: “Although the team has concluded that a laboratory leak is the least likely hypothesis, this requires further investigation, potentially with additional missions involving specialist experts, which I am ready to deploy… I do not believe that this assessment was extensive enough. Further data and studies will be needed to reach more robust conclusions.” Significantly, Tedros himself also did not appear at the WHO media briefing – but rather let Ben Embarek, a WHO food safety expert who coordinated the mission by the international expert team to China, appear as the single WHO interlocutor on the public stage. And not long after the press conference was finished, some 14 governments led by the United States, Australia and Canada, but also including Denmark, Japan, Norway, Korea and the United Kingdom, issued a joint statement expressing, “shared concerns regarding the recent WHO-convened study in China, while at the same time reinforcing the importance of working together towards the development and use of a swift, effective, transparent, science-based, and independent process for international evaluations of such outbreaks of unknown origin in the future.” The group of 14 member states complained about the fact that the study was “significantly delayed and lacked access to complete, original data and samples”, stating that going forward, there is a need for “further studies of animals to find the means of introduction into humans. “Going forward,” the member states added,”it is critical for independent experts to have full access to all pertinent human, animal, and environmental data, research, and personnel involved in the early stages of the outbreak relevant to determining how this pandemic emerged. With all data in hand, the international community may independently assess COVID-19 origins, learn valuable lessons from this pandemic, and prevent future devastating consequences from outbreaks of disease.” Half Empty -missing and incomplete data Among the specifics being raised by experts and observers in the wake of the report’s release are the following: Weak rationale for the team’s dismissal of a coronavirus laboratory escape. As the international team members admitted themselves in the WHO press briefing, they lacked the competencies to carry out a ful-fledged laboratory investigation. The Wuhan Virology Institute staff, told the WHO team that although researchers at the institute had sequenced the genome of the RaTG13 horseshoe bat virus, which is the closest known relative to SARS CoV2, researchers did not maintain live samples of the virus on hand at the institute. that claim sounds disingenuous, because such samples were indeed collected by the institute in 2013 from a horseshoe-bat colony in Yunnan province, where a group of miners had died in 2012 from a mysterious SARS-like illness. And the institute’s research into those same coronaviruses is a matter of scientific record. In addition, the WHO team did not have access to raw data on the virology institute’s inventory samples or to data on the health status of institute employees, or serological testing, was made available to the investigators. Early spread of the coronavirus in Wuhan – the WHO-mandated team did not get full access to clinical patient data from the earliest known patients, or to the genomic sequences of the viruses with whch they were infected. Serological data available from blood banks, which could have been examined in retrospective studies similar to those carried out on Italy to identify asymptomatic virus carriers, also was not made available by the Chinese authorities. Such data would be critical to understanding where and how widely the virus was circulating prior to December 2019. Despite that, as team member Marion Kooperman’s noted at the WHO press briefing – data that the team did access suggested that as of December, there were already several coronavirus strains circulating in the city. Spread through the food cold chain – the theory touted by the Chinese government of virus spread through imported frozen food products is termed as a “possible pathway” in the report – when in fact little real evidence exists that such contamination could have triggered the Wuhan pandemic, and the conclusion that it is even “plausible” lacks analytical rigour. Evidence about spread through an intermediate wild animal host -while highly plausible as a theory, remains very incomplete, with the mapping of animal supply chains and products only at the initial stages. Half Full – Key insights gleaned Dr. Peter Daszak – President of the EcoHealth Alliance Despite the shortcomings, committee members at the briefing stressed the new evidence that they had gathered, which provides a basis to push ahead with more studies. Chief among those is a direct line of supply chain provision of wild animal products from regions such as Yunnan province, which are known to harbour bat coronaviruses similar to the SARS-CoV2 – to the Huanan Market in Wuhan – where the most intensive cluster of initial cases first appeared. Mapping of stalls in Wuhan’s Huanan market that sold farmed wildlife products from rural regions that are coronavirus hotspots. “Some of the market stalls in the (Huanan Seafood) market in Wuhan were selling [wild animal] foods foods originating from wildlife farms in known coronavirus hotspots” elsewhere in China, said Ben Embarek, citing what is perhaps one of the most important findings of the study. “From the animal side, … the events began to fit together when we looked at the molecular data the epi data and the animal data – they all seemed to fit to form a big picture story about what likely happened, and I think that’s quite exciting,” added Peter Daszak, a leading team member and president of the EcoHealth Alliance. “From the outside, it would have been incredible to have a bat with the exact same lineage of viruses, we didn’t see that yet – that will come in the future I think. “What we did see on the animal side is clear evidence… that there was a pathway to that market and animals that we know are Coronavirus carriers, from places where the nearest related viruses are. What that does is it shows you there is a pathway, that this virus could have taken to move 800-1000 miles from the rural parts of South China, Southeast Asia, into this market, that was exciting to see.” Those insights are all the more critical as the world grapples with a rapid pace of ecosystem deterioration, and more industrialized forms of animal food production, which present considerable risks of virus emergence that need to be better understood by the public at large. Dr. Marion Koopmans, Dutch virologist and epidemiologist On the patient side, despite the Chinese authorities’ fragmented provision of patient and epidemiological data, the evidence culled by the team still remains clear. Already in December 2019, there were diverse strains of the SARS-CoV2 virus already circulating in the city – suggesting that that the infection had already made its way into the city’s population some time before. Said Marion Koopmans, a Dutch virologist and epidemiologist: “The SARS CoV-2 virus was circulating in the Wuhan market market in December 2019, but it was also circulating elsewhere in the city, in cases unrelated to each other,” she noted at the press briefing. . The team also noted that despite the multiple restrictions and barriers put up by Chinese governmental authorities – the atmosphere between scientists remained positive – creating what Ben Embarek called a “space” for the scientists to do their work. And despite considerable pressure from China to point the finger abroad, the team’s testimony makes it clear that the next research steps on the virus trail must be taken in Wuhan, China as well as in rural areas that harbor bat coronaviruses – rather than more far-flung parts of the world. Moving Ahead – Balancing Political and Scientific Pressure What remains is a long road ahead, requiring investment in more rigorous, and as some team members rightly noted – more expensive studies – based upon evidence-driven demands and requests to Chinese authorities for more detailed data – on both the food safety as well as the human epidemiological side of the virus coin. In light of the WHO Director General’s comments about the inadequate analysis of the laboratory biosafety risks – it is also likely that WHO member states in Europe or the Americas (read USA), may demand a fresh query into that hypothesis – involving actual biosafety experts who were not members of the original virus origins team. Ultimately, It will be up to the WHO member states that mandated the report, informed by outside, independent experts and observers, to nurse the origins study – or studies – through to more significant, and final conclusions. In that quest, Europe, the United States and their allies will need to steer a delicate course between exertion of the right amount of political pressure on the one hand – and alienating attacks that only foster anger and geopolitical tensions of the kind visibly on display during the era of former US President Donald Trump. And from the point of view of scientists – It is a process that may require months, if not several years – WHO’s Ben Embarek warned. “”How long will it take? That is always difficult to predict.” he said, pleading with the world to “please be patient.” Although, despite the heat that the WHO team has received, his appeal was shadowed with appreciation for the fact that a certain amount of vigilance – may also be constructive: “It’s an exciting adventure that I hope the whole world will continue to follow.. it’s a fascinating journey and a critical one because it’s the only way we can understand what happened, and more recently tried to prevent something similar for happening again.” Image Credits: Sputnik, WHO. Global Leaders Call For New Treaty To Bolster Resilience Against Future Pandemics 30/03/2021 Svĕt Lustig Vijay Charles Michel, President of the European Council After the COVID-19 pandemic exposed fundamental flaws in the global health architecture, a proposal for a new pandemic treaty that could strengthen the world’s capacity to contain the current pandemic and prepare for future ones, is gaining momentum. That was a key message at a World Health Organization (WHO) launch of an open letter by 25 global leaders calling for the world to negotiate such a treaty, featuring Charles Michel, President of the European Council, and two dozen other global leaders that are now backing the treaty initiative. Other signatories now include the United Kingdom’s Boris Johnson, Germany’s Angela Merkel, France’s Emmanuel Macron, along with the leaders of Indonesia, Kenya, Rwanda and South Africa’s Cyril Ramaphosa. But China, the United States and Russia have yet to sign the call. “Today, we are calling for an international treaty on pandemics [to] foster a comprehensive approach to better predict, prevent and respond to pandemics,” said Michel, who has championed the treaty since late last year saying that the treaty would support the principle of “health for all”. If ratified, the treaty will give the WHO the political clout to better carry out part of its mandate in terms of improved pandemic alert systems, better investments in coronavirus research, and sharing of crucial data on infectious pathogens, vaccine supply chains and vaccine formulas. WHO’s director-general Dr. Tedros Adhanom Ghebreyesus echoed Michel’s sentiments, saying: “The time to act is now”. “The world cannot afford to wait until the pandemic is over to start planning for the next one. We cannot do things the way we have done them before and expect a different result. Without an internationally coordinated response…we remain vulnerable,” said Dr Tedros. Pandemic Treaty Rooted In WHO Constitution No single country can address pandemics alone. An international #PandemicTreaty would promote a global system to better prevent, predict & recover from future pandemics like #COVID19. Find out more on why we need a new treaty on pandemics ➡️https://t.co/iY2qUGLcPn pic.twitter.com/YkEL0LEzKl — EU Council (@EUCouncil) March 30, 2021 The treaty “would be rooted in the constitution of the World Health Organisation, drawing in other relevant organizations key to this endeavour,” said the letter, also signed by the heads of: Albania, Chile, Costa Rica, Greece, Korea, Trinidad and Tobago, the Netherlands, Senegal, Spain, Norway, Serbia, Indonesia, and Ukraine. “Existing global health instruments, especially the International Health Regulations, would underpin such a treaty, ensuring a firm and tested foundation on which we can build and improve.” The Pandemic Treaty Will Strengthen WHO’s Mandate According to Michel, “Such a treaty [could] play an interesting role in order to make sure that we have more transparency on the supply chains [and] on the level of productions of vaccines and of tests; it will mean more rust and better cooperation.” Michel suggested that the treaty could also be used to expand vaccine production by facilitating technology transfer in low- and middle-income countries, referring to the “third way” initially proposed by the World Trade Organisation’s (WTO) new chief Ngozi Okonjo-Iweala. “Certainly there is a debate in the international community about how to improve our vaccine production capacities to improve vaccine coverage, particularly in the African continent,” said Michel, adding that “we are closely following the debate at the WTO for the ‘third way’ voiced by Ngozi”. US and China Didn’t Sign Call – But Sent Positive ‘Comments’ WHO’s director-general Dr. Tedros Adhanom Ghebreyesus Although China and the US did not sign Tuesday’s op-ed, Dr Tedros said that that both countries had voiced “positive” comments during informal discussions with Member States – and that it was not necessarily an issue that the op-ed had only been signed by two dozen countries. “It doesn’t need to be all 194 countries [to write an op-ed],” said Dr. Tedros. “I don’t want it to be seen as a problem, it wasn’t even a problem. When the discussion on the global pandemic treaty starts, all Member States will be represented.” The Pandemic Treaty Will Synergize With The International Health Regulations Meanwhile, Mike Ryan, WHO’s Director of Emergency Programmes, emphasised that the treaty would “by no means” undermine the existing global framework that governs WHO countries’ behaviour during health emergencies – the legally binding International Health Regulations (IHRs). These regulations set out the mandates under which countries are obliged to report on disease outbreak risks, and share epidemic information, with WHO and other member states. Rather, the pandemic treaty would generate the necessary political commitment to ensure that the IHRs are implemented; and bolster global pandemic preparedness and response by covering a broader set of issues than those covered by the IHRs, such as the sharing of crucial data. “The IHRs…is a really really good instrument,” said Ryan. “But in itself [it] is a piece of legislation that is without meaning unless countries are fully committed to its implementation.” “IHR only works if we have trust, if we have transparency, if we have accountability. Such a treaty would provide that political framework in which we in public health can do our work much more effectively.” “The proposed treaty will definitely bring strong political commitment and support for the IHR implementation,” added Jaouad Mahjour, WHO Regional Director for the Eastern Mediterranean region, who also spoke at Tuesday’s press conference. In an initial response to the initiative, the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) said that pharma partners should play a role in shaping such a treaty. The statement reflected IFPMA concerns over preserving what it described as the patent “incentive system” for developing new vaccines and medicines. “The discussions around a possible International Pandemic Treaty need to take into account the important role played by the innovative biopharmaceutical industry and its supply chain in fighting the virus,” said the IFPMA statement. “It will be important to acknowledge the critical role played by the incentive system in developing tests, therapeutics, and vaccines to contain and defeat the coronavirus. We hope that the discussions on an International Pandemic Treaty will address enablers for future pandemic preparedness – the importance of incentives for future innovation, the immediate and unrestricted access to pathogens, and the importance of the free flow of goods and workforce during the pandemic – in addition to continuing the multi stakeholder approach undertaken in ACT-A and COVAX.” Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Pfizer Vaccine ‘Safe and Protective’ for Adolescents – Early Data Release 31/03/2021 Chandre Prince Pfizer and its German partner BioNTech say their COVID-19 vaccine is safe and protective in children as young as 12. The Pfizer-BioNTech COVID-19 vaccine is safe and protective in children as young as 12 with no serious side effects in adolescents who received the vaccination, the company said on Wednesday. Interim results of a recent clinical trial of some 2,260 adolescents ages 12-15 years old was published by the pharma company – although it has not yet undergone peer review. The adolescents who participated in the trial produced strong antibody responses and experienced no serious side effects, the company said, saying the vaccine had demonstrated “100 % efficacy”. Pfizer and its German partner BioNTech plan to ask the U.S. Food and Drug Administration and European regulators to allow emergency use of the shots among adolescents, beginning at age 12. Pfizer’s vaccine is already authorised by regulatory authorities for teens ages 16 and older.“We share th e urgency to expand the use of our vaccine,” Pfizer CEO Albert Bourla said in a statement. He expressed “the hope of starting to vaccinate this age group before the start of the next school year” in the United States. Pfizer isn’t the only company seeking to lower the age limit for its vaccine. Results also are expected soon from a U.S. study of Moderna’s vaccine in 12- to 17-year-olds. Another vaccine study of safety and efficacy in children ages 6 months to 11 years is also underway, but that has yet to yield preliminary results. See the full release here. Germany Suspends Use of AstraZeneca For Younger Population Over Reports of Rare Blood Cloth Cases 31/03/2021 Chandre Prince German Health Minister Jens Spahn and German Chancellor Angela Merkel during a joint press conference announcing the suspension of the use of the AstraZeneca COVID-19 vaccine. Germany has suspended the use of the AstraZeneca coronavirus vaccine for people under the age of 60 amidst fresh concerns of unusual blood clot cases among some people receiving the vaccine, particularly women, and leading to the deaths of nine people in all. German Chancellor Angela Merkel and Health Minister Jens Spahn made the announcement on Tuesday after the country’s Standing Committee on Vaccination (STIKO) reviewed more data on emerging cases of rare blood clots in people immunised with the vaccine, produced by the Anglo-Swedish drug maker. Germany’s medical regulator made the call after researchers at the federal government’s Paul Ehrlich Institute, said they had recorded 31 cases of rare blot clot abnormalities, among the 2.7-million Germans who have thus far received the AstraZeneca vaccine. All cases were younger than 63, and all but two were women. The cases involved cerebral venous thrombosis (CSVT), a rare clot in blood draining from the brain, but also related to abnormally low levels of platelets, which help blood clot, and bleeding near the site of vaccination. “The experts of the Paul-Ehrlich-Institut now see a striking accumulation of a special form of very rare cerebral vein thrombosis (sinus vein thrombosis) in connection with a deficiency of blood platelets (thrombocytopenia) and bleeding in temporal proximity to vaccinations with the COVID-19 vaccine AstraZeneca,” said a news release of PEI, the Federal Institute for Vaccines and Biomedicines. Several German regions — including the capital Berlin and the country’s most populous state, North Rhine-Westphalia — had already suspended use of the shots in younger people earlier on Tuesday. Merkel said that the government “cannot ignore” STIKO’s recommendation or the data about blood clots developing following shots with the vaccine. Germany Has Other Vaccine Options For Younger People Germany has suspended the use of the AstraZeneca vaccine in people under 60 years of age. “We all know that vaccination is the most important tool against the coronavirus,” said Merkel, adding there were other options for younger people. “We are not faced with the question of AstraZeneca or no vaccine,” she said. “Instead we have several vaccines at our disposal.” Spahn said the vaccine would only be administered to people aged 60 or older, unless they belong to a high-risk category for serious illness from COVID-19 and have agreed to take the vaccine despite the small risk of a serious side-effect. “In sum it’s about weighing the risk of a side effect that is statistically small, but needs to be taken seriously, and the risk of falling ill with corona,” Spahn said during a press briefing. He said the decision was taken “on the basis of currently available data on the occurrence of rare, but very serious thrombosis-related side-effects.” The commission said that it would issue guidelines on what to do for adults under 60 who had received a first AstraZeneca shot and were due another by the end of April. Suspension – A Blow To Germany’s Vaccine Roll-out The decision to suspend use of the vaccine for under-60s was “without doubt a setback” for the vaccination campaign, in which the AstraZeneca vaccine was a centrepiece, Spahn acknowledged. It comes as Germany, along with other European countries, scrambles to ramp up its vaccine programme, which lags far behind those in Britain and the United States. By Monday, some 13.2 million people in Germany, a country of some 83 million people, had received at least one dose of one of Europe’s approved vaccines, while only 4 million had received two vaccine doses. Germany is due to receive 15 million more AstraZeneca doses in the second quarter of 2021. Spahn said the new supply would be made available to people over 60 who might otherwise have had to wait longer, reducing their risk of falling seriously ill with COVID-19. Germany’s U-turn On AstraZeneca Use of the AstraZeneca vaccine was temporarily halted in Germany, as well as in several other European countries, earlier this month when concerns about occurrences of the rare blood clots first emerged. Then, just under two weeks ago, the European Medicines Agency said that the vaccine is safe and that its benefits outweigh the risks, and the vaccine rollout in Germany and elsewhere in Europe resumed. Paradoxically, earlier in the vaccine rollout, Germany had refrained from administering the AstraZeneca vaccine to people 65 and over, citing insufficient evidence of its efficacy in that age group at the time. Other Countries Restrict Use of AstraZeneca On March 29, Canada’s vaccination committee also recommended suspending the AstraZeneca jab for people under 55, citing reports coming out of Europe of blood clotting incidents. France limited its use to people older than 55. Norway, where regulators say four people died of blood clots among about 120,000 people who received the AstraZeneca jab, has also suspended the vaccine. Sweden has resumed AstraZeneca use for people older than 65. The vaccine is not yet cleared for use in the United States. An independent panel of medical experts overseeing the US trials took the unusual move last week of accusing the company of providing an “incomplete view” of efficacy data in its U.S. trials. On Monday, Canada also recommended halting the use of the jab for people under 55 “pending further analysis”. Researchers Find Association with Clots; AstraZeneca says Vaccine is “safe and effective” The suspensions also come in the wake of a March 28 pre-print report from researchers in Germany, Canada and Austria, including a scientist at the Paul-Ehrlich-Institute, which linked the vaccine to the development of a blood clotting disorder. However, some academics have said that the paper’s implication of a causal association isn’t backed up by evidence. In a statement ahead of the announcement, AstraZeneca said tens of millions of people worldwide have received its vaccines. The company said it would would analyse its own records to understand whether the rare blood clots reported occur more commonly “than would be expected naturally in a population of millions of people.” Image Credits: Clemens Bilan. SARS-CoV2 Virus Origins Report – Only Beginning Of Process Says WHO; 14 Member States Call For More Transparency 30/03/2021 Elaine Ruth Fletcher The most important takeaway about the just-released WHO report on the origins of the SARS-CoV2 virus that has infected over 100 million people to date may not be its initial findings, which need to be held under the microscope, but the fact that it has been issued at all. Speaking at a press conference on Tuesday, WHO’s Peter Ben Embarek, who coordinated the politically fraught WHO mission to Wuhan, China in January and the report produced after the visit – stressed that it was the beginning of a process – and a quest. It will take much more time for the 17 members of the international expert committee – and the world – to unravel. Glass Half Full – Half Empty WHO press briefing Tuesday with members of the international team tasked with tracing the origins of SARS-CoV2 The weaknesses of the report are already apparent, say experts, whose views were shared confidentially with Health Policy Watch. The committee’s methodology for ranking some scenarios, like transmission through food products, as very likely, while ranking others, like a laboratory biosafety incident, as “extremely unlikely” was foggy, with no real objective criteria measurement cited. The team discounted too rapidly the possibility that the virus could have emerged from a lab biosafety accident at the Wuhan Virology Institute – world-famous for its study of bat coronaviruses that are the closest known relatives of SARS-CoV2. WHO’s Peter Ben Embarek, head of the SARS CoV2 origins task team. Asked at the press briefing, how the team decided to rank the probability of the four different theories it considered, Ben Embarek said that the method was debate and discussion among the team members until they reached a consensus. And so it was also no surprise that WHO DIrector General Dr Tedros Adhanom Ghebreyesus, was already walking back on one of the report’s key conclusions. In a closed-door briefing to WHO member states, that preceded the report’s public release, the WHO Director General stated: “Although the team has concluded that a laboratory leak is the least likely hypothesis, this requires further investigation, potentially with additional missions involving specialist experts, which I am ready to deploy… I do not believe that this assessment was extensive enough. Further data and studies will be needed to reach more robust conclusions.” Significantly, Tedros himself also did not appear at the WHO media briefing – but rather let Ben Embarek, a WHO food safety expert who coordinated the mission by the international expert team to China, appear as the single WHO interlocutor on the public stage. And not long after the press conference was finished, some 14 governments led by the United States, Australia and Canada, but also including Denmark, Japan, Norway, Korea and the United Kingdom, issued a joint statement expressing, “shared concerns regarding the recent WHO-convened study in China, while at the same time reinforcing the importance of working together towards the development and use of a swift, effective, transparent, science-based, and independent process for international evaluations of such outbreaks of unknown origin in the future.” The group of 14 member states complained about the fact that the study was “significantly delayed and lacked access to complete, original data and samples”, stating that going forward, there is a need for “further studies of animals to find the means of introduction into humans. “Going forward,” the member states added,”it is critical for independent experts to have full access to all pertinent human, animal, and environmental data, research, and personnel involved in the early stages of the outbreak relevant to determining how this pandemic emerged. With all data in hand, the international community may independently assess COVID-19 origins, learn valuable lessons from this pandemic, and prevent future devastating consequences from outbreaks of disease.” Half Empty -missing and incomplete data Among the specifics being raised by experts and observers in the wake of the report’s release are the following: Weak rationale for the team’s dismissal of a coronavirus laboratory escape. As the international team members admitted themselves in the WHO press briefing, they lacked the competencies to carry out a ful-fledged laboratory investigation. The Wuhan Virology Institute staff, told the WHO team that although researchers at the institute had sequenced the genome of the RaTG13 horseshoe bat virus, which is the closest known relative to SARS CoV2, researchers did not maintain live samples of the virus on hand at the institute. that claim sounds disingenuous, because such samples were indeed collected by the institute in 2013 from a horseshoe-bat colony in Yunnan province, where a group of miners had died in 2012 from a mysterious SARS-like illness. And the institute’s research into those same coronaviruses is a matter of scientific record. In addition, the WHO team did not have access to raw data on the virology institute’s inventory samples or to data on the health status of institute employees, or serological testing, was made available to the investigators. Early spread of the coronavirus in Wuhan – the WHO-mandated team did not get full access to clinical patient data from the earliest known patients, or to the genomic sequences of the viruses with whch they were infected. Serological data available from blood banks, which could have been examined in retrospective studies similar to those carried out on Italy to identify asymptomatic virus carriers, also was not made available by the Chinese authorities. Such data would be critical to understanding where and how widely the virus was circulating prior to December 2019. Despite that, as team member Marion Kooperman’s noted at the WHO press briefing – data that the team did access suggested that as of December, there were already several coronavirus strains circulating in the city. Spread through the food cold chain – the theory touted by the Chinese government of virus spread through imported frozen food products is termed as a “possible pathway” in the report – when in fact little real evidence exists that such contamination could have triggered the Wuhan pandemic, and the conclusion that it is even “plausible” lacks analytical rigour. Evidence about spread through an intermediate wild animal host -while highly plausible as a theory, remains very incomplete, with the mapping of animal supply chains and products only at the initial stages. Half Full – Key insights gleaned Dr. Peter Daszak – President of the EcoHealth Alliance Despite the shortcomings, committee members at the briefing stressed the new evidence that they had gathered, which provides a basis to push ahead with more studies. Chief among those is a direct line of supply chain provision of wild animal products from regions such as Yunnan province, which are known to harbour bat coronaviruses similar to the SARS-CoV2 – to the Huanan Market in Wuhan – where the most intensive cluster of initial cases first appeared. Mapping of stalls in Wuhan’s Huanan market that sold farmed wildlife products from rural regions that are coronavirus hotspots. “Some of the market stalls in the (Huanan Seafood) market in Wuhan were selling [wild animal] foods foods originating from wildlife farms in known coronavirus hotspots” elsewhere in China, said Ben Embarek, citing what is perhaps one of the most important findings of the study. “From the animal side, … the events began to fit together when we looked at the molecular data the epi data and the animal data – they all seemed to fit to form a big picture story about what likely happened, and I think that’s quite exciting,” added Peter Daszak, a leading team member and president of the EcoHealth Alliance. “From the outside, it would have been incredible to have a bat with the exact same lineage of viruses, we didn’t see that yet – that will come in the future I think. “What we did see on the animal side is clear evidence… that there was a pathway to that market and animals that we know are Coronavirus carriers, from places where the nearest related viruses are. What that does is it shows you there is a pathway, that this virus could have taken to move 800-1000 miles from the rural parts of South China, Southeast Asia, into this market, that was exciting to see.” Those insights are all the more critical as the world grapples with a rapid pace of ecosystem deterioration, and more industrialized forms of animal food production, which present considerable risks of virus emergence that need to be better understood by the public at large. Dr. Marion Koopmans, Dutch virologist and epidemiologist On the patient side, despite the Chinese authorities’ fragmented provision of patient and epidemiological data, the evidence culled by the team still remains clear. Already in December 2019, there were diverse strains of the SARS-CoV2 virus already circulating in the city – suggesting that that the infection had already made its way into the city’s population some time before. Said Marion Koopmans, a Dutch virologist and epidemiologist: “The SARS CoV-2 virus was circulating in the Wuhan market market in December 2019, but it was also circulating elsewhere in the city, in cases unrelated to each other,” she noted at the press briefing. . The team also noted that despite the multiple restrictions and barriers put up by Chinese governmental authorities – the atmosphere between scientists remained positive – creating what Ben Embarek called a “space” for the scientists to do their work. And despite considerable pressure from China to point the finger abroad, the team’s testimony makes it clear that the next research steps on the virus trail must be taken in Wuhan, China as well as in rural areas that harbor bat coronaviruses – rather than more far-flung parts of the world. Moving Ahead – Balancing Political and Scientific Pressure What remains is a long road ahead, requiring investment in more rigorous, and as some team members rightly noted – more expensive studies – based upon evidence-driven demands and requests to Chinese authorities for more detailed data – on both the food safety as well as the human epidemiological side of the virus coin. In light of the WHO Director General’s comments about the inadequate analysis of the laboratory biosafety risks – it is also likely that WHO member states in Europe or the Americas (read USA), may demand a fresh query into that hypothesis – involving actual biosafety experts who were not members of the original virus origins team. Ultimately, It will be up to the WHO member states that mandated the report, informed by outside, independent experts and observers, to nurse the origins study – or studies – through to more significant, and final conclusions. In that quest, Europe, the United States and their allies will need to steer a delicate course between exertion of the right amount of political pressure on the one hand – and alienating attacks that only foster anger and geopolitical tensions of the kind visibly on display during the era of former US President Donald Trump. And from the point of view of scientists – It is a process that may require months, if not several years – WHO’s Ben Embarek warned. “”How long will it take? That is always difficult to predict.” he said, pleading with the world to “please be patient.” Although, despite the heat that the WHO team has received, his appeal was shadowed with appreciation for the fact that a certain amount of vigilance – may also be constructive: “It’s an exciting adventure that I hope the whole world will continue to follow.. it’s a fascinating journey and a critical one because it’s the only way we can understand what happened, and more recently tried to prevent something similar for happening again.” Image Credits: Sputnik, WHO. Global Leaders Call For New Treaty To Bolster Resilience Against Future Pandemics 30/03/2021 Svĕt Lustig Vijay Charles Michel, President of the European Council After the COVID-19 pandemic exposed fundamental flaws in the global health architecture, a proposal for a new pandemic treaty that could strengthen the world’s capacity to contain the current pandemic and prepare for future ones, is gaining momentum. That was a key message at a World Health Organization (WHO) launch of an open letter by 25 global leaders calling for the world to negotiate such a treaty, featuring Charles Michel, President of the European Council, and two dozen other global leaders that are now backing the treaty initiative. Other signatories now include the United Kingdom’s Boris Johnson, Germany’s Angela Merkel, France’s Emmanuel Macron, along with the leaders of Indonesia, Kenya, Rwanda and South Africa’s Cyril Ramaphosa. But China, the United States and Russia have yet to sign the call. “Today, we are calling for an international treaty on pandemics [to] foster a comprehensive approach to better predict, prevent and respond to pandemics,” said Michel, who has championed the treaty since late last year saying that the treaty would support the principle of “health for all”. If ratified, the treaty will give the WHO the political clout to better carry out part of its mandate in terms of improved pandemic alert systems, better investments in coronavirus research, and sharing of crucial data on infectious pathogens, vaccine supply chains and vaccine formulas. WHO’s director-general Dr. Tedros Adhanom Ghebreyesus echoed Michel’s sentiments, saying: “The time to act is now”. “The world cannot afford to wait until the pandemic is over to start planning for the next one. We cannot do things the way we have done them before and expect a different result. Without an internationally coordinated response…we remain vulnerable,” said Dr Tedros. Pandemic Treaty Rooted In WHO Constitution No single country can address pandemics alone. An international #PandemicTreaty would promote a global system to better prevent, predict & recover from future pandemics like #COVID19. Find out more on why we need a new treaty on pandemics ➡️https://t.co/iY2qUGLcPn pic.twitter.com/YkEL0LEzKl — EU Council (@EUCouncil) March 30, 2021 The treaty “would be rooted in the constitution of the World Health Organisation, drawing in other relevant organizations key to this endeavour,” said the letter, also signed by the heads of: Albania, Chile, Costa Rica, Greece, Korea, Trinidad and Tobago, the Netherlands, Senegal, Spain, Norway, Serbia, Indonesia, and Ukraine. “Existing global health instruments, especially the International Health Regulations, would underpin such a treaty, ensuring a firm and tested foundation on which we can build and improve.” The Pandemic Treaty Will Strengthen WHO’s Mandate According to Michel, “Such a treaty [could] play an interesting role in order to make sure that we have more transparency on the supply chains [and] on the level of productions of vaccines and of tests; it will mean more rust and better cooperation.” Michel suggested that the treaty could also be used to expand vaccine production by facilitating technology transfer in low- and middle-income countries, referring to the “third way” initially proposed by the World Trade Organisation’s (WTO) new chief Ngozi Okonjo-Iweala. “Certainly there is a debate in the international community about how to improve our vaccine production capacities to improve vaccine coverage, particularly in the African continent,” said Michel, adding that “we are closely following the debate at the WTO for the ‘third way’ voiced by Ngozi”. US and China Didn’t Sign Call – But Sent Positive ‘Comments’ WHO’s director-general Dr. Tedros Adhanom Ghebreyesus Although China and the US did not sign Tuesday’s op-ed, Dr Tedros said that that both countries had voiced “positive” comments during informal discussions with Member States – and that it was not necessarily an issue that the op-ed had only been signed by two dozen countries. “It doesn’t need to be all 194 countries [to write an op-ed],” said Dr. Tedros. “I don’t want it to be seen as a problem, it wasn’t even a problem. When the discussion on the global pandemic treaty starts, all Member States will be represented.” The Pandemic Treaty Will Synergize With The International Health Regulations Meanwhile, Mike Ryan, WHO’s Director of Emergency Programmes, emphasised that the treaty would “by no means” undermine the existing global framework that governs WHO countries’ behaviour during health emergencies – the legally binding International Health Regulations (IHRs). These regulations set out the mandates under which countries are obliged to report on disease outbreak risks, and share epidemic information, with WHO and other member states. Rather, the pandemic treaty would generate the necessary political commitment to ensure that the IHRs are implemented; and bolster global pandemic preparedness and response by covering a broader set of issues than those covered by the IHRs, such as the sharing of crucial data. “The IHRs…is a really really good instrument,” said Ryan. “But in itself [it] is a piece of legislation that is without meaning unless countries are fully committed to its implementation.” “IHR only works if we have trust, if we have transparency, if we have accountability. Such a treaty would provide that political framework in which we in public health can do our work much more effectively.” “The proposed treaty will definitely bring strong political commitment and support for the IHR implementation,” added Jaouad Mahjour, WHO Regional Director for the Eastern Mediterranean region, who also spoke at Tuesday’s press conference. In an initial response to the initiative, the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) said that pharma partners should play a role in shaping such a treaty. The statement reflected IFPMA concerns over preserving what it described as the patent “incentive system” for developing new vaccines and medicines. “The discussions around a possible International Pandemic Treaty need to take into account the important role played by the innovative biopharmaceutical industry and its supply chain in fighting the virus,” said the IFPMA statement. “It will be important to acknowledge the critical role played by the incentive system in developing tests, therapeutics, and vaccines to contain and defeat the coronavirus. We hope that the discussions on an International Pandemic Treaty will address enablers for future pandemic preparedness – the importance of incentives for future innovation, the immediate and unrestricted access to pathogens, and the importance of the free flow of goods and workforce during the pandemic – in addition to continuing the multi stakeholder approach undertaken in ACT-A and COVAX.” Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Germany Suspends Use of AstraZeneca For Younger Population Over Reports of Rare Blood Cloth Cases 31/03/2021 Chandre Prince German Health Minister Jens Spahn and German Chancellor Angela Merkel during a joint press conference announcing the suspension of the use of the AstraZeneca COVID-19 vaccine. Germany has suspended the use of the AstraZeneca coronavirus vaccine for people under the age of 60 amidst fresh concerns of unusual blood clot cases among some people receiving the vaccine, particularly women, and leading to the deaths of nine people in all. German Chancellor Angela Merkel and Health Minister Jens Spahn made the announcement on Tuesday after the country’s Standing Committee on Vaccination (STIKO) reviewed more data on emerging cases of rare blood clots in people immunised with the vaccine, produced by the Anglo-Swedish drug maker. Germany’s medical regulator made the call after researchers at the federal government’s Paul Ehrlich Institute, said they had recorded 31 cases of rare blot clot abnormalities, among the 2.7-million Germans who have thus far received the AstraZeneca vaccine. All cases were younger than 63, and all but two were women. The cases involved cerebral venous thrombosis (CSVT), a rare clot in blood draining from the brain, but also related to abnormally low levels of platelets, which help blood clot, and bleeding near the site of vaccination. “The experts of the Paul-Ehrlich-Institut now see a striking accumulation of a special form of very rare cerebral vein thrombosis (sinus vein thrombosis) in connection with a deficiency of blood platelets (thrombocytopenia) and bleeding in temporal proximity to vaccinations with the COVID-19 vaccine AstraZeneca,” said a news release of PEI, the Federal Institute for Vaccines and Biomedicines. Several German regions — including the capital Berlin and the country’s most populous state, North Rhine-Westphalia — had already suspended use of the shots in younger people earlier on Tuesday. Merkel said that the government “cannot ignore” STIKO’s recommendation or the data about blood clots developing following shots with the vaccine. Germany Has Other Vaccine Options For Younger People Germany has suspended the use of the AstraZeneca vaccine in people under 60 years of age. “We all know that vaccination is the most important tool against the coronavirus,” said Merkel, adding there were other options for younger people. “We are not faced with the question of AstraZeneca or no vaccine,” she said. “Instead we have several vaccines at our disposal.” Spahn said the vaccine would only be administered to people aged 60 or older, unless they belong to a high-risk category for serious illness from COVID-19 and have agreed to take the vaccine despite the small risk of a serious side-effect. “In sum it’s about weighing the risk of a side effect that is statistically small, but needs to be taken seriously, and the risk of falling ill with corona,” Spahn said during a press briefing. He said the decision was taken “on the basis of currently available data on the occurrence of rare, but very serious thrombosis-related side-effects.” The commission said that it would issue guidelines on what to do for adults under 60 who had received a first AstraZeneca shot and were due another by the end of April. Suspension – A Blow To Germany’s Vaccine Roll-out The decision to suspend use of the vaccine for under-60s was “without doubt a setback” for the vaccination campaign, in which the AstraZeneca vaccine was a centrepiece, Spahn acknowledged. It comes as Germany, along with other European countries, scrambles to ramp up its vaccine programme, which lags far behind those in Britain and the United States. By Monday, some 13.2 million people in Germany, a country of some 83 million people, had received at least one dose of one of Europe’s approved vaccines, while only 4 million had received two vaccine doses. Germany is due to receive 15 million more AstraZeneca doses in the second quarter of 2021. Spahn said the new supply would be made available to people over 60 who might otherwise have had to wait longer, reducing their risk of falling seriously ill with COVID-19. Germany’s U-turn On AstraZeneca Use of the AstraZeneca vaccine was temporarily halted in Germany, as well as in several other European countries, earlier this month when concerns about occurrences of the rare blood clots first emerged. Then, just under two weeks ago, the European Medicines Agency said that the vaccine is safe and that its benefits outweigh the risks, and the vaccine rollout in Germany and elsewhere in Europe resumed. Paradoxically, earlier in the vaccine rollout, Germany had refrained from administering the AstraZeneca vaccine to people 65 and over, citing insufficient evidence of its efficacy in that age group at the time. Other Countries Restrict Use of AstraZeneca On March 29, Canada’s vaccination committee also recommended suspending the AstraZeneca jab for people under 55, citing reports coming out of Europe of blood clotting incidents. France limited its use to people older than 55. Norway, where regulators say four people died of blood clots among about 120,000 people who received the AstraZeneca jab, has also suspended the vaccine. Sweden has resumed AstraZeneca use for people older than 65. The vaccine is not yet cleared for use in the United States. An independent panel of medical experts overseeing the US trials took the unusual move last week of accusing the company of providing an “incomplete view” of efficacy data in its U.S. trials. On Monday, Canada also recommended halting the use of the jab for people under 55 “pending further analysis”. Researchers Find Association with Clots; AstraZeneca says Vaccine is “safe and effective” The suspensions also come in the wake of a March 28 pre-print report from researchers in Germany, Canada and Austria, including a scientist at the Paul-Ehrlich-Institute, which linked the vaccine to the development of a blood clotting disorder. However, some academics have said that the paper’s implication of a causal association isn’t backed up by evidence. In a statement ahead of the announcement, AstraZeneca said tens of millions of people worldwide have received its vaccines. The company said it would would analyse its own records to understand whether the rare blood clots reported occur more commonly “than would be expected naturally in a population of millions of people.” Image Credits: Clemens Bilan. SARS-CoV2 Virus Origins Report – Only Beginning Of Process Says WHO; 14 Member States Call For More Transparency 30/03/2021 Elaine Ruth Fletcher The most important takeaway about the just-released WHO report on the origins of the SARS-CoV2 virus that has infected over 100 million people to date may not be its initial findings, which need to be held under the microscope, but the fact that it has been issued at all. Speaking at a press conference on Tuesday, WHO’s Peter Ben Embarek, who coordinated the politically fraught WHO mission to Wuhan, China in January and the report produced after the visit – stressed that it was the beginning of a process – and a quest. It will take much more time for the 17 members of the international expert committee – and the world – to unravel. Glass Half Full – Half Empty WHO press briefing Tuesday with members of the international team tasked with tracing the origins of SARS-CoV2 The weaknesses of the report are already apparent, say experts, whose views were shared confidentially with Health Policy Watch. The committee’s methodology for ranking some scenarios, like transmission through food products, as very likely, while ranking others, like a laboratory biosafety incident, as “extremely unlikely” was foggy, with no real objective criteria measurement cited. The team discounted too rapidly the possibility that the virus could have emerged from a lab biosafety accident at the Wuhan Virology Institute – world-famous for its study of bat coronaviruses that are the closest known relatives of SARS-CoV2. WHO’s Peter Ben Embarek, head of the SARS CoV2 origins task team. Asked at the press briefing, how the team decided to rank the probability of the four different theories it considered, Ben Embarek said that the method was debate and discussion among the team members until they reached a consensus. And so it was also no surprise that WHO DIrector General Dr Tedros Adhanom Ghebreyesus, was already walking back on one of the report’s key conclusions. In a closed-door briefing to WHO member states, that preceded the report’s public release, the WHO Director General stated: “Although the team has concluded that a laboratory leak is the least likely hypothesis, this requires further investigation, potentially with additional missions involving specialist experts, which I am ready to deploy… I do not believe that this assessment was extensive enough. Further data and studies will be needed to reach more robust conclusions.” Significantly, Tedros himself also did not appear at the WHO media briefing – but rather let Ben Embarek, a WHO food safety expert who coordinated the mission by the international expert team to China, appear as the single WHO interlocutor on the public stage. And not long after the press conference was finished, some 14 governments led by the United States, Australia and Canada, but also including Denmark, Japan, Norway, Korea and the United Kingdom, issued a joint statement expressing, “shared concerns regarding the recent WHO-convened study in China, while at the same time reinforcing the importance of working together towards the development and use of a swift, effective, transparent, science-based, and independent process for international evaluations of such outbreaks of unknown origin in the future.” The group of 14 member states complained about the fact that the study was “significantly delayed and lacked access to complete, original data and samples”, stating that going forward, there is a need for “further studies of animals to find the means of introduction into humans. “Going forward,” the member states added,”it is critical for independent experts to have full access to all pertinent human, animal, and environmental data, research, and personnel involved in the early stages of the outbreak relevant to determining how this pandemic emerged. With all data in hand, the international community may independently assess COVID-19 origins, learn valuable lessons from this pandemic, and prevent future devastating consequences from outbreaks of disease.” Half Empty -missing and incomplete data Among the specifics being raised by experts and observers in the wake of the report’s release are the following: Weak rationale for the team’s dismissal of a coronavirus laboratory escape. As the international team members admitted themselves in the WHO press briefing, they lacked the competencies to carry out a ful-fledged laboratory investigation. The Wuhan Virology Institute staff, told the WHO team that although researchers at the institute had sequenced the genome of the RaTG13 horseshoe bat virus, which is the closest known relative to SARS CoV2, researchers did not maintain live samples of the virus on hand at the institute. that claim sounds disingenuous, because such samples were indeed collected by the institute in 2013 from a horseshoe-bat colony in Yunnan province, where a group of miners had died in 2012 from a mysterious SARS-like illness. And the institute’s research into those same coronaviruses is a matter of scientific record. In addition, the WHO team did not have access to raw data on the virology institute’s inventory samples or to data on the health status of institute employees, or serological testing, was made available to the investigators. Early spread of the coronavirus in Wuhan – the WHO-mandated team did not get full access to clinical patient data from the earliest known patients, or to the genomic sequences of the viruses with whch they were infected. Serological data available from blood banks, which could have been examined in retrospective studies similar to those carried out on Italy to identify asymptomatic virus carriers, also was not made available by the Chinese authorities. Such data would be critical to understanding where and how widely the virus was circulating prior to December 2019. Despite that, as team member Marion Kooperman’s noted at the WHO press briefing – data that the team did access suggested that as of December, there were already several coronavirus strains circulating in the city. Spread through the food cold chain – the theory touted by the Chinese government of virus spread through imported frozen food products is termed as a “possible pathway” in the report – when in fact little real evidence exists that such contamination could have triggered the Wuhan pandemic, and the conclusion that it is even “plausible” lacks analytical rigour. Evidence about spread through an intermediate wild animal host -while highly plausible as a theory, remains very incomplete, with the mapping of animal supply chains and products only at the initial stages. Half Full – Key insights gleaned Dr. Peter Daszak – President of the EcoHealth Alliance Despite the shortcomings, committee members at the briefing stressed the new evidence that they had gathered, which provides a basis to push ahead with more studies. Chief among those is a direct line of supply chain provision of wild animal products from regions such as Yunnan province, which are known to harbour bat coronaviruses similar to the SARS-CoV2 – to the Huanan Market in Wuhan – where the most intensive cluster of initial cases first appeared. Mapping of stalls in Wuhan’s Huanan market that sold farmed wildlife products from rural regions that are coronavirus hotspots. “Some of the market stalls in the (Huanan Seafood) market in Wuhan were selling [wild animal] foods foods originating from wildlife farms in known coronavirus hotspots” elsewhere in China, said Ben Embarek, citing what is perhaps one of the most important findings of the study. “From the animal side, … the events began to fit together when we looked at the molecular data the epi data and the animal data – they all seemed to fit to form a big picture story about what likely happened, and I think that’s quite exciting,” added Peter Daszak, a leading team member and president of the EcoHealth Alliance. “From the outside, it would have been incredible to have a bat with the exact same lineage of viruses, we didn’t see that yet – that will come in the future I think. “What we did see on the animal side is clear evidence… that there was a pathway to that market and animals that we know are Coronavirus carriers, from places where the nearest related viruses are. What that does is it shows you there is a pathway, that this virus could have taken to move 800-1000 miles from the rural parts of South China, Southeast Asia, into this market, that was exciting to see.” Those insights are all the more critical as the world grapples with a rapid pace of ecosystem deterioration, and more industrialized forms of animal food production, which present considerable risks of virus emergence that need to be better understood by the public at large. Dr. Marion Koopmans, Dutch virologist and epidemiologist On the patient side, despite the Chinese authorities’ fragmented provision of patient and epidemiological data, the evidence culled by the team still remains clear. Already in December 2019, there were diverse strains of the SARS-CoV2 virus already circulating in the city – suggesting that that the infection had already made its way into the city’s population some time before. Said Marion Koopmans, a Dutch virologist and epidemiologist: “The SARS CoV-2 virus was circulating in the Wuhan market market in December 2019, but it was also circulating elsewhere in the city, in cases unrelated to each other,” she noted at the press briefing. . The team also noted that despite the multiple restrictions and barriers put up by Chinese governmental authorities – the atmosphere between scientists remained positive – creating what Ben Embarek called a “space” for the scientists to do their work. And despite considerable pressure from China to point the finger abroad, the team’s testimony makes it clear that the next research steps on the virus trail must be taken in Wuhan, China as well as in rural areas that harbor bat coronaviruses – rather than more far-flung parts of the world. Moving Ahead – Balancing Political and Scientific Pressure What remains is a long road ahead, requiring investment in more rigorous, and as some team members rightly noted – more expensive studies – based upon evidence-driven demands and requests to Chinese authorities for more detailed data – on both the food safety as well as the human epidemiological side of the virus coin. In light of the WHO Director General’s comments about the inadequate analysis of the laboratory biosafety risks – it is also likely that WHO member states in Europe or the Americas (read USA), may demand a fresh query into that hypothesis – involving actual biosafety experts who were not members of the original virus origins team. Ultimately, It will be up to the WHO member states that mandated the report, informed by outside, independent experts and observers, to nurse the origins study – or studies – through to more significant, and final conclusions. In that quest, Europe, the United States and their allies will need to steer a delicate course between exertion of the right amount of political pressure on the one hand – and alienating attacks that only foster anger and geopolitical tensions of the kind visibly on display during the era of former US President Donald Trump. And from the point of view of scientists – It is a process that may require months, if not several years – WHO’s Ben Embarek warned. “”How long will it take? That is always difficult to predict.” he said, pleading with the world to “please be patient.” Although, despite the heat that the WHO team has received, his appeal was shadowed with appreciation for the fact that a certain amount of vigilance – may also be constructive: “It’s an exciting adventure that I hope the whole world will continue to follow.. it’s a fascinating journey and a critical one because it’s the only way we can understand what happened, and more recently tried to prevent something similar for happening again.” Image Credits: Sputnik, WHO. Global Leaders Call For New Treaty To Bolster Resilience Against Future Pandemics 30/03/2021 Svĕt Lustig Vijay Charles Michel, President of the European Council After the COVID-19 pandemic exposed fundamental flaws in the global health architecture, a proposal for a new pandemic treaty that could strengthen the world’s capacity to contain the current pandemic and prepare for future ones, is gaining momentum. That was a key message at a World Health Organization (WHO) launch of an open letter by 25 global leaders calling for the world to negotiate such a treaty, featuring Charles Michel, President of the European Council, and two dozen other global leaders that are now backing the treaty initiative. Other signatories now include the United Kingdom’s Boris Johnson, Germany’s Angela Merkel, France’s Emmanuel Macron, along with the leaders of Indonesia, Kenya, Rwanda and South Africa’s Cyril Ramaphosa. But China, the United States and Russia have yet to sign the call. “Today, we are calling for an international treaty on pandemics [to] foster a comprehensive approach to better predict, prevent and respond to pandemics,” said Michel, who has championed the treaty since late last year saying that the treaty would support the principle of “health for all”. If ratified, the treaty will give the WHO the political clout to better carry out part of its mandate in terms of improved pandemic alert systems, better investments in coronavirus research, and sharing of crucial data on infectious pathogens, vaccine supply chains and vaccine formulas. WHO’s director-general Dr. Tedros Adhanom Ghebreyesus echoed Michel’s sentiments, saying: “The time to act is now”. “The world cannot afford to wait until the pandemic is over to start planning for the next one. We cannot do things the way we have done them before and expect a different result. Without an internationally coordinated response…we remain vulnerable,” said Dr Tedros. Pandemic Treaty Rooted In WHO Constitution No single country can address pandemics alone. An international #PandemicTreaty would promote a global system to better prevent, predict & recover from future pandemics like #COVID19. Find out more on why we need a new treaty on pandemics ➡️https://t.co/iY2qUGLcPn pic.twitter.com/YkEL0LEzKl — EU Council (@EUCouncil) March 30, 2021 The treaty “would be rooted in the constitution of the World Health Organisation, drawing in other relevant organizations key to this endeavour,” said the letter, also signed by the heads of: Albania, Chile, Costa Rica, Greece, Korea, Trinidad and Tobago, the Netherlands, Senegal, Spain, Norway, Serbia, Indonesia, and Ukraine. “Existing global health instruments, especially the International Health Regulations, would underpin such a treaty, ensuring a firm and tested foundation on which we can build and improve.” The Pandemic Treaty Will Strengthen WHO’s Mandate According to Michel, “Such a treaty [could] play an interesting role in order to make sure that we have more transparency on the supply chains [and] on the level of productions of vaccines and of tests; it will mean more rust and better cooperation.” Michel suggested that the treaty could also be used to expand vaccine production by facilitating technology transfer in low- and middle-income countries, referring to the “third way” initially proposed by the World Trade Organisation’s (WTO) new chief Ngozi Okonjo-Iweala. “Certainly there is a debate in the international community about how to improve our vaccine production capacities to improve vaccine coverage, particularly in the African continent,” said Michel, adding that “we are closely following the debate at the WTO for the ‘third way’ voiced by Ngozi”. US and China Didn’t Sign Call – But Sent Positive ‘Comments’ WHO’s director-general Dr. Tedros Adhanom Ghebreyesus Although China and the US did not sign Tuesday’s op-ed, Dr Tedros said that that both countries had voiced “positive” comments during informal discussions with Member States – and that it was not necessarily an issue that the op-ed had only been signed by two dozen countries. “It doesn’t need to be all 194 countries [to write an op-ed],” said Dr. Tedros. “I don’t want it to be seen as a problem, it wasn’t even a problem. When the discussion on the global pandemic treaty starts, all Member States will be represented.” The Pandemic Treaty Will Synergize With The International Health Regulations Meanwhile, Mike Ryan, WHO’s Director of Emergency Programmes, emphasised that the treaty would “by no means” undermine the existing global framework that governs WHO countries’ behaviour during health emergencies – the legally binding International Health Regulations (IHRs). These regulations set out the mandates under which countries are obliged to report on disease outbreak risks, and share epidemic information, with WHO and other member states. Rather, the pandemic treaty would generate the necessary political commitment to ensure that the IHRs are implemented; and bolster global pandemic preparedness and response by covering a broader set of issues than those covered by the IHRs, such as the sharing of crucial data. “The IHRs…is a really really good instrument,” said Ryan. “But in itself [it] is a piece of legislation that is without meaning unless countries are fully committed to its implementation.” “IHR only works if we have trust, if we have transparency, if we have accountability. Such a treaty would provide that political framework in which we in public health can do our work much more effectively.” “The proposed treaty will definitely bring strong political commitment and support for the IHR implementation,” added Jaouad Mahjour, WHO Regional Director for the Eastern Mediterranean region, who also spoke at Tuesday’s press conference. In an initial response to the initiative, the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) said that pharma partners should play a role in shaping such a treaty. The statement reflected IFPMA concerns over preserving what it described as the patent “incentive system” for developing new vaccines and medicines. “The discussions around a possible International Pandemic Treaty need to take into account the important role played by the innovative biopharmaceutical industry and its supply chain in fighting the virus,” said the IFPMA statement. “It will be important to acknowledge the critical role played by the incentive system in developing tests, therapeutics, and vaccines to contain and defeat the coronavirus. We hope that the discussions on an International Pandemic Treaty will address enablers for future pandemic preparedness – the importance of incentives for future innovation, the immediate and unrestricted access to pathogens, and the importance of the free flow of goods and workforce during the pandemic – in addition to continuing the multi stakeholder approach undertaken in ACT-A and COVAX.” Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
SARS-CoV2 Virus Origins Report – Only Beginning Of Process Says WHO; 14 Member States Call For More Transparency 30/03/2021 Elaine Ruth Fletcher The most important takeaway about the just-released WHO report on the origins of the SARS-CoV2 virus that has infected over 100 million people to date may not be its initial findings, which need to be held under the microscope, but the fact that it has been issued at all. Speaking at a press conference on Tuesday, WHO’s Peter Ben Embarek, who coordinated the politically fraught WHO mission to Wuhan, China in January and the report produced after the visit – stressed that it was the beginning of a process – and a quest. It will take much more time for the 17 members of the international expert committee – and the world – to unravel. Glass Half Full – Half Empty WHO press briefing Tuesday with members of the international team tasked with tracing the origins of SARS-CoV2 The weaknesses of the report are already apparent, say experts, whose views were shared confidentially with Health Policy Watch. The committee’s methodology for ranking some scenarios, like transmission through food products, as very likely, while ranking others, like a laboratory biosafety incident, as “extremely unlikely” was foggy, with no real objective criteria measurement cited. The team discounted too rapidly the possibility that the virus could have emerged from a lab biosafety accident at the Wuhan Virology Institute – world-famous for its study of bat coronaviruses that are the closest known relatives of SARS-CoV2. WHO’s Peter Ben Embarek, head of the SARS CoV2 origins task team. Asked at the press briefing, how the team decided to rank the probability of the four different theories it considered, Ben Embarek said that the method was debate and discussion among the team members until they reached a consensus. And so it was also no surprise that WHO DIrector General Dr Tedros Adhanom Ghebreyesus, was already walking back on one of the report’s key conclusions. In a closed-door briefing to WHO member states, that preceded the report’s public release, the WHO Director General stated: “Although the team has concluded that a laboratory leak is the least likely hypothesis, this requires further investigation, potentially with additional missions involving specialist experts, which I am ready to deploy… I do not believe that this assessment was extensive enough. Further data and studies will be needed to reach more robust conclusions.” Significantly, Tedros himself also did not appear at the WHO media briefing – but rather let Ben Embarek, a WHO food safety expert who coordinated the mission by the international expert team to China, appear as the single WHO interlocutor on the public stage. And not long after the press conference was finished, some 14 governments led by the United States, Australia and Canada, but also including Denmark, Japan, Norway, Korea and the United Kingdom, issued a joint statement expressing, “shared concerns regarding the recent WHO-convened study in China, while at the same time reinforcing the importance of working together towards the development and use of a swift, effective, transparent, science-based, and independent process for international evaluations of such outbreaks of unknown origin in the future.” The group of 14 member states complained about the fact that the study was “significantly delayed and lacked access to complete, original data and samples”, stating that going forward, there is a need for “further studies of animals to find the means of introduction into humans. “Going forward,” the member states added,”it is critical for independent experts to have full access to all pertinent human, animal, and environmental data, research, and personnel involved in the early stages of the outbreak relevant to determining how this pandemic emerged. With all data in hand, the international community may independently assess COVID-19 origins, learn valuable lessons from this pandemic, and prevent future devastating consequences from outbreaks of disease.” Half Empty -missing and incomplete data Among the specifics being raised by experts and observers in the wake of the report’s release are the following: Weak rationale for the team’s dismissal of a coronavirus laboratory escape. As the international team members admitted themselves in the WHO press briefing, they lacked the competencies to carry out a ful-fledged laboratory investigation. The Wuhan Virology Institute staff, told the WHO team that although researchers at the institute had sequenced the genome of the RaTG13 horseshoe bat virus, which is the closest known relative to SARS CoV2, researchers did not maintain live samples of the virus on hand at the institute. that claim sounds disingenuous, because such samples were indeed collected by the institute in 2013 from a horseshoe-bat colony in Yunnan province, where a group of miners had died in 2012 from a mysterious SARS-like illness. And the institute’s research into those same coronaviruses is a matter of scientific record. In addition, the WHO team did not have access to raw data on the virology institute’s inventory samples or to data on the health status of institute employees, or serological testing, was made available to the investigators. Early spread of the coronavirus in Wuhan – the WHO-mandated team did not get full access to clinical patient data from the earliest known patients, or to the genomic sequences of the viruses with whch they were infected. Serological data available from blood banks, which could have been examined in retrospective studies similar to those carried out on Italy to identify asymptomatic virus carriers, also was not made available by the Chinese authorities. Such data would be critical to understanding where and how widely the virus was circulating prior to December 2019. Despite that, as team member Marion Kooperman’s noted at the WHO press briefing – data that the team did access suggested that as of December, there were already several coronavirus strains circulating in the city. Spread through the food cold chain – the theory touted by the Chinese government of virus spread through imported frozen food products is termed as a “possible pathway” in the report – when in fact little real evidence exists that such contamination could have triggered the Wuhan pandemic, and the conclusion that it is even “plausible” lacks analytical rigour. Evidence about spread through an intermediate wild animal host -while highly plausible as a theory, remains very incomplete, with the mapping of animal supply chains and products only at the initial stages. Half Full – Key insights gleaned Dr. Peter Daszak – President of the EcoHealth Alliance Despite the shortcomings, committee members at the briefing stressed the new evidence that they had gathered, which provides a basis to push ahead with more studies. Chief among those is a direct line of supply chain provision of wild animal products from regions such as Yunnan province, which are known to harbour bat coronaviruses similar to the SARS-CoV2 – to the Huanan Market in Wuhan – where the most intensive cluster of initial cases first appeared. Mapping of stalls in Wuhan’s Huanan market that sold farmed wildlife products from rural regions that are coronavirus hotspots. “Some of the market stalls in the (Huanan Seafood) market in Wuhan were selling [wild animal] foods foods originating from wildlife farms in known coronavirus hotspots” elsewhere in China, said Ben Embarek, citing what is perhaps one of the most important findings of the study. “From the animal side, … the events began to fit together when we looked at the molecular data the epi data and the animal data – they all seemed to fit to form a big picture story about what likely happened, and I think that’s quite exciting,” added Peter Daszak, a leading team member and president of the EcoHealth Alliance. “From the outside, it would have been incredible to have a bat with the exact same lineage of viruses, we didn’t see that yet – that will come in the future I think. “What we did see on the animal side is clear evidence… that there was a pathway to that market and animals that we know are Coronavirus carriers, from places where the nearest related viruses are. What that does is it shows you there is a pathway, that this virus could have taken to move 800-1000 miles from the rural parts of South China, Southeast Asia, into this market, that was exciting to see.” Those insights are all the more critical as the world grapples with a rapid pace of ecosystem deterioration, and more industrialized forms of animal food production, which present considerable risks of virus emergence that need to be better understood by the public at large. Dr. Marion Koopmans, Dutch virologist and epidemiologist On the patient side, despite the Chinese authorities’ fragmented provision of patient and epidemiological data, the evidence culled by the team still remains clear. Already in December 2019, there were diverse strains of the SARS-CoV2 virus already circulating in the city – suggesting that that the infection had already made its way into the city’s population some time before. Said Marion Koopmans, a Dutch virologist and epidemiologist: “The SARS CoV-2 virus was circulating in the Wuhan market market in December 2019, but it was also circulating elsewhere in the city, in cases unrelated to each other,” she noted at the press briefing. . The team also noted that despite the multiple restrictions and barriers put up by Chinese governmental authorities – the atmosphere between scientists remained positive – creating what Ben Embarek called a “space” for the scientists to do their work. And despite considerable pressure from China to point the finger abroad, the team’s testimony makes it clear that the next research steps on the virus trail must be taken in Wuhan, China as well as in rural areas that harbor bat coronaviruses – rather than more far-flung parts of the world. Moving Ahead – Balancing Political and Scientific Pressure What remains is a long road ahead, requiring investment in more rigorous, and as some team members rightly noted – more expensive studies – based upon evidence-driven demands and requests to Chinese authorities for more detailed data – on both the food safety as well as the human epidemiological side of the virus coin. In light of the WHO Director General’s comments about the inadequate analysis of the laboratory biosafety risks – it is also likely that WHO member states in Europe or the Americas (read USA), may demand a fresh query into that hypothesis – involving actual biosafety experts who were not members of the original virus origins team. Ultimately, It will be up to the WHO member states that mandated the report, informed by outside, independent experts and observers, to nurse the origins study – or studies – through to more significant, and final conclusions. In that quest, Europe, the United States and their allies will need to steer a delicate course between exertion of the right amount of political pressure on the one hand – and alienating attacks that only foster anger and geopolitical tensions of the kind visibly on display during the era of former US President Donald Trump. And from the point of view of scientists – It is a process that may require months, if not several years – WHO’s Ben Embarek warned. “”How long will it take? That is always difficult to predict.” he said, pleading with the world to “please be patient.” Although, despite the heat that the WHO team has received, his appeal was shadowed with appreciation for the fact that a certain amount of vigilance – may also be constructive: “It’s an exciting adventure that I hope the whole world will continue to follow.. it’s a fascinating journey and a critical one because it’s the only way we can understand what happened, and more recently tried to prevent something similar for happening again.” Image Credits: Sputnik, WHO. Global Leaders Call For New Treaty To Bolster Resilience Against Future Pandemics 30/03/2021 Svĕt Lustig Vijay Charles Michel, President of the European Council After the COVID-19 pandemic exposed fundamental flaws in the global health architecture, a proposal for a new pandemic treaty that could strengthen the world’s capacity to contain the current pandemic and prepare for future ones, is gaining momentum. That was a key message at a World Health Organization (WHO) launch of an open letter by 25 global leaders calling for the world to negotiate such a treaty, featuring Charles Michel, President of the European Council, and two dozen other global leaders that are now backing the treaty initiative. Other signatories now include the United Kingdom’s Boris Johnson, Germany’s Angela Merkel, France’s Emmanuel Macron, along with the leaders of Indonesia, Kenya, Rwanda and South Africa’s Cyril Ramaphosa. But China, the United States and Russia have yet to sign the call. “Today, we are calling for an international treaty on pandemics [to] foster a comprehensive approach to better predict, prevent and respond to pandemics,” said Michel, who has championed the treaty since late last year saying that the treaty would support the principle of “health for all”. If ratified, the treaty will give the WHO the political clout to better carry out part of its mandate in terms of improved pandemic alert systems, better investments in coronavirus research, and sharing of crucial data on infectious pathogens, vaccine supply chains and vaccine formulas. WHO’s director-general Dr. Tedros Adhanom Ghebreyesus echoed Michel’s sentiments, saying: “The time to act is now”. “The world cannot afford to wait until the pandemic is over to start planning for the next one. We cannot do things the way we have done them before and expect a different result. Without an internationally coordinated response…we remain vulnerable,” said Dr Tedros. Pandemic Treaty Rooted In WHO Constitution No single country can address pandemics alone. An international #PandemicTreaty would promote a global system to better prevent, predict & recover from future pandemics like #COVID19. Find out more on why we need a new treaty on pandemics ➡️https://t.co/iY2qUGLcPn pic.twitter.com/YkEL0LEzKl — EU Council (@EUCouncil) March 30, 2021 The treaty “would be rooted in the constitution of the World Health Organisation, drawing in other relevant organizations key to this endeavour,” said the letter, also signed by the heads of: Albania, Chile, Costa Rica, Greece, Korea, Trinidad and Tobago, the Netherlands, Senegal, Spain, Norway, Serbia, Indonesia, and Ukraine. “Existing global health instruments, especially the International Health Regulations, would underpin such a treaty, ensuring a firm and tested foundation on which we can build and improve.” The Pandemic Treaty Will Strengthen WHO’s Mandate According to Michel, “Such a treaty [could] play an interesting role in order to make sure that we have more transparency on the supply chains [and] on the level of productions of vaccines and of tests; it will mean more rust and better cooperation.” Michel suggested that the treaty could also be used to expand vaccine production by facilitating technology transfer in low- and middle-income countries, referring to the “third way” initially proposed by the World Trade Organisation’s (WTO) new chief Ngozi Okonjo-Iweala. “Certainly there is a debate in the international community about how to improve our vaccine production capacities to improve vaccine coverage, particularly in the African continent,” said Michel, adding that “we are closely following the debate at the WTO for the ‘third way’ voiced by Ngozi”. US and China Didn’t Sign Call – But Sent Positive ‘Comments’ WHO’s director-general Dr. Tedros Adhanom Ghebreyesus Although China and the US did not sign Tuesday’s op-ed, Dr Tedros said that that both countries had voiced “positive” comments during informal discussions with Member States – and that it was not necessarily an issue that the op-ed had only been signed by two dozen countries. “It doesn’t need to be all 194 countries [to write an op-ed],” said Dr. Tedros. “I don’t want it to be seen as a problem, it wasn’t even a problem. When the discussion on the global pandemic treaty starts, all Member States will be represented.” The Pandemic Treaty Will Synergize With The International Health Regulations Meanwhile, Mike Ryan, WHO’s Director of Emergency Programmes, emphasised that the treaty would “by no means” undermine the existing global framework that governs WHO countries’ behaviour during health emergencies – the legally binding International Health Regulations (IHRs). These regulations set out the mandates under which countries are obliged to report on disease outbreak risks, and share epidemic information, with WHO and other member states. Rather, the pandemic treaty would generate the necessary political commitment to ensure that the IHRs are implemented; and bolster global pandemic preparedness and response by covering a broader set of issues than those covered by the IHRs, such as the sharing of crucial data. “The IHRs…is a really really good instrument,” said Ryan. “But in itself [it] is a piece of legislation that is without meaning unless countries are fully committed to its implementation.” “IHR only works if we have trust, if we have transparency, if we have accountability. Such a treaty would provide that political framework in which we in public health can do our work much more effectively.” “The proposed treaty will definitely bring strong political commitment and support for the IHR implementation,” added Jaouad Mahjour, WHO Regional Director for the Eastern Mediterranean region, who also spoke at Tuesday’s press conference. In an initial response to the initiative, the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) said that pharma partners should play a role in shaping such a treaty. The statement reflected IFPMA concerns over preserving what it described as the patent “incentive system” for developing new vaccines and medicines. “The discussions around a possible International Pandemic Treaty need to take into account the important role played by the innovative biopharmaceutical industry and its supply chain in fighting the virus,” said the IFPMA statement. “It will be important to acknowledge the critical role played by the incentive system in developing tests, therapeutics, and vaccines to contain and defeat the coronavirus. We hope that the discussions on an International Pandemic Treaty will address enablers for future pandemic preparedness – the importance of incentives for future innovation, the immediate and unrestricted access to pathogens, and the importance of the free flow of goods and workforce during the pandemic – in addition to continuing the multi stakeholder approach undertaken in ACT-A and COVAX.” Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Global Leaders Call For New Treaty To Bolster Resilience Against Future Pandemics 30/03/2021 Svĕt Lustig Vijay Charles Michel, President of the European Council After the COVID-19 pandemic exposed fundamental flaws in the global health architecture, a proposal for a new pandemic treaty that could strengthen the world’s capacity to contain the current pandemic and prepare for future ones, is gaining momentum. That was a key message at a World Health Organization (WHO) launch of an open letter by 25 global leaders calling for the world to negotiate such a treaty, featuring Charles Michel, President of the European Council, and two dozen other global leaders that are now backing the treaty initiative. Other signatories now include the United Kingdom’s Boris Johnson, Germany’s Angela Merkel, France’s Emmanuel Macron, along with the leaders of Indonesia, Kenya, Rwanda and South Africa’s Cyril Ramaphosa. But China, the United States and Russia have yet to sign the call. “Today, we are calling for an international treaty on pandemics [to] foster a comprehensive approach to better predict, prevent and respond to pandemics,” said Michel, who has championed the treaty since late last year saying that the treaty would support the principle of “health for all”. If ratified, the treaty will give the WHO the political clout to better carry out part of its mandate in terms of improved pandemic alert systems, better investments in coronavirus research, and sharing of crucial data on infectious pathogens, vaccine supply chains and vaccine formulas. WHO’s director-general Dr. Tedros Adhanom Ghebreyesus echoed Michel’s sentiments, saying: “The time to act is now”. “The world cannot afford to wait until the pandemic is over to start planning for the next one. We cannot do things the way we have done them before and expect a different result. Without an internationally coordinated response…we remain vulnerable,” said Dr Tedros. Pandemic Treaty Rooted In WHO Constitution No single country can address pandemics alone. An international #PandemicTreaty would promote a global system to better prevent, predict & recover from future pandemics like #COVID19. Find out more on why we need a new treaty on pandemics ➡️https://t.co/iY2qUGLcPn pic.twitter.com/YkEL0LEzKl — EU Council (@EUCouncil) March 30, 2021 The treaty “would be rooted in the constitution of the World Health Organisation, drawing in other relevant organizations key to this endeavour,” said the letter, also signed by the heads of: Albania, Chile, Costa Rica, Greece, Korea, Trinidad and Tobago, the Netherlands, Senegal, Spain, Norway, Serbia, Indonesia, and Ukraine. “Existing global health instruments, especially the International Health Regulations, would underpin such a treaty, ensuring a firm and tested foundation on which we can build and improve.” The Pandemic Treaty Will Strengthen WHO’s Mandate According to Michel, “Such a treaty [could] play an interesting role in order to make sure that we have more transparency on the supply chains [and] on the level of productions of vaccines and of tests; it will mean more rust and better cooperation.” Michel suggested that the treaty could also be used to expand vaccine production by facilitating technology transfer in low- and middle-income countries, referring to the “third way” initially proposed by the World Trade Organisation’s (WTO) new chief Ngozi Okonjo-Iweala. “Certainly there is a debate in the international community about how to improve our vaccine production capacities to improve vaccine coverage, particularly in the African continent,” said Michel, adding that “we are closely following the debate at the WTO for the ‘third way’ voiced by Ngozi”. US and China Didn’t Sign Call – But Sent Positive ‘Comments’ WHO’s director-general Dr. Tedros Adhanom Ghebreyesus Although China and the US did not sign Tuesday’s op-ed, Dr Tedros said that that both countries had voiced “positive” comments during informal discussions with Member States – and that it was not necessarily an issue that the op-ed had only been signed by two dozen countries. “It doesn’t need to be all 194 countries [to write an op-ed],” said Dr. Tedros. “I don’t want it to be seen as a problem, it wasn’t even a problem. When the discussion on the global pandemic treaty starts, all Member States will be represented.” The Pandemic Treaty Will Synergize With The International Health Regulations Meanwhile, Mike Ryan, WHO’s Director of Emergency Programmes, emphasised that the treaty would “by no means” undermine the existing global framework that governs WHO countries’ behaviour during health emergencies – the legally binding International Health Regulations (IHRs). These regulations set out the mandates under which countries are obliged to report on disease outbreak risks, and share epidemic information, with WHO and other member states. Rather, the pandemic treaty would generate the necessary political commitment to ensure that the IHRs are implemented; and bolster global pandemic preparedness and response by covering a broader set of issues than those covered by the IHRs, such as the sharing of crucial data. “The IHRs…is a really really good instrument,” said Ryan. “But in itself [it] is a piece of legislation that is without meaning unless countries are fully committed to its implementation.” “IHR only works if we have trust, if we have transparency, if we have accountability. Such a treaty would provide that political framework in which we in public health can do our work much more effectively.” “The proposed treaty will definitely bring strong political commitment and support for the IHR implementation,” added Jaouad Mahjour, WHO Regional Director for the Eastern Mediterranean region, who also spoke at Tuesday’s press conference. In an initial response to the initiative, the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) said that pharma partners should play a role in shaping such a treaty. The statement reflected IFPMA concerns over preserving what it described as the patent “incentive system” for developing new vaccines and medicines. “The discussions around a possible International Pandemic Treaty need to take into account the important role played by the innovative biopharmaceutical industry and its supply chain in fighting the virus,” said the IFPMA statement. “It will be important to acknowledge the critical role played by the incentive system in developing tests, therapeutics, and vaccines to contain and defeat the coronavirus. We hope that the discussions on an International Pandemic Treaty will address enablers for future pandemic preparedness – the importance of incentives for future innovation, the immediate and unrestricted access to pathogens, and the importance of the free flow of goods and workforce during the pandemic – in addition to continuing the multi stakeholder approach undertaken in ACT-A and COVAX.” Posts navigation Older postsNewer posts